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Abstract
It has been demonstrated that the bioflavonoid quercetin can synergise with 
bovine papillomavirus type 4 (BPV4) DNA plus an activated ras oncogene to fully 
transform primary fibroblasts cells derived from bovine foetal palate (PalF cells). The 
aim of this thesis has been to identify a mechanism(s) by which quercetin may be 
contributing to this transformation process.
Quercetin was shown to inhibit the growth of PalF cells in a concentration 
dependent manner. A quercetin concentration of ~20pM inhibited the growth of PalF 
cells by approximately 50%. PalF cells were shown to arrest in the G1/G0 and G2/M 
phases of the cell cycle in response to quercetin treatment. These results indicated 
that the presence of quercetin in PalF cell culture medium is not conducive to normal 
cell proliferation.
Investigations were undertaken to determine if quercetin could modulate the 
level of transcription from the viral long control region (LCR); this region of the virus 
contains sequences which are involved in regulating expression of viral genes.
Results showed that quercetin was capable of increasing the level of viral transcription 
from the LCR up to 4 fold. In keeping with earlier observations, the timing of 
exposure to quercetin was critical; the increase in transcription from the viral LCR 
was only observed when cell were exposed to quercetin after cells had been 
transfected with LCR-containing reporter plasmids. No effect on transcription was 
observed when cells were treated with quercetin before transfection. The quercetin- 
mediated effect on LCR transcription activity was also limited to the LCR functioning 
in a promoter capacity. Quercetin had no effect on the LCR when present as an 
enhancer.
Removal of nucleotides 311 to 331 from the 3’terminal end of the BPV4 LCR 
correlated with a drop in the basal level of transcription from the LCR and abrogation 
of the response of the LCR to quercetin. EMSA experiments identified a cellular 
factor, designated QX1, as binding to an oligonucleotide corresponding the sequence 
of the LCR from nucleotides 301 to 331. Although this sequence of the LCR contains 
a TRE-like binding motif, mutational analysis has confirmed that this motif is not the 
site to which QX1 specifically binds. Furthermore, AP-1 does not bind to the TRE-
XIV
like element. API and QX1 display different mobilities in a polyacrylamide gel 
showing that QX1 and API are not the same factor. Mutational analysis has thus far 
not identified specific residues critical for the binding of QX1 to this 3’tenninal region 
of the BPV4 LCR.
Western blot analysis, using a phosphotyrosine antibody, identified several 
proteins which showed changes in their phosphotyrosine status in response to 
quercetin exposure. These results confirm that quercetin can alter the phosphorylation 
status, and possibly also the activity of a number of different proteins, in PalF cells.
The observations made in the course of this thesis indicate that quercetin can 
induce PalF cells to growth arrest, possibly as a result of DNA damage. Quercetin 
also causes an increase in the level of viral transcription. Over-expression of viral 
oncoproteins such as E7, in response to quercetin treatment, would stimulate cells to 
continue proliferating. The stimulation of damaged cells to proliferate in an adverse 
environment induced by quercetin may partially explain the ability of quercetin to 
transform PalF cells in co-operation with BPV4 plus ras. Other epigenetic effects, as 
indicated by the changes induced in several phosphotyrosine-containing proteins, 
could further contribute to this synergism.
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Chapter 1 
General Introduction
1.1 Introduction
There are a large number of diseases which fall under the banner of cancer. 
Nevertheless cancer is often viewed as a single disease because, irrespective of the site 
or cell type which is initially affected, the nature of disease progression is very often 
the same. Of course, cancers originating from different cell types are in general very 
different diseases. Not all cancers progress so rapidly or are as aggressive as others, 
however many share a similar pattern of evolution. This pattern is described as the 
"Multistep nature of cancer" (Vogelstein and Kinzler, 1993).
1.2 The Step-by-step Nature of Cancer Progression
In general, cancer incidence increases dramatically with age (Miller, 1980). 
This relationship led Nordling (1953) and Armitage and Doll (1954) to hypothesise 
that several successive changes must occur in a cell to elicit cancer. The 
heterogeneous nature of tumours and their ability to change over time was studied in 
spontaneous mammary tumours by Foulds (1956) who later concluded that tumour 
progression is characterised by a series of permanent, irreversible changes that occur 
individually in each tumour (Foulds, 1975). The multistage hypothesis has since been 
supported with evidence that has come from several independent sources such as 
epidemiology, clinical observation and pathology and, more recently, molecular 
genetic studies.
Cancer is essentially a unique type of genetic disease. Unlike classic genetic 
diseases like cystic fibrosis, which involves a single germline mutation, cancer 
develops through the acquisition of several individual somatic mutations (Fearon and 
Vogelstein, 1990; Solomon etal., 1991).
The process of cancer cell evolution can be broken down into three distinct 
stages - initiation, promotion and progression. Tumour initiation begins when an 
induced change occurs in a single normal cell. Transition from one stage to the next, 
which encompasses the processes of promotion and progression, is marked by the 
acquisition of additional mutations. Each new mutation can complement and co­
operate with those already established to push the tumour towards an increasingly 
aggressive tumorigenic phenotype.
The concept that cancer originates from a single cell was first outlined in a 
review by Nowell (1976). He not only concurred with other workers (references cited
1
within Nowell, 1976) that tumour evolution was the result of sequentially acquired 
genetic changes, but proposed that all the cells in a malignant tumour derived from the 
same initial cell. In this model of clonal evolution, a change occurs within a single 
cell creating a novel cell clone which possess a selective growth advantage over 
neighbouring normal cells. As a result of genetic instability (Cheng and Loeb, 1993) 
in the expanding tumour population, mutant cells are produced. Most of the mutant 
cell variants which arise are not viable and are eliminated by the body. Occasionally a 
mutation occurs which confers on that cell a further growth advantage with respect to 
both the normal and the original tumour cells. The cell grows into a small sub­
population which possess the ability to outgrow its neighbouring cells. Within this 
limited population, a cell acquires a third mutation which gives it an even greater 
growth advantage. This process of mutation followed by selective clonal expansion 
continues. With each additional mutation the cell becomes increasing abnormal, both 
genetically and metabolically; the deregulated cells become increasingly refractory to 
the mechanisms which control proliferation, differentiation and death. Eventually the 
cells become malignant which enables them to invade and destroy surrounding tissue 
and ultimately metastasise to numerous sites throughout the body via the circulatory 
system where they form secondary (metastatic) tumours. Although benign and 
malignant tumours are implicated in the overall process of carcinogenesis, only 
malignant tumours are properly referred to as cancer.
The mutation rate for human DNA is very low (1.4xlO"10) (Cheng and Loeb, 
1993). One would expect, therefore, that it would take many years to amass mutations 
in several independent genes. As mentioned earlier, cancers occur most frequently in 
older people; the protracted, disease-free lag phase reflects the years required for an 
individual cell to accumulate the number of separate mutations necessary for a 
malignant tumour to materialise. However, it has long been debated that the normal 
rates of mutation are still insufficient to induce cancer (Loeb, 1991) and it has been 
suggested that tumour cells experience higher rates of mutation and are genetically 
unstable (Nowell, 1976; Nicolson, 1987). Indeed, some cancers which have a 
deficiency in mismatch repair mechanisms show mutation rates which are two to three 
fold higher compared to normal cells (Bhattacharyya et a l, 1994; Shibata et a l , 1994; 
Eshleman et a l, 1995). Generally though, the multiple genetic alterations which are 
found in tumour cells appear to be a consequence of gross chromosomal alterations.
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These alterations are characterised by extensive regions of chromosomal deletion or 
duplication which can arise through processes such as mitotic recombination or 
aberrant mitotic segregation, ultimately giving rise to aneuploidy. Aneuploidy, a 
condition in which the chromosome number is not an exact multiple of the diploid set, 
is found in a majority of tumour cells and, although often difficult to prove, it has 
been suggested that full or partial aneuploidy is a cause rather than the effect of 
neoplastic progression (Kinzler and Vogelstein, 1996). The mechanism(s) by which 
these gross chromosomal changes actually arise is unknown (Cheng and Leob, 1993; 
see Table 1, Nicolson, 1987, for a list of mechanisms which may generate genetic 
instability) and represents an area requiring extensive further research.
1.3 Evidence for Multistage tumour Progression
Many cancers exhibit a multistep mode of progression. Two cancers in 
particular, however, have proven to be model systems. Cancers of the colon and 
cervix lend themselves to detailed analysis at several levels; they have been 
extensively characterised at the clinical level and, because both are relatively common 
neoplasias, significant amounts of tumour material are available for analysis. Both 
forms of cancer develop separately through a series of clinically and histologically 
distinct lesions. Furthermore, the location of these lesions within the body means 
biopsy collection is relatively non-invasive. In the next three sections I will consider 
evidence from independent sources, concentrating mainly on cancer of the colon and 
cervix, which support cancer progression as a multistage process.
1.3.1 Epidemiology
The identification of potential carcinogens or risk factors which contribute to 
any stage of cancer development often comes from studies of well defined 
populations. Association between particular social or occupational behaviour and 
increased cancer incidence frequently points to individual factors as common 
denominators in one or more types of cancer.
It was in lung cancer that the first statistical evidence was presented which 
linked this common form of cancer with tobacco smoke and studies over the past three 
to four decade have demonstrated that cigarette smoking is the principal cause of lung 
cancer (for review see Shopland et al., 1991). Exposure to asbestos was identified as
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a contributory factor to developing lung cancer and mesothelioma (cancer of the 
pleura surround the lungs) (for review see Knudson, 1995) and this risk was greatly 
amplified in individuals who were smokers also (Dawson et a l, 1992).
There is strong evidence linking exposure to sources of radiation and a large 
range of cancers (IARC, 1990, Morgan et a l, 1996). Exposure to radiation, whether 
accidental, natural or iatrogenically administered as a treatment for other medical 
conditions, has been associated with leukaemias, lymphoma (IARC, 1990) and solid 
tumours, particularly those of the lung (Preston et a l, 1986; IARC, 1988, Morgan and 
Breit, 1995), bone (Rowland et a l, 1978; Mays and Spiess, 1984; Cafiero et a l,
1996), thyroid (Prentice et a l, 1982; Ron et a l, 1987) and breast (Boice and Nonson, 
1977; Boice etal., 1979; Elkind, 1996).
A number of viral infections, especially those involving specific types of 
human papillomaviruses and hepatitis B virus, have been shown to be casually linked 
to cancer of the cervix (zur Hausen, 1989) and liver respectively (Shafritz and 
Hadziyannis, 1987).
Finally, cancer of the colon is plainly influenced by the environment. This is 
reflected in the dramatic geographical variation in incidence. This form of cancer, 
which occurs most frequently in western urbanised communities, appears to correlate 
with diets which are deficient in fibre whilst containing high levels of carbohydrate 
and lipids (Giovannucci and Willett, 1994; Lee and MacDonald, 1992). The peak 
incidence of colon cancer is still, however, in the over 60 age group (Lee and 
MacDonald, 1992).
A common feature in all these cancers is that expression of the malignant 
tumour is generally only evident years or even decades after exposure to a particular 
carcinogen or infection. The long interval between exposure and malignancy suggests 
that the damage induced by the identified risk factor is, by itself, insufficient to elicit 
cancer. The delay has been attributed to the requirement for additional changes to 
accumulate within the tumour cells before malignancy is achieved; this supports the 
hypothesis that multiple independent events are necessary for the development of 
cancer.
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1.3.2 Clinical Pathology
A large number of histologically distinct lesions or tumours have been 
identified within the large intestine. These include small areas of dysplasia identified 
as aberrant crypt foci (ACF) and adenomas which arise from the colorectal epithelium 
and appear in the form of elevated polyps (Kinzler and Vogelstein, 1996). Adenomas, 
which are benign tumours, exhibit varying degrees of dysplasia graded as mild (early), 
moderate (intermediate) or severe (late); severe dysplasia implies that mucosal 
invasion is imminent (Wyllie, 1992). The risk of colorectal malignancy is 
proportional to the number of adenomas which is particularly evident in individuals 
who are genetically predisposed to adenomatous polyposis (Kinzler and Vogelstein, 
1996). In this autosomal dominant condition, individuals typically develop hundreds 
to thousands of adenomas and, although these tumours are benign, their large numbers 
virtually guarantee that some will progress to invasive carcinomas. Malignant 
tumours (carcinomas) can sometimes appear polypoid, possibly reflecting their 
adenomatous origin, and later they evolve into ulcerating lesions which can lead to 
rectal bleeding and obstruction. Adenocarcinomas of the colon are usually well or 
moderately differentiated. Commonly they penetrate the entire thickness of the 
intestinal wall which can lead to extensive spread throughout the peritoneal cavity 
(Wyllie, 1992).
Cervical squamous-cell carcinoma, like colon cancer, normally does not 
appear abruptly. Instead it develops slowly over a period of 2-10 years from normal 
epithelium which displays progressively severe degrees of abnormality. Premalignant 
change within the cervix is characterised by the presence of poorly differentiated cells 
which display loss of polarity, excessive and abnormal mitotic activity and both 
nuclear and cytoplasmic pleomorphism (Fox, 1992). The term cervical intraepithelial 
neoplasia (CIN) was introduced to describe and classify the whole range of 
premalignant lesions which can occur in the cervix (Richart, 1968, 1973). If cells are 
undifferentiated yet confined to the lower third of the epithelium, the lesion is classed 
as CIN I. Once these cells extend into the middle third of the epithelium, CIN II is 
applied. CIN IE depicts undifferentiated cells which occupy the upper third or full 
thickness of the epithelium. Not all cases of CIN I, II or III inevitably develop into 
invasive carcinomas. Indeed, a parallel system for the cytological diagnosis of 
cervical lesions which was introduced in America in 1988 (the Bethesda System (NCI
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workshop, 1989)), suggests that low grade lesions, originally classified as CIN I, will 
not progress to carcinoma in situ (CIS); only CIN II or III (alternatively classified as 
high-grade squamous intraepithelial lesion (H-SIL)) have the potential of full 
neoplastic development (Wright and Kurman, 1996). Despite HPV infection being a 
relatively frequent event, progression to malignancy is very rare in comparison and 
there is always a strong possibility that CIN (or SIL) at any stage can either remain 
stationary or regress. However there is currently no way of distinguishing particular 
lesions which will continue to evolve neoplastically and therefore all cases of CIN 
have to be regarded as potentially invasive (Fox, 1992).
Early cytogenetic studies detected aneuploidy in all grades of lesions 
(Wilbanks et a l , 1967). Over the past decade more precise methodologies have been 
applied to determine ploidy and although some level of aneuploidy is detected in some 
CIN I lesions, these lesions generally possess normal diploid karyotypes (Fu et al., 
1988). CIN II, III and carcinoma in situ (malignant lesion) in comparison all 
displayed aneuploid karyotypes; aneuploidy was detected more frequently as the 
severity of the lesions increased, i.e., the percentage of carcinomas which were 
aneuploid was greater than that detected in CIN III, which was greater than that 
detected in CIN II (Fu et a l , 1983; Fujii et a l , 1984; Fu et a l, 1988).
Analysis of the various lesions which are found in the colon or cervix presents 
a spectrum of tumours which show progressive levels of dysplasia and neoplasia. The 
bulk of clinical and histopathological data suggests that malignant tumours arise from 
pre-existing benign tumours (Sugarbaker et a l, 1985; Syijanen, 1996). Therefore, the 
concept that more neoplastic tumours originate from less aggressive precursors 
supports cancer as a stepwise process; the macroscopic changes in tumour 
morphology reflects the changes which are occurring within the tumour cell at the 
molecular level.
1.3.3 Molecular Genetics
The epidemiological and clinico-pathological support for a multistep 
mechanism of carcinogenesis, although very significant, is somewhat circumstantial. 
The underlying cause for the changes in cellular behaviour lie at a molecular level.
The development of molecular genetic technology over the past ten to fifteen years
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has provided convincing evidence that cancer progression is a consequence of 
accumulating permanent alterations to the cell's normal genetic structure.
Two distinct classes of genes have been causally linked to cancer 
development. These cancer-related genes are called oncogenes and tumour suppressor 
genes.
1.3.3.1 Oncogenes
The use of certain chemicals, radiation and some viruses has been shown 
capable of inducing cancer experimentally in animal model systems. Tumour-viruses 
in particular played a pivotal role in focusing research efforts on the identification of 
critical genes involved in neoplasia. Compared to most chemical carcinogens, tumour 
viruses rapidly induce the formation of tumours in animal models and transform cells 
in culture efficiently and reproducibly (Cooper, 1990). In addition, these viruses 
comprise small genomes with respect to the cellular genomes of higher eukaryotic 
cells which makes molecular characterisation of their DNA more amenable.
The discovery of retroviral oncogenes was very significant, providing the first 
step towards understanding the function of genes specifically involved in 
carcinogenesis. The oncogenes of acutely transforming retroviruses, such as the Rous 
sarcoma virus, are a distinct group of genes responsible for viral pathogenesis but 
which were shown not to be required for viral replication (Weiss et a l, 1985). 
Retroviral oncogenes originated from normal cellular genes called proto-oncogenes. 
Proto-oncogenes constitute a group of normal cellular genes with potentially 
transforming activity. An oncogene is an 'activated' proto-oncogene; it is a mutant 
form of a normal cellular gene which has acquired the ability to induce transformation 
as a consequence of aberrant gene expression or an alteration in structure and/or 
function of the protein product. Proto-oncogenes become incorporated into retroviral 
genomes by virus-cell recombination events (Swanstrom et a l, 1983; Neil et a l,
1984; Miles and Robinson, 1985). During the recombination event, the cellular gene 
can become mutated by truncation or point mutation of sequences critical for 
regulation or biochemical activity of the gene product. Alternatively the gene may be 
expressed aberrantly under the influence of the powerful viral promoter. The 
incorporation of a cellular proto-oncogene into a retroviral genome and its 
transmission into another cell following subsequent viral infection is called
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transduction. Even if the transduced cellular gene sustains no mutation in the transfer, 
its reinsertion into cellular DNA can lead to irregular expression of this gene in the 
vicinity of retrovirus integration which thus may cause neoplastic growth. Irrespective 
of the method of activation, retroviral transduction has lead to the identification of 
many oncogenes including src (Duesberg and Vogt, 1970), ras (Santos et a l , 1982, 
Parada et a l, 1982) and myc (Hayward et a l, 1981; Payne et a l, 1982).
It has long been recognised that many cancer cells, when viewed 
microscopically, carry damaged chromosomes. The presence of chromosome 
translocations, inversions, deletions, and amplifications, all involving large genome 
domains, has provided evidence for the existence of oncogenes for many decades. 
However, only since the generation of techniques for molecular manipulation and cell 
culture has it been possible to dissect and test the biological significance of the 
regions implicated in these gross chromosomal alterations.
The study of cancer in whole animals is difficult to control and quantitate due 
to the number of uncontrollable variables which are naturally associated with a 
complex, multicellular organism. The development of techniques for the maintenance 
and cultivation of cells in culture has proved to be invaluable in the dissection of 
neoplastic transformation. It has provided a normalised environment in which the 
growth requirements and behaviour of normal cells can be analysed, properties of 
normal and cancer cells can be compared under controlled conditions, and quantitative 
and reproducible assays for cell transformation have been developed. The 
development of sensitive and reproducible transformation assays in cell culture has 
been critical in establishing an experimental understanding of the molecular basis of 
cancer. The assays focus on characteristics such as morphological change, loss of 
contact inhibition, reduced dependency on growth factors and/or serum for growth, 
anchorage independent growth and tumorigenicity in nude mice inoculations.
Tumorigenicity studies are particularly important as they provide a link 
between cells which display transforming characteristics in vitro and the ability to 
form tumours in vivo. It is very important to be able to relate results observed in vitro 
with effects in vivo: tumorigenicity studies add validity to the in vitro transformation 
assays.
However, these assays are in no way absolute. Many cells display one or more 
transformed characteristics in vitro and yet do not induce tumours in nude mice. Such
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partially transformed cells appear only to have acquired some of the alterations needed 
to convert a normal cell to a tumorigenic phenotype adding support for a multistep 
mechanism of carcinogenesis
Quantitative in vitro assays for neoplastic transformation have defined the 
parameters that characterise the growth of normal and transformed cells and have led 
to the identification of factors which control growth and differentiation. However it 
must be remembered that cell culture is an artificial system. All results must be 
related to whole animal studies. The in vitro growth characteristics of any cell type is 
only an approximation to the phenotype of the same cells in vivo. Nevertheless, cell 
culture experiments have and continue to play a significant role in the identification 
and characterisation of potential oncogenes as well as allowing the effects of various 
chemicals, whether mutagenic, carcinogenic or therapeutic, to be assessed.
DNA from chemically transformed rodent cells was shown to be capable of 
transforming immortalised but non-transformed mouse recipient NIH 3T3 cells in a 
series of gene transfer experiments (Shih et a l , 1979). Later, DNA extracted from 
human tumours was found to induce transformation of NIH 3T3 cells with high 
efficiency in gene transfer assays (Shih et a l , 1981; Murray et a l , 1981). These 
results suggested that normal cells contained proto-oncogenes which could be 
activated experimentally by chemical carcinogens and that human tumours contained 
biologically active cellular oncogenes. Gene transfer experiments led to the 
identification of many distinct human oncogenes that were activated by mutation or 
DNA rearrangements. Some of the cellular oncogenes have been shown to be 
homologues of retroviral oncogenes, such as the ras genes, whereas others are not. In 
all cases however, the biologically active cellular oncogenes are mutant forms of 
normal proto-oncogenes. The identification of activated oncogenes in a large number 
of human tumours clearly implicates cellular genes in the pathogenesis of human 
cancers.
Further experiments which have confirmed the role of oncogenes in 
carcinogenesis includes the generation and study of transgenic mice. As mentioned 
above, cell culture experiments, whilst providing an easily manipulatable system for 
the analysis of oncogene transforming activity, represents an oversimplified 
approximation of the development of neoplasias in whole animals. In a transgenic 
mouse however, an oncogene is introduced into every cell in the animal. This enables
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the transforming potential of an activated oncogene to be assessed in an in vivo 
environment.
To generate a transgenic mouse, a construct containing an activated oncogene 
is microinjected into the pronuclei of fertilised mouse eggs. If the oncogene construct 
becomes integrated into the germ line DNA, transgenic offspring will be obtained.
The first laboratory to report the function of a cellular oncogene in transgenic 
animals was that of Philip Leder and colleagues (Stewart et a l , 1984). In their 
experiments the c-myc gene was over-expressed by placing it under the transcriptional 
control of a strong inducible promoter, the mouse mammary tumour virus (MMTV) 
LTR. Mice that expressed the MMTV/myc transgene developed mammary 
carcinomas after a latent period of several months. This study provided direct 
experimental evidence that a cellular oncogene could induce neoplastic disease in a 
complete, living animal. Important to note, however, was that the MMTV/myc 
transgene was clearly not the only factor required for cancer development in this 
system. The long latency period indicated that other changes must have occurred to 
give rise to the final tumour. Furthermore, only one tumour generally developed in 
one of the ten mammary glands present in the transgenic mouse despite all the cells 
carrying the MMTV/myc transgene. These results suggest that one activated 
oncogene (c-myc) was contributory but not sufficient for the formation of mammary 
carcinomas in these mice.
Many subsequent transgenic mouse models have confirmed the activity of 
various oncogenes in carcinogenesis (Muller et al., 1988; Tsukamoto et al., 1988). 
They have also shown that oncogenes can co-operate and further reduce the latency 
period observed for either oncogene alone (Compere et al., 1989; Thompson, 1989).
The experimental strategies outlined above have been seminal in identifying 
oncogenes which contribute to the neoplastic process. Ironically, identification of 
oncogenes and understanding their roles in transformation has lead to a greater 
understanding of proto-oncogene activity in normal cell function, including the 
regulation of proliferation, differentiation, development and death.
Oncogenes, however, are not the only, and perhaps not even the most 
important, genes associated with neoplastic progression. A second class of genes, the 
tumour suppressor genes, have also been shown to play a crucial role in the genesis of 
cancers.
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1.3.3.2 Tumour Suppressor Genes
As their name suggests, tumour suppressor genes have the ability to suppress 
neoplastic growth. The identification of tumour suppressor genes, and the elucidation 
of their role in carcinogenesis, has come from three main areas of interest; somatic 
cell hybrid analysis, the study of inherited cancer syndromes and the experimental 
reversion of the neoplastic phenotype in vitro.
In 1969 Henry Harris and co-workers fused normal cells with tumour cells 
(Harris et a l , 1969). The resultant normal-malignant cell hybrids were shown not to 
be tumorigenic. Numerous studies of this type have subsequently confirmed this 
observation which implies that normal cells contain genetic information that can 
suppress the neoplastic behaviour of tumour cells (Stanbridge, 1976, Saxon et al., 
1986). Many of the non-tumorigenic hybrids obtained after such fusions however 
continued to display some phenotypic characteristics of transformed cells in vitro, 
including loss of density-dependent inhibition of cell growth and loss of anchorage- 
dependent growth. Hence the suppression of tumorigenicity in these hybrid cells 
appears to represent only a partial reversion of cell transformation. This is consistent 
with the multihit model of carcinogenesis where the activation of dominant oncogenes 
and loss of tumour suppressor gene functions are independent events, both of which 
contribute to the fully transformed state. Furthermore, normal-malignant cell hybrids 
often revert to the tumorigenic phenotype following the loss of particular 
chromosomes which originated from the normal parent cell line (Stanbridge et a l , 
1981; Klinger, 1982). These results confirm that loss of a tumour suppressor gene(s) 
is associated with transformation.
In some human cancer families, tumour susceptibility is inherited in a 
dominant Mendelian fashion. Retinoblastoma (RB) is a disease that can arise 
sporadically or, in about 10% of cases, shows a familial pattern of inheritance (Evans,
1993). Familial retinoblastoma affects children at an early age and patients frequently 
develop multiple tumours in both eyes. Individuals with sporadic retinoblastoma 
generally develop a single tumour in one eye only and present at an older age 
compared to those with the inherited form of the disease. Alfred Knudson studied 
cases of inherited and sporadic retinoblastoma and made statistical comparisons of 
frequency and age of onset of both forms of the disease. In 1971 he proposed that
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retinoblastoma was caused by two mutations, one in each copy of the same gene 
(Knudson, 1971). In retinoblastoma families, affected individuals inherit one 
defective copy of the gene which is then present in every cell of their bodies: this kind 
of inherited mutation is called a germline mutation. Malignant tumours can develop 
from any cell that sustains a second mutation in the remaining normal gene copy by 
virtue of a somatic mutation. Sporadic retinoblastoma also involves mutation in both 
copies of the same gene, however both mutations are derived from separate somatic 
events. The presence of a germline mutation in hereditary retinoblastoma is what 
predisposes affected individuals to tumour development, earlier age of onset and the 
presence of multiple tumours in both eyes. The requirement for mutations in both 
alleles of a tumour suppressor gene has become known as Knudson’s two-hit 
hypothesis.
Various experimental strategies were applied to identify the chromosome, 
chromosome region and ultimately the gene implicated in the development of 
retinoblastoma. The mapping techniques used included karyotype analysis (Knudson 
et a l, 1976; Benedict et a l, 1983), single chromosome transfer experiments, genetic 
linkage studies looking for loss of heterozygosity (LOH) using isozyme markers 
(Sparkes et a l, 1983) and the application of restriction fragment length 
polymorphisms (RFLP) (Cavenee et a l, 1983; Dryja et a l, 1986). A gene, named Rb, 
was finally mapped to chromosome 13 band ql4. Several genetic studies have shown 
that functional loss of both copies of the retinoblastoma susceptibility gene is 
associated with tumour development (Godbout et a l, 1983; Friend et a l, 1987; 
Weichselbaum et a l, 1988). Therefore, unlike oncogenes which contribute to 
tumorigenesis through the acquisition of dominant, activating mutations, it is the loss 
of tumour suppressor gene function which can lead to neoplastic transformation.
The Rb gene has been implicated in the genesis of neoplasms other than 
retinoblastoma including osteosarcomas (Hansen et a l, 1985), sarcomas of soft tissue 
(Weichselbaum et a l , 1988) and carcinomas of the breast (Lee et al., 1988; T'Ang et 
a l,  1988), lung (Harbour et a l, 1988) and bladder (Weinberg, 1992). The gene 
encodes a protein (pRb) which has been shown to bind the E2F family of transcription 
factors that are required for DNA transcription and replication (Adams and Kaelin,
1995). Binding of E2F to the hypophosphorylated form of pRb renders it unavailable
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to participate in DNA replication. Therefore by sequestering E2F, pRb effectively 
inhibits DNA replication.
Since the identification of Rb, several other tumour suppressor genes have also 
been identified including ARC (Kinzler and Vogelstein, 1996), DCC (Cho and Fearon,
1995), WT-1 (Coppes et a l, 1994; Hastie, 1994), NF-1 (Ponder, 1992; Upadhyaya et 
a l, 1995,1997) andp53.
p53 has been mapped to chromosome location 17ql3.1 (McBride et a l, 1986). 
This region is frequently deleted in tumours (Baker et a l, 1989; Nigro et a l, 1989) 
and mutations in the p53 gene have been identified in a very large number of disparate 
cancers (for review see Caron de Fromentel and Soussi, 1992). Indeed, more 
mutations have been reported in the p53 gene than in any other gene to date (Hollstein 
et a l, 1991) which highlights the critical role this gene must play in cancer 
development.
Early experiments identified p53 as a putative oncogene: it was shown to be 
capable of transforming early passage rodent cells in conjunction with an activated c- 
H-ras gene (Eliyahu et a l, 1984; Jenkins et a l, 1984; Parada et a l, 1984). In 
subsequent studies however it was determined that the p53 clone used in these early 
studies was in fact a mutant cDNA. Wild type p53 does not co-operate with ras but 
rather inhibits cellular transformation induced by other oncogenes and ras (Eliyahu et 
al, 1989; Hinds et a l, 1989).
A rare familial cancer syndrome called Li-Fraumeni syndrome (LFS) has been 
identified in which affected individuals inherit an autosomal dominant p53 mutation. 
As with inherited Retinoblastoma, LFS patients inherit a predisposition to developing 
an array of diverse tumour types including sarcomas, carcinomas and leukaemia, at an 
early age (Li et al, 1988).
Over-expression of wild type p53 in tumour cell lines is antiproliferative 
(Baker et a l, 1990; Chen et a l, 1990; Diller et a l, 1990). This ability to reverse the 
tumorigenic phenotype confirms the tumour suppressor status of p53.
p53 is up-regulated in response to a number of DNA damaging agents, 
including radiation, which subsequently leads to growth arrest (Maltzman and Cyzyk, 
1984; Kastan et a l, 1991; Kuerbitz et a l, 1992) and activation of DNA repair 
mechanisms (Kastan et a l, 1992). The induction of growth arrest thus enables cells to 
repair any endogenous DNA damage and is undoubtedly an important regulatory
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mechanism which protects cells from accumulating genetic mutations or alterations 
that may ultimately lead to a malignant phenotype. p53 mediated growth arrest has 
also been reported where the specific cell culture environment is not conducive to 
continued cell proliferation, i.e., when serum (Reich et al., 1984) or isoleucine 
concentration (Steinmeyer et al., 1990) in culture medium is low. The ability of a cell 
to growth arrest when exposed to cellular stress is again an advantageous response, 
providing the cell an opportunity to survive in adverse conditions whilst remaining 
ready to grow when suitable conditions are re-established. In extreme situations 
where, for example, the level of DNA damage is extensive, p53 has been shown to 
play a role in inducing programmed cell death (apoptosis) (Shaw et al., 1992; Lowe et 
al., 1993; Clarke et al., 1993).
The role of p53 in tumorigenesis is, however, quite complex. Particular 
mutations have been identified which have lead to the production of proteins with 
novel, aberrant functions. These kinds of mutations, termed gain of function 
mutations, instead of leading to gene inactivation, result in the acquisition of 
transforming potential (Wolf et al., 1984; Dittmer et al., 1993).
The inactivation or loss of tumour suppressor genes like p53 and Rb clearly 
has severe implications in terms of the ability of the cell to regulate vital cellular 
mechanisms including DNA transcription, DNA repair and replication, and cell death. 
Loss of tumour suppressor gene function can be achieved not only by genetic mutation 
and/or deletion but also through the action of particular viral gene products. The role 
played by viral oncoproteins in the inactivation of p53 and pRb, and the significance 
of this in virus-associated cellular transformation, is discussed in detail in sections
1.5.3.1 and 1.5.3.2.
As observed for Rb, mutations and/or loss of p53 is never the only event 
detected in a malignant tumour. Disruption of the normal function of p53 alone, 
whilst creating an unstable environment in which other genetic changes are more 
likely to occur, is not sufficient to induce full transformation. p53 dysfunction or loss 
is one more event which can contribute to neoplastic progression. Nevertheless 
because tumours classically possess changes in several individual genes, which may or 
may not include p53, leads us back to the hypothesis that cancer progression is a 
multistep event that marries the functions of numerous genes in different 
combinations.
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Finally, it would be inaccurate and unrealistic to think that all cancers can be 
neatly fitted into the multistep concept outlined above. Cancer, as already mentioned, 
is a collective term for a large number of diseases which display a very varied 
spectrum of individual characteristics. "No unitary concept can give a satisfactory 
explanation o f the intimate nature o f cancer" (Vriel, 1979). Cancer is a dynamic, 
complex process. A successful tumour cell can exploit its immediate, unique 
environment to gain proliferative dominance, immortality and autonomy. However, a 
model like the "multistep" scenario, where applicable, provides a framework which 
can help us understand the progress of cancer and allow certain prognostic predictions 
to be made. By gaining a better understanding of the mechanism(s) of cancer 
progression, efficient treatments and strategies can be developed in an attempt to 
disrupt or prevent the advance of the carcinogenic process.
1.4 Viruses and Cancer
Identifying risk factors is an important step in understanding the aetiology of 
individual cancers. Indeed, eliminating risk factors can dramatically reduce the cancer 
incidence rate as exemplified when comparing cohorts of smokers with non-smokers 
and the frequency of lung cancer. Experimental and epidemiological studies have 
identified certain viral agents as risk factors in the development of human tumours. It 
has been estimated that viral infections are directly implicated in 15% of human 
cancers world-wide (zur Hausen, 1986). Cancer of the cervix and hepatocellular 
carcinoma both include a viral component in their aetiology and together account for 
approximately 80% of virus-associated cancers (zur Hausen, 1991b). The 
mechanisms by which different viruses contribute to tumorigenesis are varied.
Human immunodeficiency virus (HIV) infection induces immunosuppression 
in affected individuals (Feinberg, 1996). This acquired immunosuppression results in 
a considerable increased risk of developing Kaposi's sarcoma and non-Hodgkin’s 
lymphoma (Biggar et a l , 1994; Schulz et al., 1996). The virus itself has not been 
shown to be directly transforming however it creates an environment where cells 
transformed by other physical, chemical or infectious agents can persist: the longer a 
transformed cell escapes elimination by the body’s defence mechanisms the greater 
the chance that cell will progress to a more neoplastic state. Immunosuppression in
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general, whether drug induced, as in the case of transplant patients (London et a l ,
1995), or genetic (Barnett et a l , 1983; Fuchs and Pfister, 1996), is associated with 
increased risk of tumour formation.
Other viruses have a more direct effect on tumour induction compared to HTV. 
Human T cell leukaemia-lymphoma virus type I (HTLV-I) is a retrovirus and has been 
associated with malignant adult T cell leukaemia-lymphoma (ATLL). ATLL is most 
prevalent in coastal areas of southern Japan, in the Caribbean and in regions of central 
Africa (zur Hausen, 1991b). The latency period between primary infection and 
presentation of leukaemia spans several decades indicating that virus infection per se 
is not sufficient for development of malignant disease. The elucidation of other 
cellular changes necessary for full neoplastic transformation has not been well 
characterised. Nevertheless, identification of this retrovirus as a primary element of 
risk for ATLL development contributed to the isolation of other pathogenic 
retroviruses including HTLV-II and HIV.
Epstein-Barr virus (EBV) has been linked to several separate human cancers 
including Burkitt's lymphoma, undifferentiated nasopharyngeal carcinoma, gastric 
cancer, peripheral T cell lymphoma and Hodgkin's Disease in immunosuppressed 
individuals (zur Hausen, 1991b). EBV is a widespread viral infection which can be 
present in up to 100% of a population and persists in the infected host throughout life 
(zur Hausen, 1991b). The way in which EBV infection contributes to the 
development of malignant tumours is obscure and not well understood however it 
remains the first human tumour virus to be identified as a cofactor in cancer genesis 
(Epstein et a l , 1964).
The link between chronic hepatitis B virus (HBV) and hepatocellular 
carcinoma was initially suspected from epidemiological observations. Areas of the 
world which show endemic HBV infection, including south-east Asia and China, 
coincidentally report the highest incidence of primary liver cancer (Bosch and Munoz, 
1989). Although current evidence suggests that primary liver cancer is multifactorial 
in origin, HBV infection and chemical agents remain the major risk factors for this 
type of disease (Saracco, 1995). Ailatoxins are believed to be particularly important 
cofactors as they are a common food contaminant and potent liver carcinogens as 
demonstrated in a variety of animal species. The risk of developing primary liver 
cancer following HBV infection and aflatoxin exposure is increased (Saracco, 1995).
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The appearance of primary liver cancer in humans is generally only observed after 
several decades of chronic liver disease and persistent HBV infection. Several other 
reports indicate that HBV genome persistence is critical for progression to the 
tumorigenic state (for review see zur Hausen, 1991b); HBV genome sequences have 
been detected in malignant tumours originating in individuals from high-risk areas 
(Nagaya et a l , 1987).
Papillomaviruses are another group of viruses which possess transforming 
characteristics and have been isolated from a variety of animal species including 
humans. In the great majority of cases these viruses induce benign lesions of the skin 
and mucosa, however infection with selective variants has been link to the 
development of malignancies (Syverton, 1952; zur Hausen, 1991a; Campo et a l,
1994). In humans, infection with 'high-risk' HPV types 16 and 18 has been associated 
with anogenital cancers, in particular cancer of the cervix. More than 90% of cervical 
cancer tumours contain viral DNA (Munoz and Bosch, 1996); in the majority of cases 
the DNA has integrated into the host cell genome (Durst et a l, 1985; Schwarz et a l,
1985). The transforming potential of the high-risk HP Vs has been attributed to 
specific transcripts derived from the viral genes E6 and E7 (Vousden, 1994).
The role of HPV infection in the formation of neoplastic lesions is of direct 
relevance to the work in this thesis. In subsequent sections, I will review all aspects of 
papillomavirus biology concentrating particularly on bovine papillomavirus type 4, the 
specific papillomavirus which has been the focus of the experimental work presented 
in later chapters.
1.5 Papillomaviruses: Historical Overview
Although the first papillomavirus was identified more than 60 years ago, 
progress in trying to understand the molecular biology of these viruses has been slow.
Early work on animal papillomas was limited mainly to transmission studies. 
Transmission of the canine oral papilloma was performed back in 1898 (McFadyean 
and Hobday, 1898); the experimental transfer of a skin papilloma from horse to horse 
was successfully achieved in 1901 (Cadeac, 1901). The fact that papillomas could 
exhibit such contagious behaviour suggested the involvement of an infectious agent.
A bacterial or protozoan aetiology was ruled out when Ciuffo demonstrated in 1907 
that transmission of common human warts was possible using cell-free filtrates
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(Ciuffo, 1907). Then in 1933 the first papillomavirus, the cottontail rabbit (Shope) 
papillomavirus (CRPV), was isolated and characterised (Shope and Hurst, 1933).
This was the first virus to be identified which was known to cause tumours.
Since that time very many more papillomaviruses have been identified and 
isolated from a wide species range. They have been shown to be transmissible not 
only between animals of the same species, but the naturally occurring 
papillomaviruses from cattle, sheep, deer and cottontail rabbit have been shown to 
cause tumours in other species also (Olson, 1987).
Even though an extensive spectrum of investigations was carried out on 
papillomaviruses since the early 1930s up until the mid to late 1970s, little insight was 
gained about how these viruses were actually producing papillomas. Much of this was 
due to the limited amount of viral material/DNA available for study; initially 
papillomavirus particles had to be purified from warts or papillomavirus lesions. The 
amount of virus present in a lesion is very variable and large amounts of virus infected 
tissue was required to purify significant amounts of virus for analysis. Up until the 
early 1970s it was believed that there was in fact only one type of human 
papillomavirus and that the morphological and behavioural differences seen between 
papillomavirus-induced lesions was influenced purely by the location at which the 
lesion occurred on the body (Rowson and Mahy, 1967). Development of an efficient 
in vitro culture system for the propagation of papillomaviruses has proved elusive 
even to the present day. However, the advent of molecular cloning technology 
provided the first real opportunity to begin experimental analysis of the various 
molecular events involved in papillomavirus-associated tumour induction and 
progression to malignancy.
1.5.1 Papillomavirus Structure and Classification
The papillomaviruses (PVs) are distinct from other members of the 
papovaviridae family, such as SV40 and polyoma viruses, in that they have larger 
virions, their closed circular double-stranded superhelical DNA genome is larger and 
transcription of the large, overlapping open reading frames (ORF) occurs from only 
one DNA strand (Danos et a l, 1982; Chen et a l, 1982). PV genomes are on average 
~7.9kb in size: virus sizes can range from ~7.2kb, as observed for BPV4 (Campo et
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a l , 1980), HPV9, 15, 17, 22 and 23 (Kremsdorf et a l , 1982, 1984), up to ~8.4kb for 
the deer papillomavirus (DPV)(Groff and Lancaster, 1985).
Genes encoded by PVs are subdivided into two groups, namely the 'early' and 
'late' genes. Early genes are expressed prior to DNA replication. They encode 
proteins which control and modulate vegetative viral DNA replication and 
transcription. The early genes are also responsible for cell transformation. The late 
genes encode structural proteins, LI (major protein) and L2 (minor protein), which 
aggregate to form the viral capsid. There is also a non-coding region (NCR), 
alternatively termed the LCR (long control region) or URR (upstream regulatory 
region), which contains several cfs-acting regulatory elements (Ward et a l, 1989).
The LCR is defined as the region that extends from the stop codon of the LI open 
reading frame (ORF) to the start codon of E6; this non-coding region is the least 
conserved between papillomavirus types.
Papillomaviruses infect epithelial cells of the skin and mucosa. A few 
papillomaviruses, such as BPV1, 2 and 5, DPV, EEPV, RPV and sheep 
papillomavirus, are capable of inducing fibroblast tumours as well as being tropic for 
epithelial cells. Infection by human papillomaviruses (HPVs) however is purely 
epitheliotropic in nature.
Papillomavirus replication and virion assembly occurs in keratinocytes and is 
closely coupled to keratinocyte differentiation. Virus is undetectable in basal stem 
cells although the basal layer is believed to be a site of latent viral infection. Viral 
DNA has been detected in suprabasal cells and in successive layers by in situ 
hybridisation (McDougall et a l, 1986). Mature virions are only found in the most 
superficial and highly differentiated epithelial layers. The vegetative life cycle of 
papillomaviruses therefore apparently requires specific host cellular factors that are 
sequentially produced in a predefined order according to the differentiation program 
of keratinisation. The synchronisation of papillomavirus gene expression and particle 
maturation with keratinocyte differentiation has consequences for normal host cell 
function. Papillomavirus infection causes modifications of host gene expression and 
interferes with normal cellular control mechanisms. In normal tissue, DNA 
replication is restricted to basal and parabasal cells. In papillomavirus infected cells, 
however, DNA synthesis has been detected in keratinising cells (Rashad, 1969). 
Hence papillomavirus infection must be capable of altering the tolerance of
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differentiating cells to DNA replication. Differentiation markers, such as keratins, 
desmosome-related antigens and cell surface glycoproteins, all show changed 
expression in the presence of a papillomavirus infection (Steinberg, 1986). At a gross 
level, changes in the normal pattern of differentiation and maturation gives rise to an 
anomalous morphology in the form of a papilloma.
Individual PV types are generally classified according to criteria such as host 
range and by comparing levels of nucleic acid homology. A nomenclature for the 
classification and organisation of papillomaviruses was originally proposed in 1979 
and was determined by heterologous DNA reassociation kinetics (Coggin and zur 
Hausen, 1979). The definition for classifying new virus isolates has been amended 
several times since then and today a papillomavirus is recognised as a novel type if the 
sequence of its entire LI ORF shares less than 90% identity with any other LI 
sequence. There have been more than 75 HPV types cloned over the past 15 years, 
approximately 63 of these HP Vs have been completely sequenced (van Ranst et al., 
1996). The final tally, if ever realised, relies very much on the continued enthusiasm 
in the search for new types; at present perhaps the sky's the limit.
In terms of evolution, however, host specificity does not always reflect the 
existence of a natural relationship. For example, BPV1, 2 and 5 (Group A) infect 
cattle as do BPV3, 4 and 6 (Group B). There is however little DNA homology 
between the group A and B bovine papillomaviruses (Lancaster and Olsen, 1978; 
Jarrett et a l , 1984). BP VI in fact shows a greater degree of homology with viruses 
that infect other animal species, namely the deer (DPV), European Elk (EEPV) and 
reindeer (RPV). Likewise HPV1 is more closely related to BPV1 (cattle) and 
CRPV(cottontail rabbit) than to some other HPVs, e.g. HPV2 or 4.
Interestingly, PVs that are related at the molecular level exhibit similar 
biological properties such as type of lesion produced and site of infection.
Homologies which exist both at the molecular and biological level between viruses 
from quite divergent species cannot be wholly attributed to tissue tropism. A better 
understanding of the various individual viral genomes' organisation and biological 
properties must be attained before evolutionary relationships can be more accurately 
assessed.
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1.5.2 Papillomavirus Disease and Cancer
Infection by a papillomavirus results in hyperproliferation of epithelial (and in 
a few cases fibroblast) cells. This leads to the formation of papillomas (condylomas 
or warts) which can exhibit many different morphological and histological patterns 
depending primarily on the identity of the infecting PV type. Individual virus types 
are remarkably species and tissue specific. The majority of lesions produced are 
benign. These benign tumours can either persist in this inert form or can 
spontaneously regress. However, infection by a few specific PV types is associated 
with the formation of papillomas which have the potential to progress to carcinomas 
providing additional cofactors, such as genetic background, environment and/or other 
viral or microbial infections, exist in parallel.
1.5.2.1 Cottontail Rabbit Papillomavirus (CRPV)
Papillomatosis is endemic in rabbits in particular states in America, 
specifically those states which lie in the Mississippi valley (Kreider and Bartlett,
1981). The aetiological agent, identified by Shope, was shown to be a virus (Shope 
and Hurst, 1933). The Shope or cottontail rabbit papillomavirus (CRPV) was later 
identified as the first DNA virus capable of inducing tumours.
CRPV naturally infects the hairy epithelium of cottontail rabbits (Kidd and 
Parsons, 1936). It will induce papillomas in both cottontail and domestic rabbits 
(Shope, 1935). Interestingly it has been observed that, whereas 25% of papilloma- 
carrying cottontail rabbits eventually developed malignant lesions, 75% of domestic 
rabbits also with benign papillomas ultimately developed carcinomas (Syverton,
1952). This suggests therefore that papillomas in domestic rabbits are more likely to 
progress to fully malignant and even metastatic tumours than papillomas in the natural 
host, the cottontail rabbit. The genetic background of the domestic rabbit apparently 
renders it considerably more susceptible to CRPV-associated carcinogenesis 
compared to the virus' natural host, the cottontail rabbit (Kreider, 1980).
Carcinomas in either domestic or cottontail rabbits only appeared several 
months after viral infection or inoculation (Syverton et a l, 1950a, b; Syverton, 1952). 
The delay implicates cofactors as necessary elements in the development of malignant 
disease. CPRV infections were later shown to synergise with the actions of known 
carcinogenic chemicals, especially tar (Rous and Kidd, 1936; Kidd and Rous, 1937).
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The interaction between virus and chemical carcinogen(s) greatly reduced the latency 
period between infection and cancer (ibid).
Finally, viral particles were not detected in cancerous lesions (Syverton, 1952) 
suggesting that production of mature CRPV virions is not permitted in malignant cells 
possibly as a result of disruption to cellular differentiation.
1.5.2.2 Human Papillomaviruses
Genetic background was shown to influence the susceptibility of domestic 
rabbits in developing cancer when infected with the cottontail rabbit papillomavirus 
(CRPV). Genetic background is also a fundamental contributory factor to cancer 
development in Epidermodysplasia verruciformis (EV) patients. EV is a rare, 
lifelong, multifactorial disease which involves genetic and extrinsic factors in addition 
to HPV infections. This condition can arise sporadically or is inherited; generally 
inheritance of this disease follows an autosomal dominant pattern however there is 
one report of a pedigree where inheritance is X-linked (Androphy et a l, 1985). 
Lesions, induced by a range of specific (Group D) HP Vs, are widespread and some 
can undergo malignant transformation. The development of multiple skin carcinomas 
arises 10 to 30 years after the onset of the disease and is observed in 30-50% of EV 
individuals (Iftner et al., 1990); these cancers occur most frequently in sun exposed 
areas of the skin. The risk of malignant conversion very much depends on the HPV 
type present in the lesion and also on skin type; malignant conversion is very rare in 
black-skin patients (Jacyk and de Villiers, 1993). More than 20 HPV types have been 
isolated from EV-associated skin lesions however, HPV5 and 8 are the predominant 
types, being found in 90% of squamous cell carcinomas from EV patients (Arends et 
a l , 1990).
Many EV patients have been shown to have impaired cell-mediated immunity 
(Jablonska and Orth, 1985). Immunosuppression in general, whether it be genetic, 
acquired through infection (HIV)(Vemon et a l, 1995; Adams et a l, 1995) or 
iatrogenically induced (renal allograft recipients)(Trenfield et a l, 1993; Petry et a l,
1994), is often accompanied by an increased incidence of warts and skin cancers 
(Benton and Arends, 1996). Dysfunctional immune responses to PV in these 
situations, as in EV, appears also to be cell-mediated in nature.
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A number of other HP Vs have been implicated in the genesis of anogenital 
(zur Hausen, 1991a; Arends et al., 1990 and refs, therein) and oral/upper respiratory 
tract cancers (Kahn et a l, 1986; Brandsma et al., 1986; Zarod, 1988; Watts et al., 
1991). In particular, HPV16 and 18 have been classified as 'High-risk' types for 
genital cancer. These are related to HPV6 and 11 which are representative of the 'Low 
risk' group of HPV types. Why high and low risk HP Vs have different malignant 
potentials is not well understood, zur Hausen (zur Hausen, 1991a) suggested that it 
may be partially due to differential reliance on exogenous cofactors for carcinogenic 
advance. As will be subsequently discussed (section 1.5.3), the ability of some viral 
proteins to interact with important cellular, regulatory proteins must also be an 
important determinant of HPV oncogenic potential.
Cervical cancer is the second most common cancer in women world -wide 
exceeded only by breast cancer (Parkin et al., 1993). Around 2,000 women die of 
cervical carcinoma in the United Kingdom each year although this number is slowly 
decreasing due to improvements in screening and treatment of identified premalignant 
lesions. World wide, there are an estimated 500,000 new cases of cervical cancer 
each year (Scheffner et al., 1994). In sub-Saharan Africa alone, an estimated 53,000- 
130,000 women develop this malignancy each year (Feldmeier, et al., 1996). Analysis 
of invasive squamous cervical carcinomas, cervical adenocarcinomas and cell lines 
derived from these tumour have identified HPV specific sequences in more than 90% 
of cases (Munoz and Bosch, 1996 for review); HPV 16 was the predominant type 
isolated from carcinomas whereas HPV 18 was the most common isolate in 
adenocarcinomas . The high level of HPV detection in cancers of the cervix strongly 
supports a role for this virus in initiation, progression to and maintenance of the 
malignant phenotype, although HPV infection is considered to have its greatest effect 
early in the transformation programme.
The long latency period seen between HPV infection and carcinoma in situ 
(CIS) presentation combined with the low frequency of lesions progressing to full 
malignancy implicates additional agents or cofactors in the genesis of cervical cancer. 
Apart from the clear association between cervical cancer and certain HPV infections, 
epidemiological studies have identified other contributory factors which increase the 
risk of malignant conversion; these include age (20-29 years being the age group at 
highest risk), multiple sexual partners/increased sexual activity per week, a history of
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genital warts in the proband or any sexual partner and cigarette smoking (Kataja et a l , 
1993; Syijanen, 1996).
1.5.2.3 Bovine Papillomaviruses
Six separate bovine papillomaviruses have been identified to date. These have 
been divided into two groups, groups A and B (Campo et a l, 1980, 1981; Jarrett et 
a l, 1984). The group A BP Vs include BPV1,2 and 5 while the group B BP Vs 
include BPV3, 4 and 6. Group A BPVs can infect both fibroblast and epithelial cells 
and induce fibropapillomas; Group B BPVs, like HPVs, are purely epitheliotropic in 
nature. Of the six BPVs so far identified, BPVI has been most extensively studied 
and much of the early work on papillomavirus biology was performed using BPV1.
BPV1 infections induce only benign fibropapillomas in cattle. Infection with 
BPV4 and 2 however is associated with the development of alimentary canal cancer 
(Campo et a l, 1994) and urinary bladder cancer (Campo et a l, 1992) respectively in 
the natural host. In both cases, cattle's consumption of bracken fern has been 
identified as a cofactor. Bracken fern is known to contain a selection of biologically 
potent chemicals including mutagens, carcinogens (Evans, I. A. et a l, 1982) and 
immunosuppressants (Evans, W. C .e t a l, 1982) however the exact mechanism of 
synergy between BPV4 or 2 and bracken has not been elucidated. The role of BPV4 
in upper gastrointestinal (GI) tract cancer in cattle appears to differ from that of the 
high-risk genital HPVs 16 and 18. Whereas high-risk HPV DNA has been detected in 
the large majority of cervical tumours and derived cells lines, BPV4 DNA has not 
been detected in naturally occurring cancers in cattle (Campo et a l, 1985). Similarly, 
when bovine palatine tissue was infected with BPV4 in vitro and subsequently placed 
into the renal capsule of nude mice, malignant cells developed. Nevertheless no 
BPV4 DNA was detected in these malignant cells (Gaukroger et a l, 1991).
Therefore, unlike high-risk HPVs, such as types 16 and 18, which persist in cervical 
tumours to malignancy, a 'hit and run' mechanism has been proposed for the 
contribution of BPV4 in upper GI cancer in cattle (Smith and Campo, 1988). BPV4 is 
implicated only in the early stages of transformation and viral DNA is lost as 
subsequent genetic alterations are acquired. BPV4 is apparently not necessary for 
progression to, or maintenance of, the malignant phenotype.
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Papillomavirus infections, apart from having the potential in some cases to 
cause cancer, also produce benign lesions which in their own right can be life 
threatening, as in the case of laryngeal papillomatosis (Steinberg, 1987; Kashima and 
Mounts, 1987; Kashima et a l , 1996), disfiguring and, in individuals with anogenital 
warts, can severely reduce quality of life (Oriel, 1971). There is also increasing 
interest in establishing the role of HPV infection in nonmelanoma skin cancers from 
both normal and immunosuppressed patients (Shamanin et a l , 1996). Infection of 
cattle and horses have agricultural and financial implications (Jarrett, 1985).
Therefore, there are several very serious conditions, including cancer, that justify the 
need for developing methods of controlling and/or preventing papillomavirus 
infections. Strategies for the treatment and control of papillomavirus infections are 
areas which presently attract active research (Kinbauer et a l , 1996; Campo, 1997). 
Nevertheless, in order for such strategies to be optimally successful and efficient, 
researchers require an in-depth understanding of the natural biology of the viruses 
implicated, putative cofactors which synergise with the viruses in the disease process, 
the location of pools of latent virus infection, the pathology of the diseases induced 
and the nature of host immune responses to these infections. The identification of key 
viral transforming genes and analysis of their functions and interactions are areas of 
prime importance.
1.5.3 Papillomavirus Genes and Transformation
Transcription of papillomavirus genes is dependent on both viral and cellular 
transcription factors which can interact with the viral regulatory sequences present in 
the LCR. Both viral El and E2 gene products are necessary for viral replication 
(Lambert, 1991; Yang et a l, 1991). El of BP VI is important for maintenance of the 
viral genome as extrachromosomal episomes (Arends et a l, 1990). The BPV1 E2 
protein can function as a transcriptional transactivator when present as a full length 
molecule or as a repressor in its truncated form (Lambert et a l, 1987). The E2 
proteins from high risk HPVs, such as HPV 18 and 16, in general function as repressor 
proteins (Romanczuk et a l, 1990;). In a large majority of cervical carcinomas and in 
all cell lines derived from cervical cancers, viral DNA has integrated into the host 
genome (Yee et a l, 1985; Durst et a l, 1987a; Popescu et a l, 1987). Integration 
appears to be a random event with viral DNA located at different genomic sites in
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different cancers and cells lines. However the site at which the viral genome is 
disrupted for integration shows remarkable specificity. Integration regularly involves 
cleavage within the E1/E2 region. As a consequence the E2 gene product(s) is either 
lost or altered. As mentioned above, E2 acts primarily as a repressor of transcription 
from the E6/E7 promoter of HPV 16 and 18 which results in the downregulation or 
even ’switching-off of genital HPV expression (Romanczuk et a l, 1990). Loss of E2 
repressor function, as a consequence of integration, may lead to high levels of viral 
gene expression; irregular expression of viral oncongenes E6 and E7 is associated 
with cellular transformation (Vousden, 1994).
Often one of the consequences of viral genome integration is that synthesis of 
the capsid proteins LI and L2 is lost. These structural proteins almost certainly 
contain important epitopes which, if displayed on the outside of the virion, may allow 
host immune systems to recognise virus and virus infected cells. Integration of the 
viral genome therefore may provide a mechanism whereby a virus-infected cell could 
evade recognition by host immune surveillance which previously prevented any 
further progression of a premalignant lesions to carcinoma.
The mechanism for achieving cell transformation is not the same for all 
papillomaviruses. Only the E6 gene product of EV specific HPV8 has transforming 
ability (Iftner et a l, 1988). Generally papillomaviruses express two oncogenes which 
co-operatively achieve transformation. Table 1.1 highlights the oncogenes which 
have been identified in several papillomaviruses.
Table 1.1 Summary of the oncogenes which have been identified in several 
Papillomaviruses
E5 E6 E7 E8
BP VI + +
BPV4 - - + +
CRPV - + + -
HPV16 + + + -
HPV8 - - -
Symbols: + : indicates recognised oncogenes
- : indicates either non-transforming or absent ORF
(Taken from Campo, 1992)
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I.5.3.1 E7
E7 has been identified as one of the major oncogenes present in high-risk 
HPVs including HPV16 and 18 (Bedell et al, 1987; Vousden et al., 1988; Dyson et al, 
1989b; Munger et a l , 1989a; Hudson et al., 1990). Indeed, in BPV4, E7 is the major 
in vitro transforming gene (Pennie et al., 1993). HPV 16 E7 contains a pRb binding 
domain (Munger et al., 1989b), two zinc binding Cys-x-x-Cys motifs (Barbosa et al., 
1989) and casein kinase II (CKII) phosphorylation sites (Barbosa et al., 1990). The 
zinc finger regions of E7 are essential for the transactivating activity of this viral 
oncoprotein (Phelps et al., 1988). The CKII sites are important for transformation by 
HPV 16 E7 but to a lesser extent than the pRb and zinc finger binding domains 
(Barbosa et a l, 1990; Storey et a l, 1990). The E7 proteins of BP VI and HPV8 
contain neither Rb-binding or CKII sites and are consequently non-transforming 
(Iftner et a l, 1990); BPV4 E7 is transforming however it does not possess a CKII 
phosphorylation site (Jackson et a l, 1996).
pRb, an important tumour suppressor gene product, when bound to E7 cannot 
interact with its natural target, namely E2F (Chellappan et a l, 1992; Morris et a l, 
1993). The ability of HPV E7 to interact with pRb, which can lead to inappropriate 
DNA synthesis, RNA expression and cell proliferation, is proposed as the major 
mechanism by which E7 contributes to cellular transformation. This is supported by 
the observation that the E7 proteins encoded by low risk genital HPV, like HPV6 and
II, bind pRb with a much lower affinity than high-risk HPV types 16 or 18 and this 
activity correlates with transforming potential (Munger et a l, 1991). BPV4 E7 also 
contains the pRb binding region (Jackson et a l,  1991) however it has not yet been 
determined if it can bind the pRb protein. Experiments are currently underway to 
address this question.
Work by Jewers et al (1992) has shown that, in the context of the whole 
HPV 16 genome, binding of pRb by E7 is not necessary for the immortalisation of 
primary human keratinocytes. Instead, immortalisation has been linked to one of the 
Cys-x-x-Cys motifs in the C-terminus of E7. These results suggest that the ability of 
E7 to induce immortalisation in human primary keratinocytes is independent of its 
ability to bind pRb.
27
It is very likely that E7's interaction with pRb is not the only function of this 
viral protein in transformation. Indeed, E7 has been shown to associate with several 
other proteins including the Rb-related protein, p i07 (Davis et a l, 1993), cyclin A and 
the protein kinase p33CDK2 (Tommasino et a l, 1993) and members of the API family 
including c-Jun, JunB JunD and c-Fos (Antinore et a l, 1996). The significance of 
these interactions with E7 in relation to cellular transformation is at present unclear. 
The induction of chromosomal abnormalities, whether dependent on the disruption of 
normal pRb function or not, is another interesting feature of E7 from high-risk genital 
HPVs (Hashida and Yasumoto, 1991; White et a l, 1994).
1.5.3.2 E6
Mutation in p53, whilst commonly detected in a wide range of cancers, is 
rarely detected in cancers of the cervix (Fujita et a l, 1992; Busby-Earle et a l, 1994). 
This is attributed to the ability of a viral gene, E6, to bind p53 and effectively disrupt 
its function, negating the need for further inactivation by mutation. The E6 open 
reading frame (ORF) is present in all PVs isolated to date except the group B BPVs 
(BPV3, 4 and 6)(Jackson et a l, 1991). E6 has been shown not only to bind p53 but 
also to target the cell cycle regulator and tumour suppressor protein for ubiquitin- 
mediated degradation (Scheffiier et a l, 1990; Lechner and Laimins, 1994). E6 
proteins from high-risk HPVs have a greater affinity for p53 compared to low-risk 
HPVs (Lechner and Laimins, 1994); low risk HPV E6 proteins also show no clear 
degradative activity compared to high-risk HPV E6 proteins (Scheffher et a l, 1990). 
This variation in affinity and degradative potential of different E6 proteins for p53 
may partially explain the differences in oncogenic potential seen between HPV types. 
Other viral proteins, including SV40 large T and adenovirus E1B, have been shown to 
form stable complexes with p53 yet neither protein results in the ubiquitin-linked 
degradation of p53; SV40 large T and adenovirus E1B proteins however increase the 
half-life of the p53 protein. Unlike papillomaviruses, adenovirus or SV40 have not 
been linked to any form of cancer in their natural hosts.
The ability of E6 to lead to the degradation of p53 appears to be a crucial extra 
function of this viral oncoprotein in transformation. While binding of p53 can 
abrogate its activities of DNA binding and transcriptional transactivation/ 
transrepression (Lechner et a l, 1992; Lechner et a l, 1994; Crook et a l, 1994),
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degradation of the protein has been shown necessary to abrogate p53 induced GI 
arrest (Foster et al., 1994; Slebos et al., 1995) and establish resistance to p53 mediated 
apoptosis (Haupt et al., 1995). The E6 domains involved in binding p53 and targeting 
p53 for degradation are separate suggesting that the two functions of E6 are 
independent (Crook et al., 1991; Thomas et al., 1995; Mansur et a l , 1995).
The interaction of E6 with p53 is undoubtedly central to its role in 
transformation however other roles for E6 in transformation have been suggested. In 
work by Linda Scobie (unpublished results), introduction of HPV 16 E6 into p53 null 
mouse fibroblasts was shown to confer immortality. Work by Pirn and colleagues 
(Pirn et al., 1994) also demonstrated that the ability of E6 to immortalise primary 
mouse fibroblasts was independent of its interaction with p53. The ability of E6 to act 
as a repressor (Etscheid et al., 1994) and/or activator of transcription (Akutsu et al.,
1996) has also been shown to be independent of p53. Several other proteins have 
been shown to interact with E6, in particular E6BP, a calcium binding protein which 
appears to associate only with high-risk E6 proteins (Chen et al., 1995), however the 
significance of any of these interactions in relation to cellular transformation has not 
as yet been determined. An interesting observation is that while E6 is the main 
oncogene in EV-associated HPV8, no complex formation has been detected between 
the HPV8 E6 protein and cellular p53 (Steger and Pfister, 1992). This suggests that 
E6 proteins from separate HPV types employ different strategies of achieving cellular 
transformation.
The disruption of p53 activities by high-risk HPV E6 appears to be important 
in the early stages of tumorigenesis only (Crook and Vousden, 1996). This correlates 
well with the model that HPV infection contributes most significantly to the initiation 
of the carcinogenic process while playing a less critical role in the progression to or 
maintenance of the malignant phenotype. Like E7, expression of E6 has been shown 
to generate genomic instability, presumably through its disruption of p53 functions 
(White et al., 1994). Perhaps the generation of genomic instability, through the 
deregulation of proliferation, is the single most critical contribution of papillomavirus 
infection to neoplastic transformation.
Other functions of E6 which have been reported and can be associated with 
cellular transformation include the inhibition of differentiation in human keratinocytes 
(Sherman and Schlegel, 1996) and the activation of telomerase (Klingelhutz et al.,
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1996); telomerase activation is associated with cell immortalisation and can be 
detected in a majority of cell lines and tumours.
As mentioned above, the group B BPVs including BPV4 do not possess an E6 
ORF. Despite the contributions of E6 to transformation observed for other 
papillomaviruses, it is evident that cellular transformation can be achieved by BPV4 
without the actions of E6. It has not been determined if other viral proteins encoded 
by BPV4 can substitute for the absence of E6 or indeed if E6 functions are not 
necessary for transformation by BPV. It has been shown however that E6 provides 
additional functions not supplied by the other BPV4 viral oncoproteins, E7 and E8, as 
HPV 16 E6 can confer immortality on primary bovine palate fibroblasts (PalF cells) in 
the presence of BPV4 E7 and ras with or without BPV4 E8 (Pennie et al., 1993).
1.5.3.3 E5
E5 from BPV1 (DiMaio et al., 1986; Schiller et al., 1986; Schlegel et a l ,
1986) and HPV 16 (Bouvard et al., 1994; Valle and Banks, 1995) among others have 
been shown to possess transforming potential, although BPV1 E5 is more strikingly 
transforming compared to HPV16 E5.
BPV1 E5 can activate membrane receptors such as EGF and PDGF (Martin et 
al., 1989; Petti et al., 1991); this has been attributed to the ability of BP VI E5 to bind 
and stimulate phosphorylation of the PDGF (Petti DiMaio, 1992; Cohen et al., 1993) 
and EGF receptors (Cohen et al., 1993). BPV1 E5 also binds the cellular protein 16K 
ductin which is a constituent of gap junctions and vacuolar ATPases (Goldstein and 
Schlegel, 1990; Goldstein et al., 1991). Complex formation between E5 and 16K of 
vacuolar ATPases may result in altered intercellular pH which favours prolonged 
ligand-receptor interaction. Thus a receptor would be actively signalling for longer 
which may contribute to cellular transformation. Furthermore, by interfering with 
16K ductin of gap junctions, effective cell-cell communication may be reduced 
sufficiently for the E5 expressing cell to escape proliferative control signals provided 
by neighbouring cells (Campo, 1992).
The transforming functions of E5 appear to be more complex than its direct 
activation of particular growth factor receptors and inhibition of receptor 
downregulation via its interaction with the ductin component of vacuolar H+-ATPase. 
Recent experiments have shown that mutations within the transmembrane region of
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E5, while maintaining the ability of E5 to complex ductin, renders the protein non­
transforming (Sparkowski et al., 1996). In addition, BPV1 E5 retained in the 
endoplasmic reticulum can still induce autophosphorylation of the PDGF receptor but 
is no longer able to transform cells (Sparkowski et a l, 1995).
The HPV16 E5 gene, unlike HPV16 E6 and E7, is generally lost in advanced 
carcinomas often as a consequence of viral integration. Hence E5 appears not to play 
a role in the conversion of HPV transformed cells to a fully malignant phenotype. 
Nevertheless, E5 may play a significant role in the early stages of carcinogenesis 
perhaps principally by increasing the cell’s responsiveness to particular growth factors 
and/or making cells less responsive to the regulatory effects of neighbouring cells 
through the downregulation of intercellular gap junctional communication.
1.5.3.4 BPV4E8
BPV4 does not possess an E6 ORF. There is however a small ORF upstream 
of the E7 ORF designated E8. The E8 peptide is homologous to BPV1 E5 in that it is 
very hydrophobic with a high leucine content (Jackson et a l, 1991). It encodes a 
polypeptide 42 residues in length and is found in Golgi and endoplasmic reticulum 
(ER) membranes of transformed cells; occasionally E8 has been detected in the 
plasma membrane (Campo, 1992; Pennie et a l, 1993). E8 is a true early protein being 
expressed in the basal and suprabasal layers of a papilloma and at early stages of 
tumour development (Anderson et a l, 1997); E8 is not detected in areas of vegetative 
viral DNA replication and expression levels are decreased in late stage papillomas 
{ibid.). Over-expression of E8 plus activated ras alone is lethal to PalF cells in vitro 
(Campo, 1992) but when co-expressed with E7 or expressed within the context of the 
whole BPV4 genome induces anchorage-independent growth (Pennie et a l,  1993).
E8, like BPV1 E5, can complex with 16K ductin in vitro. Furthermore E8 expressing 
cells show significant loss of gap junction intercellular communication (Faccini et a l,
1996). It is still unclear if E8 binds gap junctions or H+-ATPases or both in vivo. The 
precise mechanism by which E8 contributes to cell transformation is not fully 
understood.
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1.5.4 Transcriptional regulation of viral genes
The long control region (LCR) is the least conserved region between different 
papillomavirus genomes, however different LCRs share a general level of organisation 
in that each possess a promoter and tissue specific enhancer. Analysis of several 
papillomavirus LCRs has identified binding sites for numerous regulatory factors, 
both viral and cellular in origin, which are arranged in a complex modular structure. 
Cellular factors which bind and modulate papillomavirus gene expression include 
AP-1 (Offord et a l, 1990,1993; Mack and Laimins et al., 1991; Thierry et a l, 1992), 
Spl (Dong e ta l,  1994; Tan et al, 1992,1994), NF-l/CTF (Gloss e ta l,  1989a, 1989b; 
Apt et a l, 1993), Oct-1 (Chong et a l, 1991; Sibbet et a l, 1995), PVF and NFA 
(Chong et a l, 1990), TEF (Ishiji et a l, 1992), KRF-1 (Mack and Laimins, 1991), 
glucocorticoid and progesterone response elements (Chan et a l, 1989), PEF-1 (Cuthill 
et a l, 1993; Sibbet et a l, 1995), PEBP2 (Jackson and Campo, 1995) and C/EBP 
(McCaffery and Jackson, 1994; Aubom et a l, 1991). Not all the cellular factors 
identified above bind each LCR from every papillomavirus.
In addition to the number and range of transcription factor binding sites, their 
arrangement is such that many of the elements are closely spaced, and in some cases 
they even overlap. The location of the various binding sites in relation to one another 
suggests that the regulation of viral transcription may involve competition and/or co­
operation between the different transcription factors.
Papillomaviruses exhibit an extremely limited host cell range. One way in 
which gene expression can be limited to a particular cell or tissue type is by virtue of a 
factor or factors which are present exclusively in the target tissue, such as MyoD in 
striated muscle (Weintruab et a l, 1991). While papillomavirus gene expression is 
limited to epithelial cells, no such epithelial-specific factor has, as yet, been identified. 
The nuclear factors which have been shown to bind to the various papillomavirus 
LCRs, including AP-1, NF-1 and Oct-1, are generally ubiquitous proteins and thus 
cannot explain the tissue specific nature of papillomavirus gene expression.
Tissue specificity may be achieved by regulatory factors of partial or low cell 
specificity, depending on the combination of factors binding to the LCR at any one 
particular time. It is known that the range of genes expressed can change as a cell 
differentiates. The vegetative life cycle of papillomaviruses is closely coupled to the 
differentiation program of keratinocytes therefore the temporal expression of
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particular transcription factors may be an important aspect of papillomavirus 
transcriptional regulation. Alternatively, the stability of a particular protein may be 
variable in different cell types. Indeed, API proteins levels have been shown to be 
higher and more stable in keratinocytes compared to fibroblast cells (Offord et a l , 
1993).
Another way in which gene transcription can be limited to a specific cell type 
is through the action of co-activator proteins. In a series of experiments by Ishiji et al 
(1992), it was demonstrated that the HPV16 E6 and E7 promoter can be activated by 
TEF-1 only in the presence of a co-activator protein. However, the cell specificity 
displayed by HPV16 is more restricted than that of TEF-1 and its associated co- 
activator indicating that this interaction only partially contributes to the complex 
mechanism which regulates viral transcription.
In low grade cervical lesions, HPV DNA is generally present as episomes and 
a wide spectrum of viral early genes are expressed (Durst et al., 1985). In high grade 
CIN and cervical carcinomas, and in cell lines derived from cervical cancers, the viral 
DNA is frequently found integrated into the host cell genome (Durst et al., 1985; 
Schwarz et al., 1985) and only the E6 and E7 ORFs are expressed at high levels 
(Schwarz et a l , 1985; Pater and Pater, 1985; Baker et a l , 1987). While the site of 
integration within the host genome is random, disruption of the HPV genome within 
the El or E2 ORF is common.
Papillomavirus LCRs contain multiple binding sites for the viral DNA-binding 
protein E2. The E2 ORF can encode a full length or truncated form of the protein.
The full length E2 protein has been shown to possess transcriptional transactivating 
activity (Spalholz et a l , 1985; Cripe et a l , 1987; Lees et a l , 1990) whereas the 
truncated protein, which lacks the N-terminal transactivation domain, functions as a 
repressor of transcription (Cripe et a l , 1987; Chin et a l , 1988; Thierry and Yaniv, 
1987; Romanczuk et a l , 1990; Dong et a l, 1994; Jackson and Campo, 1995). 
Integration into the cellular genome is often accompanied by the loss, disruption or 
inactivation of the E2 ORF (Schneider-Gadicke and Schwarz, 1986; Smotkin and 
Wettstein, 1986; Baker et a l, 1987; Cullen et a l, 1991). Loss of E2 repressor activity 
has been linked to the unregulated expression of the transforming viral early genes, E6 
and E7. Therefore loss of E2 functions could represent an important event in the 
progression to invasive carcinoma.
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1.5.5 Co-operation with Cellular Genes to Achieve Transformation
The expression of the E6 and E7 ORFs from high-risk HPV types has been 
shown necessary and sufficient to transform and immortalise human keratinocytes and 
fibroblast cells in vitro (Durst et a l, 1987b; Pirisi et a l, 1987; Munger et a l, 1989a; 
Kaur and McDougall, 1989). Nevertheless, such cells are not tumorigenic when 
transplanted into nude mice {ibid.). Tumorigenicity is only achieved when these cells 
are grown for long periods in culture (Kaur and McDougall, 1989; Hurlin et a l, 1991) 
or additional activated oncogenes, such as ras, are cotransfected (Durst et a l, 1989; 
DiPaolo et a l, 1989; Schneider et a l, 1991). Co-operation between virus and cellular 
genes in the attainment of a fully transformed phenotype is consistent with the 
observation that papillomavirus infection alone in insufficient to induce a malignant 
state (zur Hausen, 1991a) and indeed that carcinogenesis is a multistep process.
Cytogenetic analysis of HPV-associated lesions have identified a correlation 
between grade of lesion and the severity of genetic change. Low grade, preinvasive 
cervical lesions (CINI and/or II) in general possess apparently normal, diploid 
genomes compared to high grade (CIN El) and cancerous lesions which more often 
display chromosomal anomalies including aneuploidy (Kirkland et a l, 1967, 1970). 
No one specific chromosomal abnormality or rearrangement has been consistently or 
exclusively identified in cervical cancers in association with HPV infection, however 
several chromosomes have been implicated including chromosomes 1, 3, 4, 6, 11, 13, 
17, 18 and 21 (for reviews see DiPaolo et a l, 1993; Stanley and Sarkar, 1996). Of 
these, aberrations involving chromosome 1 have been reported most frequently (Atkin 
and Baker, 1977, 1979, 1982; Sreekantaiah et a l , 1988) however genetic changes in 
chromosome 1 are also very common in other solid epithelial tumours (Rodriguez et 
a l, 1994).
Loss of a whole chromosome or chromosome region in cancer progression 
generally indicates the presence of a putative tumour suppressor gene. Allelic 
deletions involving regions of chromosomes 3 and 11, among others, have been 
implicated in cervical carcinogenesis. The transfer of a single chromosome 11 into 
the immortal cervical cancer cell line HeLa lead to a loss of tumorigenic potential as 
determined in nude mouse assays (Saxon et a l, 1986). This result, in combination 
with several other studies (Koi et a l, 1989; Hampton et a l, 1994), not only support 
the existence of a tumour suppressor gene on the long arm of chromosome 11 but
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further suggest that loss of this chromosome region is a late event in cervical cancer 
and is associated with the acquisition of a tumorigenic phenotype.
A deletion of 1 lp induced anchorage independence in embryonic human 
fibroblasts (Smits et a l , 1988). The transcriptional activity of HPV 16 was 
subsequently shown to be greater in cells which carry a deletion of loci on 
chromosome 1 lp (Smits et a l , 1993) which has been associated with the loss of 
transcriptional repressor proteins that bind the TATAA motif in the viral promoter.
At present however there is no strong evidence supporting the existence of a tumour 
suppressor gene on 1 lp.
Loss of heterozygosity in cervical carcinomas has also been detected at loci on 
chromosome 3 at relatively high frequency (Kohno et a l, 1993). Alterations of 
chromosome 3 including deletions and rearrangements are often found in primary 
cervical cancers and HPV transformed cell lines indicating that genes relevant to the 
development of cervical cancer are located on the short arm of chromosome 3. Loci 
on chromosome 3p however appear not to be specifically associated with cervical 
cancer development as similar deletions have been reported in other epithelial cancers 
(Rodriguez et a l, 1994).
The activation of specific oncogenes in the genesis of cervical cancer has not 
been extensively characterised. c-Ha-ras mutations have been detected in naturally 
occurring alimentary canal cancer in cattle which are believed to have arisen from 
BPV4 induced lesions (Campo and Jarrett, 1987). Mutations in c-H-ras have been 
reported in association with late stage cervical cancers (Riou et a l, 1985, 1988). 
Furthermore, in some cervical cancers carrying mutations in ras, high levels of c-myc 
expression were concomitantly detected (Riou et a l, 1985). The amplification and 
over-expression of c-myc has been associated with recurrent disease and progression 
to malignancy in vivo (Ocadiz et a l, 1987; Riou et a l, 1987). Integration of HPV 
near c-myc has also been reported in cervical cancers (Couturier et a l, 1991) and 
amplification of cellular sequences adjacent to the site of HPV integration has been 
observed in several cases (Lazo et a l, 1989; Wagatsuma et a l, 1990).
Amplification and overexpression of c-myc has been detected in HPV 16 
transformed rodent cells (Crook et a l, 1989) and a HPV 16 immortalised human 
keratinocyte cell line (Crook et a l, 1990) in vitro. In certain cell lines, integration of 
HPV DNA has been identified at a locus close to c-myc; the deregulation of c-myc in
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these cells lines may be a consequence of local HPV integration (Durst et a l, 1987a; 
Popescu et al., 1987). In vitro, an activated ras gene is necessary for BPV4 to induce 
morphological changes and anchorage independent growth in primary foetal bovine 
palate fibroblast cells (PalF cells)(Jaggar et al., 1990; Pennie and Campo, 1992).
HPV 16 was shown to co-operate with a v-fos gene in the transformation of primary 
mouse epithelial cells however these cells were dependent on glucocorticoid 
hormones for proliferation (Crook et al., 1989).
As mentioned earlier, analysis of cervical cancer tissue, cell lines derived from 
cervical cancers or HPV transformed cells lines has not revealed highly consistent or 
characteristic genetic aberrations. This is in contrast to colorectal cancer in which a 
number of defined mutations in both proto-oncogenes and tumour suppressor genes 
have been characterised. Karyotype analysis of HPV transformed cell lines, for 
example, as outlined above has revealed complex and variable profiles regardless of 
the HPV type used (Durst et al., 1987b; Smith et al., 1989; Popescu et a l , 1990;
Gilles et a l , 1993). This may be a reflection of the overall genetic instability 
generated by the expression of the viral oncoproteins E6 and E7. Papillomavirus 
infection is considered to be an initiation event occurring early in cervical 
carcinogenesis. The establishment of genetic instability as a consequence of viral 
infection thus generates an environment in which a range of genetic changes are more 
likely to occur (White et a l, 1994), ultimately leading to continued cellular 
transformation and progression to malignancy. It is clear however that an 
accumulation of genetic changes, which can involve a wide range of different gene 
combinations, is required for papillomavirus transformed cells to progress to 
malignancy.
1.6 Bovine Papilloma Virus type-4 (BPV4)
Animal model systems can be used to increase our understanding of similar 
processes occurring in human diseases, such as cervical cancer. There are many 
aspects of a BPV4 infection which make it an ideal animal model system for studying 
papillomavirus-associated carcinogenesis. BPV4 infects the mucous epithelium of the 
upper gastrointestinal tract in cattle and induces papillomatosis (Jarrett et a l, 1978a; 
Campo et a l, 1980). Like HPV 16 and 18 infections in humans, BPV4 infection is 
associated with the development of cancer in its natural host. Also like humans, cattle
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are large, long lived animals. The major advantage of the BPV4-cattle system is that, 
unlike humans, cattle are amenable to experimental manipulations. This provides an 
opportunity to identify putative cofactors which can synergise with the virus to induce 
cancer. Furthermore, it facilitates the efficacy of novel therapeutic and/or prophylactic 
vaccines to be assessed (Kinbauer et a l , 1996; Campo 1997).
There are however two major difference between BPV4 and the high-risk 
human papillomaviruses, such as HPV16 and 18; in HPV induced cervical carcinomas 
the viral DNA is generally retained whereas in BPV4 associated cancers the viral 
DNA is not detected (Campo et a l , 1985; Gaukroger et a l, 1991). Also, the E6 ORF, 
which is one of the two transforming genes in high-risk HPV, is not present in the 
BPV4 genome (Jackson et a l, 1991) suggesting that the mechanisms of 
transformation by these viruses are quite different.
Despite the differences between BPV4 and high-risk HPVs , BPV4 remains 
one of only a few papillomaviruses which is associated with cancer in its natural host. 
Indeed, the unique ability of BPV4 to induce cancer in the absence of the powerful 
transforming E6 gene is perhaps one of the most intriguing features of this particular 
papillomavirus. BPV4 alone is a poorly transforming virus and the carcinogenic 
potential of BPV4 is only realised in the presence of potent cofactors, such as bracken 
fern (Campo et a l, 1994) which will be discussed further in section 1.7.1.
1.6.1 Genome Structure
BPV4 is one of the smallest papillomaviruses isolated to date possessing a 
genome only 7265 nucleotides in length. The general structure of the BPV4 genome 
however is very similar to that of other papillomaviruses, as is illustrated in Figure 
1.1. It comprises a series of early and late ORFs in addition to a non-coding LCR. 
Some of the properties of the various ORF in BPV4 have been discussed earlier in 
section 1.5.3. T
The BPV4 genome possess eleven separate ORFs, however two of the eleven 
ORFs, E3 and E5, contain no ATG and are therefore suspected of having no function. 
The ORFs are divided into the early and late genes, accounting for the 'E' or 'L' prefix. 
There are three polyadenylation sites within the BPV4 genome located at nucleotides 
4004, 7155 and 7191.
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Figure 1.1
Figure 1.1 Genetic Maps of three papillomaviruses
The figure compares the genetic maps of three papillomaviruses - BPV1, BPV4 and 
HPV 18. The genomic organisation of each virus was deduced from their primary 
DNA sequence.
Each genome is displayed in a linear fashion. The various open reading frames 
(ORFs) of the early (E) and late (L) regions are indicated. The dotted vertical line in 
each ORF represents the first ATG codon. ORFs without an ATG codon are shown as 
thin-lined boxes
The LCR extends continuously from the end of the LI ORF through to the beginning 
of the E6 ORF in each viral genome.
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Transcription of the early genes terminates at the 4004 polyadenylation (polyA) site 
whereas the late gene transcripts terminate at either of the two remaining polyA sites. 
In common with other papillomaviruses, mRNA molecules are generated by a series 
of complex splicing events between ORFs (Smith et a l, 1986; Stamps and Campo, 
1988).
The El ORF is transcribed into a number of separate mRNAs however the 
function(s) of any of these transcripts has not yet been determined. The BPV4 El 
ORF shows a high degree of homology with El ORFs from other papillomaviruses, 
such as BP VI E l, suggesting that this protein plays a role in the replication of viral 
DNA (Lambert, 1991).
Similar to the El ORF, the E4 ORF gives rise to several mRNA molecules. 
Two of the transcripts, 7E11 and a 1.6Kb transcript, encode E1-E4 fusion proteins, 
although the two proteins utilise different regions of El. The exact function of E4 has 
not been elucidated however its expression is greatest in the differentiating layers of 
papillomas (Anderson et al., 1997). This coincides with productive viral DNA 
replication (Campo et a l, 1994). A similar pattern of expression has been 
demonstrated for HPV1 E4 (Breitburd et a l, 1987) and this E1-E4 fusion protein has 
been shown to alter cytokeratin assembly (Doorbar et a l, 1990). The BPV4 7E11 
transcript may fulfil a similar function and by interfering with normal epithelial 
differentiation may in some way contribute to BPV4 virion production.
Transcripts corresponding to the full length BPV4 E2 ORF have so far not 
been identified. A smaller unspliced transcript, that relates only to the 3' portion of 
the E2 and E4 ORFs, possibly represents an N-terminal truncated form of E2; N- 
terminal truncated E2 proteins have been shown to function primarily as repressors of 
transcription in other systems (Cripe et a l, 1987; Lambert et a l, 1987; Chin et a l, 
1988; Thierry and Yaniv, 1987; Romanczuk et a l, 1990; Dong et a l, 1994; Jackson 
and Campo, 1995). The role of E2 in the autoregulation of BPV4 transcription is 
discussed fully in section 1.6.2.
E7 and E8 have been identified as the primary transforming genes of BPV4 
(see sections 1.5.3.1 and 1.5.3.4). BPV4 E7 is homologous to other E7 proteins from 
high-risk HPVs, such as HPV 16 E7 (Jaggar et a l, 1990; Jackson et a l, 1991). It 
contains two Cys-x-x-Cys zinc-binding motifs and a putative Rb-binding domain; the 
Rb-binding domain has not yet been shown to functionally bind pRb. Deletion of the
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3' terminal third of the BPV4 E7 ORF, which includes one of the two Cys-x-x-Cys 
domains (Jaggar et a l , 1990), or mutations in the Cys-x-x-Cys or Rb-binding motif, 
have all been shown to abolish the protein's transforming potential in vitro (Jackson et 
a l , 1996). The structural and functional characteristics of BPV4 E8, as detailed in 
section 1.5.3.4, suggest that E8 may transform cells in a way analogous to that of 
BP VI E5. The effects of E7 and E8 on the transformation of established and primary 
cells is outlined in sections 1.6.3 and 1.6.4.
There are four late ORFs, numbered LI to L4. LI and L2 are the main 
structural proteins of the BPV4 capsid; LI is the major capsid protein and L2 is the 
minor protein. Two related transcripts, 2.8kb and 4.2kb, have been identified. The 
2.8kb transcript encodes the LI protein and the 4.2kb transcript has the capacity to 
encode the LI and L2 proteins. The two remaining late ORFs, L3 and L4, each 
possess an ATG start codon, however their function in relation to BPV4 replication or 
virion assembly has not been determined.
1.6.2 Long Control Region (LCR)
DNasel footprinting of the BPV4 LCR revealed 16 sites where nuclease 
digestion was prevented by the binding of nuclear factors (Jackson and Campo, 1991). 
Figure 1.2 is a schematic illustration of the putative nuclear factor binding sites and 
various control elements which have been identified within the BPV4 LCR. Among 
these sites are three consensus E2 binding sites - E2(l), E2(2) and E2(4). In addition 
to the three consensus sites, a fourth degenerative E2 site, called E2(3), which differs 
from the consensus E2 binding mofit at one nucleotide only, has been identified 
(Jackson and Campo, 1991). E2(l) has been associated with E2 mediated 
transactivation. E2(4) is the main binding site for E2 functioning as a repressor. This 
E2 site is located immediately upstream of the TATA box in the viral promoter. 
Binding of E2 to the E2(4) site may prevent binding of proteins involved in the 
initiation of transcription thus preventing or repressing viral transcription.
E2(2) is an important cis-regulatory element in the BPV4 LCR which may 
bind several cellular nuclear factors, including PEBP2, in addition to viral E2 
(Jackson and Campo, 1995). Indeed, PEBP2 was shown to bind within the E2(2) site 
in EMSA (ibid). In view of the PEBP2 binding motif being located within the E2(2), 
PEBP2 and E2 would be expected to compete for binding to the E2(2) site.
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Figure 1.2
Figure 1.2 Schematic representation of the BPV4 LCR showing the positions of 
several transcription factor binding sites and positive and negative regulatory 
elements
The BPV4 LCR (nucleotides 6710-331) maps between the 3’ end of the LI ORF and 
the 5’ end of the E8 ORF.
CE1-3 are positive transcription regulatory elements and NR 1-3 are the negative 
elements.
The in vitro footprints, identifying binding sites for regulatory factors, are indicated in 
relation to the negative and positive cw-elements (for details, see Jackson and Campo,
1991).
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Other cellular factors in addition to E2 and PEBP2 are suspected of binding to this 
region of the LCR. Deletion or mutation of sequences at this site have resulted in a 60 
to 85% drop in LCR activity (Jackson and Campo, 1991, 1995).
The four E2 binding sites within the BPV4 LCR display differential affinity 
for E2; E2(l) and E2(2) formed more stable complexes with oligonucleotides 
containing the E2 binding motif compared to E2(3) and E2(4). The arrangement of 
the E2 sites along the BPV4 LCR is comparable with the location of E2 sites of other 
mucosal papillomaviruses, particularly the positioning of the two E2 site adjacent to 
the TATA box (Tan et al., 1992,1994; Dong et al., 1994). Depending on the cellular 
concentrations of the E2 protein, the activity of the LCR can be stimulated or 
inhibited; at low concentrations of E2, the protein occupies the E2(l) site primarily 
and the LCR is transactivated. As the level of E2 protein increases the other E2 sites 
become occupied, positive transcription factors, such as PEBP2 or the transcription 
initiation machinery which bind the TATA box, become displaced or are prevented 
from binding and the activity of the LCR is repressed (Jackson and Campo, 1995).
Another interesting observation was that when all four E2 binding sites were 
mutated and E2 binding within the LCR was apparently abolished, BPV4 E2 was still 
capable of inducing a twofold increase in LCR activity (Jackson and Campo, 1995). 
Such transcriptional transactivation, independent of DNA binding, has also been 
reported for BPV1 E2 (Haugen et al., 1988) however the mechanism of how E2 
achieves this is unknown.
In addition to the E2 binding sites, several E2-independent regulatory 
elements, both positive and negative, have been mapped along the LCR. These cis- 
acting elements are arranged in such a way that each positive element is paired closely 
with a negative element (see figure 1.2). The pairing of positive and negative 
elements along the LCR reflects the complex yet highly ordered and regulated nature 
of BPV4 transcription.
1.6.3 Work in Established Cells
BPV4 has been identified as the aetiological agent of papillomatosis in the 
upper alimentary canal of cattle (Jarrett et al., 1978a; Campo et al., 1980). BPV4 
induced lesions are, in general, benign papillomas which eventually regress 
spontaneously (Jarrett, 1985). In bracken-grazing cattle however, the level and
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persistence of BPV4 induced papillomatosis is more widespread when compared to 
animals which have not been exposed to bracken. Furthermore, animals infected with 
BPV4 and grazing on a diet which contains bracken fern are at high risk of developing 
squamous cell carcinomas within the areas of papillomatosis (Jarrett et a l, 1978b). 
The synergism between BPV4 and bracken in the induction of upper GI tract cancer in 
cattle has been reproduced experimentally (Campo et a l, 1994) and is discussed fully 
in section 1.7.1.
In an attempt to characterise the transforming properties of BPV4, established 
mouse fibroblast cell lines, in particular NIH3T3 cells and a sub-line of C l27 cells 
(C127sc), were transfected with the whole BPV4 genome in vitro. BPV4 was 
demonstrated to transform both cell lines in vitro and several of the subclones 
generated were further capable of inducing tumours when implanted into nude mice 
(Campo and Spandidos, 1983; Smith and Campo, 1988).
Transformation of C l27 cells was however dependent on a number of 
experimental parameters. For example, cells had to be grown either at low density or 
in the presence of the tumour promoting agent, TP A, for cells to be morphologically 
transformed by BPV4. The dependence on low cell density or TP A, which is known 
to disrupt intercellular communication (Murray and Fitzgerald, 1979; Yotti et a l, 
1979), suggests transformation may be prevented by inhibitory effects of neighbouring 
cells (Smith and Campo, 1988). High serum levels in the culture medium also 
contributed to a higher focus frequency as compared to low serum levels (ibid.); 
growth factors in the serum have been postulated as allowing expression of the 
transformed phenotype.
Finally, the physical state of the viral DNA transfected into Cl 27 cells 
significantly affected the level of transformation achieved; a circular BPV4 genome 
was unable to fully transform C l27 cells unlike a linear or fragmented genome. This 
suggests that repressor functions of the BPV4 genome are lost or disrupted when the 
genome is linearised or fragmented. Indeed, integration of HPV DNA into the host 
cell genome, as observed in many cervical cancers, is often accompanied by loss of 
the E2 repressor protein (Cripe et a l, 1987; Dong et a l, 1994; Jackson and Campo, 
1995). Alternatively, deletion of negative elements, several of which have been 
identified within the BPV4 LCR (Jackson and Campo, 1991; McCaffery and Jackson,
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1994) may lead to enhanced transformation potential by the remaining BPV4 
sequences.
A small viral fragment which contained the E7 and E8 ORFs was shown to 
retain the ability to transform C l27 cells (Smith and Campo, 1988). This was the first 
indication that E7 and E8 were the main transforming proteins of BPV4. Recent work 
on the specific role of E8 in cellular transformation has shown that, while E8 is only 
weakly transforming when expressed alone in established rodent fibroblasts, cells 
were capable of anchorage independent growth in semi-solid medium (O'Brien, V., 
unpublished results). Confirmation of E7 and E8’s role in cellular transformation was 
obtained from subsequent transfection experiments performed in primary cells (see 
section 1.6.4).
An important observation from these early in vitro experiments was that viral 
DNA was generally absent in fully transformed C l27 cell lines. Out of 60 cell lines 
analysed, only nine had retained BPV4 DNA (Smith and Campo, 1988); it was 
apparent that BPV4 DNA was progressively lost the longer cells were cultured in 
vitro. Even in the minority of cell lines which retained BPV4, viral sequences were 
not expressed (Smith and Campo, unpublished data). These results reflect the 
mechanism of transformation by BPV4 in vivo where viral DNA is only rarely 
detected in carcinomas (Campo et a l, 1985). Therefore, not only is the in vitro 
transformation of established mouse fibroblasts consistent with BPV4 transformation 
in vivo (Campo et a l, 1985), these results indicate that BPV4 gene expression is not 
required for maintenance of the malignant phenotype. The absence of viral DNA 
from cancerous lesions has so far only been reported for BPV4.
1.6.4 Work in Primary Cells
BPV4 is a weakly transforming papillomavirus. Unlike high-risk HP Vs such 
as HPV 16 or 18, which individually and alone can immortalise primary epithelial cells 
(Woodworth et a l, 1989), BPV4 can only morphologically transform primary 
fibroblast in association with another activated oncogene, such as ras (Jaggar et a l, 
1990). This is in keeping with transformation by BPV4 in vivo where cofactors, in 
addition to virus infection, are necessary for the generation of a malignant phenotype 
(Jarrett et a l, 1978b).
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In an attempt to establish an experimental system which provides a more 
accurate representation of the papillomavirus-host cell interaction in vivo, BPV4 was 
transfected, in vitro, into primary fibroblasts cells which had been explanted from the 
soft palate of a bovine foetus (PalF cells) (Jaggar et a l , 1990). Unlike established 
cells which empirically possess certain characteristics of transformation, primary PalF 
cells are behaviourally and genetically more similar to the virus' target cells in vivo. 
Furthermore PalF cells are derived from the species and anatomical site which BPV4 
infects naturally. PalF cells however are not the natural host cell of BPV4. 
Nevertheless, transfection experiments using PalF cells, as detailed below, have 
supplied very interesting and informative results about the transforming potentials of 
the complete BPV4 genome and individual BPV4 ORFs.
PalF cells transfected with BPV4 alone are non-transformed (Jaggar et al., 
1990). When PalF cells are transfected with BPV4 in the presence of an activated ras 
gene, the cells are morphologically transformed, have an extended life span and can 
grow in methocel, independent of anchorage (Pennie et al., 1993). These cells 
however are not immortal nor are they tumorigenic when transferred into nude mice 
(Jaggar et al., 1990; Pennie et a l, 1993). Various subgenomic fragments of BPV4 
have been transfected into PalF cells in an attempt to assign individual transforming 
characteristics to particular viral ORFs. Table 1.2 summarises the results of a series 
experiments in which combinations of BPV4 subgenomic fragments where transfected 
into PalF cells. Several characteristics of transformation were assessed. These 
included, morphological transformation, anchorage independent growth, immortality 
and tumorigenicity in nude mice. To reiterate, all the BPV4-induced transformation 
results discussed here were dependent on the cotransfection of an activated ras gene.
Transfection of PalF cells with the E7 ORF resulted in morphological 
transformation (Pennie et a l, 1993). Introduction of a subgenomic fragment 
containing E7 and E8 produced cells which were morphologically transformed and 
capable of anchorage independent growth (ibid.). When the E8 ORF and ras were 
transfected into PalF cells in the absence of any other BPV4 sequences, it was found 
to be lethal to recipient cells. The mechanism of how or why E8 expression is lethal 
to PalF cells is not fully understood, however work by V. O'Brien in our laboratory is 
currently addressing these questions.
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Table 1.2 Summary of transforming potential of BPV genes in PalF cells either 
alone or in combination with the HPV16 E6 gene or quercetin
Transfected DNA 
(all included ras)
Morphological
Transformation
Anchorage
Independence
Immortality Tumorigenic 
in nude mice
BPV4 (whole genome) + + - -
E7 + - - -
E7 +  E8 + + - -
E7 +  E8 + H P V 16E 6 + + + -
BPV4 + Quercetin + + + +
E7 + Quercetin + + + +*
E7 + E8 + Quercetin + - N/D -
+ : Phenotype detected 
- :  Phenotype not detected 
+* : Only seen when quercetin was administered soon after transfection 
N /D : Not determined
Stable PalF transfectants containing BPV4 E7, E8 and HPVI6 E6 (plus ras) 
have been generated by H. Ashrafi. These cells were examined for their ability to 
communicate via gap junctions. Results showed that PalF cells expressing E8 showed 
a loss of gap junction intercellular communication (GJIC) whereas the same cells 
without E8 did not (Faccini et al., 1996). Similar effects on gap junction 
communication have been observed with HPV 16 E5 (Oelze et a l, 1995). BPV1 E5 
shows a high degree of homology with BPV4 E8 (see section 1.5.3.3) and it has been 
suggested that these two proteins interfere with GJIC through an interaction with a 
component of gap junctions, namely ductin (Faccini et a l, 1996).
BPV4 does not possess an E6 ORF (Jackson et a l, 1991). This gene is crucial 
to the transforming ability of other papillomaviruses, such as HPV 16 and 18, as 
discussed earlier in section 1.5.3.2. It is currently unknown if other BPV4 encoded 
proteins can substitute for the actions of E6 or if the mechanism of BPV4 
transformation is independent of E6-related functions. Transformation experiments 
have demonstrated however that introduction of an exogenous E6 can provide 
additional characteristics of transformation which could not be achieved by BPV4
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alone (see Table 1.2). When HPV 16 E6 was cotransfected with BPV4 E7 (and ras) 
into PalF cells in the presence or absence of E8, colonies formed were immortal 
(Pennie et a l, 1993). The same cells could only grow in methocel, a measure of 
anchorage independent growth, when E8 was present. Hence E6 possess transforming 
activity, particularly the ability to induce cellular immortality, which has not been 
achieved by any of the BPV4 encoded proteins.
The effect of E6 on cellular p53 (see section 1.5.3.2) has been proposed as a 
very significant interaction in terms of cellular transformation. Nevertheless, 
experiments by Linda Scobie (Scobie et a l , submitted) have demonstrated that E6 can 
transform cells independent of its interaction with p53. A mouse fibroblast cells line 
which contains no endogenous p53 gene (p53-null mouse fibroblasts) was transfected 
with the entire BPV4 genome in the presence or absence of an exogenous HPV 16 E6. 
The results obtained demonstrated that an immortal phenotype was only achieved 
when the HPV16 E6 ORF was present.
An important observation in all these experiments has been that BPV4 
transformed PalF cells, even in the presence of HPV 16 E6, are not tumorigenic in 
nude mouse assays (Pennie et a l , 1993). This indicates that other cofactors are 
necessary for BPV4 transfected PalF cells to attain a hilly transformed phenotype.
The dependence on additional cofactors to achieve a malignant state is supported by 
BPV4 transformation in vivo (Jarrett et a l, 1978b; Campo et a l, 1994) as well as 
other papillomavirus-associated cancers (Jackson et a l, 1993).
1.7 Cofactors in Papillomavirus-Associated Cancer
CRPV is unique among papillomavirus in its ability to induce malignant 
tumours in domestic and cottontail rabbits in the absence of any obvious cofactors 
(Rous and Beard, 1935; Syverton e ta l, 1950a, 1950b; Syverton, 1952). Nevertheless, 
the time taken for a benign papilloma to progress to a malignant tumour was 
dramatically reduced when the skin of rabbits was treated with a carcinogen, such as 
tar (Rous and Kidd, 1936; Kidd and Rous, 1937). When the rabbits' skin was exposed 
to the carcinogen in the absence of virus, no malignant tumours developed (Rous and 
Beard, 1935). These results indicate that the carcinogen alone was insufficient to 
cause cancer however, in the presence of virus, the two could co-operate in the rapid 
induction of malignancy.
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Cigarette smoking and tobacco have been implicated as risk factors in a large 
number of cancers (Shopland et a l, 1991). Several epidemiological studies have 
likewise identified cigarette smoking as a risk factor in developing oral (Spitz et a l,
1992) and cervical cancer (Trevathan et a l, 1983; Reeves et a l, 1987; Cuzick et a l, 
1990; Basu et a l, 1991; Darling et a l, 1992). More specifically, the cervical mucous 
from smokers was shown to be mutagenic in the S. typhimurium microsomal test 
(Holly et a l, 1986), low grade cervical lesions were found to be larger in women who 
smoke compared to non-smokers (Szarewski et a l, 1996), and cigarette smoke 
condensates were shown to transform HPV18-immortalised exocervical cells to 
tumorigenicity (Nakao et a l, 1996). Furthermore, the level of nicotine in cervical 
flushes was shown to be proportional with smoking frequency (Schiffinan et a l,
1987), and a larger number of DNA adducts were detected in cervical scrapes from 
smokers (Phillips et a l, 1990; Phillips andNishe, 1993).
In addition to the toxic by-products of cigarettes and tobacco, smoking has 
also been shown to compromise the immune system (reviewed by Holt, 1987). A 
reduced immune response has been implicated in a number of HPV-associated cancers 
(see below).
Radiotherapy has been associated with the progression of laryngeal papillomas 
to carcinoma (Lindeberg et a l, 1986; Lindeberg and Elbrond, 1991). Radiation 
exposure, in the form of UV light, is thought to contribute to the carcinogenic 
progression of HPV-induced skin lesions in patients suffering from EV (see section 
1.5.2.2) (Ifner et a l, 1990). Radiation, apart from being capable of inducing DNA 
damage, has also been shown to be immunosuppressive (Boyle et a l, 1984).
EV individuals are reported as having genetically impaired cell-mediated 
immunity (Jablonska and Orth, 1985). When the immune system is compromised, as 
in the case of EV, in allograft transplant patients (Trenfield et a l, 1993; Petty et a l, 
1994), or in individuals infected with HTV (Boccalon et a l, 1996), an increased 
incidence of warts and skin cancer is often observed (Benton and Arends, 1996). So 
far HIV infection has not been shown to significantly increase the risk of developing 
cervical cancer however it is proposed as a cofactor in other HPV-linked cutaneous or 
mucocutaneous cancers (Valle, 1987). The immune system, therefore, appears to be 
an important regulator, restricting the progression of benign HPV-initiated lesions to a 
cancerous state.
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Secondary viral infections apart from HIV, including Herpes simplex virus 
type 2 (HSV2) (Merino, 1991; Yamakawa et a l, 1994), cytomegalovirus (CMV) 
(Shen et a l, 1993), and human herpes virus (HHV) (Yamakawa et a l, 1994), have all 
been suggested as cofactors in anogenital carcinogenesis. Bacterial and parasitic 
infections, including Mycoplasma hominis infection (Guijon et a l, 1992) and 
schistosomiasis (Feldmeier et a l, 1996) respectively, have also been suggested as 
possible cofactors.
The LCR of HPV 16, the most abundant papillomavirus found in cervical 
cancers, has demonstrated the presence of a progesterone and glucocorticoid response 
element (Chan et a l, 1989; Chong et a l, 1990; Mittal et a l, 1993). Changes in 
hormones levels during pregnancy or early adolescence (Shen et a l, 1993), as a result 
of altered metabolism (Aubom et a l, 1991), or as a consequence of taking an oral 
contraceptive (Beral et a l, 1988; Hildesheim et a l, 1990), may each contribute to 
changes in viral gene expression and promote, even in part, neoplastic transformation.
In vitro, several studies have shown a co-operation between papillomaviruses 
and the classical tumour promoting agent, TP A (Cuzin et a l, 1985; Tsang and Stich, 
1988; Gaukroger et a l, 1993). Apart from the ability of TP A to increase the 
expression of cellular oncogenes (Dotta et a l, 1985) and papillomavirus genes 
(Amtmann and Sauer, 1982; Smith et a l, 1987; Gius and Laimins, 1989), it has also 
been shown to stimulate viral replication in vitro (Amtmann and Sauer, 1982; Smith 
et a l, 1987; Smith and Campo, 1988) and in vivo (Amtmann et a l, 1984; Gaukroger 
et a l, 1993). An increase in viral gene expression/replication has been linked to more 
frequent and efficient in vitro transformation (Smith and Campo, 1988).
BPV4 can co-operate with a tumour promoter (TPA) or initiator (DMBA) to 
induce carcinomas arising from BPV4-infected bovine palatine tissue when implanted 
into the renal capsule of nude mice in the presence of slow releasing pellets of TP A 
and/or DMBA (Gaukroger et a l, 1993). The ability of BPV4 to co-operate with both 
chemicals in neoplastic transformation suggests that this virus can achieve 
transformation by interacting with a range of activated cellular genes.
A strong association between naturally occurring cancers in cattle and their 
consumption of bracken fern has been identified in animals in the West Highlands of 
Scotland. The effects of bracken consumption on cattle with concomitant 
papillomavirus infections are discussed in more detail below.
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1.7.1 Bracken Fern as a Cofactor in Cattle Cancer
Bracken fern, whether fresh, dried or cooked, as well as bracken fern extracts 
have been shown to be both toxic and carcinogenic in a range of domestic and 
experimental animals (Rosenberger et a l, 1960; Pamukcu, 1963,1969; Evans and 
Widdop, 1966; Hirono et a l, 1970; Evans, 1984; Santos et a l,  1986, 1990; Santos, 
1987; Campo et a l, 1992, 1994). It has been observed that cattle often suffer from 
chronic enzootic haematuria and bladder tumours when bracken is a constituent of 
their diet (Pamukcu et a l, 1967, 1976). When cattle were fed bracken fern 
experimentally, they were seen to develop haematuria and bladder tumours which 
were histopathologically identical to naturally occurring bladder tumours (Price and 
Pamukcu, 1968; Pamukcu et a l, 1976; Campo et a l 1992). Bracken fern, which is 
widespread in particular areas of the world, is known to contain mutagens, 
carcinogens (Evan, I. A. et a l, 1982) and immunosuppressants (Evans, W. C. et a l, 
1982). Apart from the toxic nature of bracken fern, infection with a papillomavirus 
has also been implicated in the development of urinary bladder tumours in cattle.
A series of experiments by Olson and co-workers showed that extracts from 
bovine cutaneous warts, when injected into the bladder of cows, induced malignant 
tumours (Olson et a l, 1959); alternatively, suspensions of naturally occurring, 
bracken-associated bovine bladder tumours gave rise to skin and vaginal warts, as 
well as bladder polyps and fibromas in test calves (Olson et a l, 1965). These early 
experiments were a strong indication that a transmissible agent was involved in the 
production of naturally occurring bladder tumours in cattle.
Subsequently, experiments by Campo and colleagues have shown a synergism 
between bovine papillomavirus type 2 (BPV2) and bracken (Campo and Jarrett, 1986; 
Campo et a l, 1992). Results from a number of long term experiments showed that 
cattle inoculated on the skin with BPV2 and fed on a diet of hay developed cutaneous 
warts at the site of injection. Likewise, animals inoculated with BPV2 and fed on 
bracken developed warts at the site of injection as expected. All animals which were 
fed bracken became severely immunosuppressed and bladder cancers frequently 
developed. These bladder tumours were histopathologically indistinguishable from 
bladder tumours which arise spontaneously. BPV2 DNA was detected in a large 
proportion of these cancers independent of whether the animal had been injected with
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BPV2 or not. This observation suggests that chemicals in the bracken, most likely 
immunosuppressants such as sesquiterpene pterosins and pterosides (Evans, W.C.  et 
a l , 1982), were responsible for the activation of a latent viral infection and together 
they contributed to bladder cancer in these animals. Immunosuppression has been 
identified as a cofactor in several other papillomavirus-associated cancers (sections 
1.5.2.1, 1.5.2.2 and 1.7)
Synergism between a second bovine papillomavirus, BPV4, and bracken has 
also been established. As mentioned earlier, BPV4 infects and induces papillomatosis 
of the upper gastrointestinal (GI) tract in cattle (Campo et a l, 1980). These lesions 
have been shown to progress to squamous cell carcinomas at high frequency in animal 
grazing on bracken fern (Jarrett et a l, 1978b; Campo et a l, 1994). In the absence of 
bracken, BPV4 gave rise to benign papillomas only at the site of injection. As 
mentioned above, animals fed on bracken fern become chronically immunosuppressed 
however immunosuppression alone, induced either by bracken or azothioprene, was 
insufficient to induce cancer of the upper gastrointestinal tract (Campo et al, 1992,
1994). Only animals inoculated with BPV4 and fed bracken developed cancer of the 
upper GI tract and lower bowel (Campo et a l, 1994). These results confirm that 
BPV4 and bracken fern can co-operate in the induction of cancer in this natural 
system. Furthermore, immunosuppression while enhancing the level of 
papillomatosis, is not sufficient to synergise with BPV4 to produce cancer and other 
components of the bracken fem must therefore play a role in this carcinogenic 
process.
1.7.2 Quercetin
In an attempt to identify individual compounds of bracken fem which have the 
potential to synergise with BPV4, one of the more potent and extensively studied 
mutagens present in bracken fem, quercetin, was selected and used in a series of in 
vitro experiments.
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Figure 1.3 The Chemical Structure of Quercetin
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Quercetin (3,3',4',5,7- pentahydroxyflavone) (see Figure 1.3) is a ubiquitous, 
naturally occurring bioflavonoid which is found in a wide range of edible plant 
products including fruits, vegetables, wine and tea (Herrmann, 1976). It has been 
shown to exhibit a variety of biological effects some of which are beneficial including 
the inhibition of tumour induction by chemical carcinogens (Kato et al., 1983), 
antiproliferative action on several tumour cells lines (Avila et a l, 1994 and references 
therein) and free-radical scavenging antioxidant properties (Bors et a l, 1987; Negre- 
Salvayre et al., 1992). However, many other reports identify other, less salutary 
effects of quercetin. These include quercetin's ability to form adducts with DNA 
(Rahman et al., 1990), to induce mutations in both prokaryotic and eukaryotic cells 
(Bjieldanes and Chang, 1977; Amacher et al., 1979; Maruta et al., 1979; Nakayasu et 
al., 1986; Ishikawa et al., 1987), to cause clastogenic damage (Ishidate et al., 1988) 
and to initiate mammalian cells in a two-stage transformation assay in vitro with TPA 
as a promoter (Sakai et al., 1990). In addition to its genotoxic effects, quercetin has 
been shown to inhibit and activate a range of enzyme activities (Avila et a l,  1994 
and ref. therein; Elliott et al., 1992) and to induce protein fragmentation (Ahmed et 
a l,  1994).
Synergism between BPV4 and quercetin has been demonstrated in a series of 
in vitro experiments (Pennie and Campo, 1992). As discussed in section 1.6.4, 
primary bovine palate fibroblasts (PalF cells) when transfected with BPV4 alone 
exhibit no morphological change. BPV4 can achieve morphological transformation 
and anchorage independent growth of PalF cells only when cotransfected with an
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additional oncogene, such as an activated ras gene (Jaggar et al., 1990). These 
partially transformed cells however are not immortal nor are they tumorigenic as 
determined in a nude mouse assay, ras alone, like BPV4 alone, is not sufficient to 
transform PalF cells.
The oncogenes of BPV4 have been identified as E7 and E8 (see sections 1.6.3 
and 1.6.4). PalF cells transfected with E7 and ras are morphologically transformed 
but remain anchorage dependent, are not immortal and are non-tumorigenic in nude 
mice (Pennie et al., 1992). Transfection of E7 + E8 + ras into PalF cells leads to 
morphologically transformation and anchorage independent growth, however these 
same cells do not achieve immortality or tumorigenicity {ibid.). Hence, it is now 
accepted that E7 can morphologically transform PalF cells while E8 can confer 
anchorage independence. Immortality of PalF cells is only observed when an 
exogenous E6 gene from HPV16 is transfected into PalF cells in combination with the 
whole BPV4 genome (or E7 + E8) plus ras. Nevertheless, when PalF cells are 
transfected with E7 and ras only and then treated with a single dose of 20pM 
quercetin, they become fully transformed attaining not only anchorage independence 
and immortality but also tumorigenicity in nude mice assays (Caimey and Campo,
1995). Therefore quercetin can confer anchorage independent growth in the absence 
of E8 and immortality in the absence of an exogenous E6. These observation 
highlight that, not only can quercetin substitute for the activities of several viral 
oncoproteins, it can provide additional functions in transformation. Synergism 
between virus and quercetin is emphasised in this transformation system as the extent 
of transformation observed cannot singly be achieved by either the virus or chemical 
treatment alone (Pennie and Campo, 1992).
In another set of experiments, the timing of exposure to quercetin was also 
shown to be important with regard to its ability to synergise with BPV4. Quercetin 
was demonstrated to synergise with BPV4 (whole genome or various subgenomic 
fragments) when cells were exposed to 20pM quercetin shortly before or soon after 
transfection with BPV4 (Caimey and Campo, 1995). The longer the time interval 
between exposure to quercetin and transfection, or vice versa, the less evident was the 
co-operation between chemical and vims in PalF cells. This temporal synergism 
would suggest that, at this concentration, quercetin was not inducing any permanent 
genetic change within the PalF cells. Furthermore, the results indicate that the effect
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of quercetin on the PalF cells was transient supporting a role for quercetin inducing 
epigenetic change rather than genetic change.
Another observation from these experiments was that expression of E8 and 
exposure to quercetin were apparently antagonistic (Caimey and Campo, 1995).
When PalF cells were transfected with E7/E8 plus ras and exposed to quercetin 
shortly before or after transfection, cells were not immortal, colonies grew poorly or 
not at all in an anchorage independent environment and cells were not tumorigenic in 
nude mice. Antagonism between E8 and quercetin was not evident however when E8 
was expressed in the context of the full BPV4 genome. This would suggest that 
expression of E8 is more tightly regulated in the context of the whole BPV4 genome 
and that E8 expression and exposure to quercetin are antagonistic only, perhaps, when 
E8 is aberrantly expressed.
While quercetin has been shown to substitute for the ability of E8 to induce 
anchorage independent growth (Pennie and Campo, 1992), treatment of cells with 
quercetin had no apparent effect on gap junction intercellular communication 
(Margaret Caimey, unpublished data). The down regulation of GJIC has been 
ascribed to the ability of E8 to physically interact with the 16k ductin component of 
gap junctions (Faccini et al., 1996), an effect which is not achieved by exposure of 
cells to the chemical quercetin.
These results suggest that quercetin is one component of bracken fern which 
has the potential to co-operate with BPV4 in vivo to achieve neoplastic 
transformation. Nevertheless, quercetin and BPV4 alone are insufficient to induce 
cancer in cattle in vivo (Campo et a l , 1992). When quercetin was administered to 
animals infected with BPV4, the papillomas remained benign. This indicates that 
other constituents of bracken fern are additionally required for the initiation of cancer 
in vivo. Immunosuppresion has been identified as a cofactor in other papillomavirus- 
associated cancers. Therefore, it may be hypothesised that immunosuppressants in 
bracken fern, in combination with quercetin, may be sufficient to induce cancer in 
vivo. Alternatively, because bracken fern is a rich source of toxic chemicals, it may be 
that a cocktail of several bracken chemicals co-operate to synergise with BPV4 to 
induce cancer in cattle.
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2.2 MATERIALS
2.2.1 Antibodies
Sigma Immuno Chemical Co.
Anti-Mouse IgG (whole molecule) alkaline phosphatase conjugate (raised in Goat) 
Amersham International pic.
Anti-Mouse IgG horseradish peroxidase linked whole antibody (raised in Sheep)
Affiniti Research Products Limited
Anti-Phosphotyrosine (PY20) IgG2b Monoclonal antibody (Mouse Host)
Santa Cruz Biotechnology, Inc
Anti-cFos (K-25)-G rabbit polyclonal IgG antibody
Anti-cJun (730-5), a polyclonal antibody raised in rabbit, and rabbit pre-immune 
serum (943-0), were both a kind gift from Dr. Elizabeth Black, Beatson Institute for 
Cancer Research, Glasgow.
Anti-JunB (725/5) and Anti-JunD (783/2) antibodies were a kind gift from Dr. David 
Gillespie, Beatson Institute for Cancer Research, Glasgow. The JunB and JunD 
antibodies were raised in rabbit against bacterially expressed fusion proteins. The 
cDNA clones used to construct the fusion proteins were of mouse origin (Kovary and 
Bravo, 1991).
2.2.2 Bacteriology
Beatson Institute Central Services
L-Broth
Becton Dickinson Labware
Falcon 1059 polypropylene tubes
Beta Laboratories
Yeast-extract
Bibby Sterilin Ltd
90mm bacteriological petri dishes
Difco Laboratories
Bacto-Agar
Bactotryptone
Fisons Scientific Equipment
Glycerol
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Gibco BRL Europe Life Technologies Ltd
E.Coli DH5a competent cells
Nunc
Sterile Disposable Inoculating Loops
Sigma Chemical Co. Ltd
Ampicillin
Lysozyme
2.2.3 Chemicals and Reagents
Chemicals and reagents used were of analytical grade (AnalaR) when possible.
Amersham International pic
ECL Western detection agent
BDH Analar Laboratory Supplies
Ammonium persulfate (APS)
D-glucose 
Ethyl Acetate 
Napthalene black 
Repelcote silicone treatment
Boehringer Mannheim Ltd
Caesium chloride 
RNase A
Fisons Scientific Equipment
Acetic acid 
Betaplate Scint 
Butan-2-ol 
Chloroform
di-Potassium hydrogen orthophosphate (anhydrous)
Diaminothanetetra-acetic acid (EDTA) disodium salt 
DMSO (dimethyl sulfoxide)
Hydrochloric acid 
Magnesium chloride 
Magnesium sulphate 
Methanol
Potassium chloride
Potassium dihydrogen orthophosphate
Propan-2-ol
Sodium acetate
Sodium carbonate
Sodium chloride
Sodium dodecyl sulphate (SDS)
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Gibco BRL Europe Life Technologies Ltd
Agarose (Ultrapure electrophoresis grade)
Tris base
James Burrough Ltd
Ethanol
National Diagnostics
Ecoscint A (Biodegradable Scintillation Solution)
Pharmacia Biotech Ltd
poly(dl-dC)
Severn Biotech Ltd
30% (w/v) acrylamide:0.8% (w/v) bis-acrylamide 
40% (w/v) acrylamide:2.1% (w/v) bis-acrylamide
Sigma Chemical Co. Ltd
P-mercaptoethanol 
Acetly Coenzyme A 
Aprotinin 
Benzamidine
Bicinchoninic Acid solution 
Bovine Serum Albumin 
Bromophenol Blue 
Coomassie Brilliant Blue R
Copper(II) sulphate (pentahydrate 4% (w/v) solution) 
Dithiothreitol (DTT)
Ethidium Bromide 
Ficoll (type 4000 
HEPES 
Leupeptin
Nonidet P-40 (NP40)
ONPG
Phenol:Chloroform:Isoamyl Alcohol (25:24:1 (v/v)) 
PMSF
Ponceau S solution
Salmon testes DNA (sodium salt)
TEMED (N,N,N’,N’-tetramethylethylenediamine) 
Tween-20 (Polyoxyethylene sorbitan nonolaurate)
Unipath
PBS tablets
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2.2.4 Enzymes and Kits
Boehringer Mannheim Ltd
Random primed DNA labelling kit
Gibco BRL Europe Life Technologies Ltd
All restriction enzymes and stock reaction buffer solutions used were obtained from 
Gibco BRL unless other otherwise stated.
NBL Gene Sciences
Alkaline phosphatase 
T4 DNA ligase
Perkin Elmer Corporation
GeneAmp PCR Core Reagents
Qiagen Ltd
QIAprep Spin plasmid miniprep kit 
QIAquick gel extraction kit
2.2.5 General Laboratory Supplies and Miscellaneous 
Aldrich Chemical Company, Inc
Pre-coated TLC sheets (Silca gel on polyester without fluorescent indicator)
Alpha Laboratories Ltd
Microcentrifuge tubes 
Pastettes
Cadisch and Sons
70pm filter nylon gauze
Canberra Packard Ltd
Superpolyethylene scintillation vials
Cruachem Ltd
Cruachem oligonucleotide purification (COP) cartridges
Du Pont (UK) Ltd 
Polyallomer ultracentrifuge tubes
Gelman Sciences Ltd
Sterile 0.2pm Acrodisc filter units
Premier Beverages
Marvel (Dried Skimmed Milk)
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Sartorius AG
Collodion Bags
Wallac Oy
Printed filtermat A (glass fibre) 
Sample bag (for filtermat A)
Whatman International Ltd
Whatman 3MM filter paper 
Whatman 1 filter paper
2.2.6 Mammalian Cells
PalF cells are primary fibroblasts explanted from bovine foetal palate.
PalK cells are primary keratinocytes explanted from bovine foetal palate.
Swiss 3T3 feeders (ATCC CCL92), originally established in 1962 by G. Todaro and 
H. Green (Todaro and Green, 1963), are an immortalised mouse fibroblast cell line 
which were a kind gift from Roselyn McCaffery, Beatson Institute for Cancer 
Research, Glasgow.
2.2.7 Membranes, Radiochemicals and X-ray Film
Amersham International pic
[methyl-3H] Thymidine
D-threo[dichloroacetyl-1 -14C]Chloramphenicol 
Hybond-C extra 
Redivue [a32P]dTTP
Decon Laboratories Limited
Decon 75
Eastman Kodak Company
X-OMATAR X-ray film 
X-OMATS X-ray film
Technical Photo Systems
Fuji RX medical X-ray film
2.2.8 Molecular Weight Markers 
Amersham International pic
Rainbow™ coloured protein molecular weight markers (14,300 - 200,000 Da)
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Gibco BRL Europe Life Technologies Ltd
(pX174 RF DNA/ Hae III fragments 
1Kb DNA ladder 
X UNAJHind III fragments
2.2.9 Plasmids Vectors
pOLuc is a promoter assay vector containing the firefly luciferase coding sequence 
cloned into a modified pGEM3 vector (Brasier et al, 1989). This plasmid was a gift 
from Dr. Maria Jackson (Beatson Institute, Glasgow).
pLCRLuc contains nucleotides 6710-331 of the BPV-4 genome cloned into the 
BamH I site of the vector pOLuc (Jackson and Campo, 1995). This vector was a gift 
from Dr Maria Jackson (Beatson Institute, Glasgow).
psLCRLuc contains nucleotides 6710-310 of the BPV-4 genome, cut from p41X-PIN 
using BamH I, and cloned into the BamH 1 site of the vector pOLuc.
p41X is an enhancer test plasmid which contains the herpes simplex virus thymidine 
kinase (TK) promoter upstream of the coding sequence for the bacterial CAT protein. 
This vector, which was originally made by Jas Lang, was a gift from Dr Maria 
Jackson (Beatson Institute, Glasgow).
p41X-PINT contains nucleotides 6710-331 of the BPV-4 genome cloned into the 
Xhol site of p41X upstream of the TK promoter and CAT coding sequence. This 
vector was a gift from Dr Maria Jackson (Beatson Institute, Glasgow).
p41X-PIN contains nucleotides 6710-310 of the BPV-4 genome cloned into the Xhol 
site of p41X (Jackson and Campo, 1991). This vector was a gift from Dr Maria 
Jackson (Beatson Institute, Glasgow).
pGL3 is a luciferase reporter vector obtained commercially from Promega.
pGL3-PINT contains nucleotides 6710-331 of the BPV-4 genome cloned into the 
Bgl II site of pGL3. This plasmid was a gift from Dr. Iain Morgan.
pGL3-PIN contains nucleotides 6710-310 of the BPV-4 genome cloned into the 
Bgl II site of pGL3. This plasmid was a gift from Dr. Iain Morgan.
pGL3-A57.1 contains nucleotides 7058-310 of the BPV-4 genome cloned into the 
Bgl II site of pGL3. This plasmid was a gift from Dr. Iain Morgan.
pGL3-A10 contains nucleotides 7131-310 of the BPV-4 genome cloned into the Bgl II 
site of pGL3. This plasmid was a gift from Dr. Iain Morgan.
pGL3-A36 contains nucleotides 7212-310 of the BPV-4 genome cloned into the Bgl II 
site of pGL3. This plasmid was a gift from Dr. Iain Morgan.
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pGL3-A170 contains nucleotides 44-310 of the BPV-4 genome cloned into the Bgl II 
site of pGL3. This plasmid was a gift from Dr. Iain Morgan.
pGL3-A151 contains nucleotides 149-310 of the BPV-4 genome cloned into the Bgl II 
site of pGL3. This plasmid was a gift from Dr. Iain Morgan.
pGL3-A114 contains nucleotides 184-310 of the BPV-4 genome cloned into the Bgl II 
site of pGL3. This plasmid was a gift from Dr. Iain Morgan.
The LCR deletion mutants, A57.1, A10, A36, A170, A151 and Al 14 were originally 
generated and cloned into the BamH I site of p41X by Dr. Maria Jackson (Jackson and 
Campo, 1991) and subsequently subcloned into pGL3 by Dr. Iain Morgan and Joan 
Grindlay.
pGL3-wtLCR contains nucleotides 6710-331 of the BPV-4 genome cloned between 
the Hind III and Kpn I sites of pGL3.
pGL3-sLCR contains nucleotides 6710-310 of the BPV-4 genome cloned between 
the Hind III and Kpn I sites of pGL3.
pGL3-APlLCR contains nucleotides 6710-331 of the BPV-4 genome cloned 
between the Hind III and Kpn I sites of pGL3. Nucleotide 316 has been mutated from 
G to T, using PCR-based mutagenesis, thus generating a consensus AP-1 binding 
motif (TGATGCA) - nucleotides 313-319.
pGL3-randLCR contains nucleotides 6710-310 of the BPV-4 genome followed by a 
stretch 21 random nucleotides cloned between the Hind III and Kpn I sites of pGL3.
pCHllO is a control eukaryotic assay vector which contains a functional lacZ gene 
which is expressed either from the SV40 early promoter or from the E.coli gpt 
promoter (Hall et al, 1983). This vector was commercially obtained from Pharmacia.
pTKCAT contains the herpes simplex virus TK promoter upstream of the coding 
sequence for the bacterial CAT protein. This plasmid was a gift from Dr. Elizabeth 
Black (Beatson Institute, Glasgow).
p5xTRE-CAT contains five copies of nucleotides -73 to -65 of the human 
collagenase gene ligated head to head, flanked by Hind RVBamHl linker sequences 
and cloned into the Hind Ul/BamH I cut vector pBL-CAT2. pBL-CAT2 was derived 
from pUC18 and contains the herpes simplex virus TK promoter upstream of the 
coding sequence for the bacterial CAT protein. This plasmid was a gift from Dr. 
Elizabeth Black (Beatson Institute, Glasgow).
pMoMuLTR-CAT contains the Moloney murine long terminal repeat element 
upstream and driving transcription of the chloramphenicol acetyl transferase (CAT) 
gene. This plasmid, originally constructed by Jack Lenz (Albert Einstein College of
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Medicine, Bronx, New York, USA), was a kind gift from Dr Jim Neil (Glasgow 
University Veterinary School).
2.2.10 Tissue Culture
Alpha Laboratories Ltd
Plastic disposable cuvettes
Beatson Institute Central Services
Kanamycin
Penicillin
Sterile distilled water 
Sterile glycerol
Sterile phosphate-buffered saline (PBS)
Sterile phosphate-buffered saline + EDTA (PE) 
Streptomycin
Becton Dickinson Labware
18 gauge sterile syringe needles
60 and 90mm tissue culture dishes
Falcon 2054 polystyrene round bottomed tubes
Falcon 2097 polypropylene tubes
Falcon 2098 polypropylene tubes
Serological plastic pipets
Sterile Plastipak syringes
Bibby Sterilin Ltd
Sterile plastic universal containers
Costar Corporation
96 well culture plates 
Disposable cell scrapers
Gibco BRL Europe Life Technologies Ltd
lOOmM sodium pyruvate
lOx Dulbecco’s Modified Eagles Medium
lOx Nutrient Mixture F-IO(HAM)
2.5% Trypsin solution 
200mM L-glutamine 
7.5% sodium bicarbonate 
Special Liquid Medium
Globepharm
Foetal Calf Serum
ICN Biomedicals Inc
Mycoplasma removal agent
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Johnson and Johnson Medical Limited
PRESEPT* effervescent disfectant tablets
Labsystems (UK) Ltd
Clinicon disposable measuring cuvettes
Promega Ltd
Luciferase Assay System 
Reporter Lysis 5x Buffer
Nunc
Cryotubes
T25, T75 and T175 cm2  culture flasks
Sigma Chemical Co. Ltd
Adenine
Cholera enterotoxin 
EGF
Hydrocortisone
Insulin
MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; Thiazolyl blue) 
Polybrene (Hexadimethrine bromide)
Quercetin (3,3 ’ ,4’ ,5,7-pentahydroxyflavone)
TP A (12-O-tetradecanolyphorbol 13-acetate)
Worthington Biochemical Company
Trypsin
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2.3 METHODS
2.3.1 Tissue Culture
Bovine foetal samples were obtained from the veterinary post-mortem room at 
the Glasgow University School of Veterinary Medicine. All cell culture work was 
performed following strict aseptic protocols inside a laminar flow hood (Class II 
Microbiological Safety Cabinets; Medical Air Technology Ltd., Manchester, UK).
2.3.1.1 Swiss 3T3 Feeder Cells
Swiss 3T3 mouse fibroblasts were routinely grown in Special Liquid Medium 
containing 10% (v/v) FCS, 2mM L-glutamine, 37.5pg/ml penicillin and lOpg/ml 
streptomycin. Cells were seeded at 106  cells/T175 tissue culture flask and incubated 
at 37°C in a humid atmosphere containing 5% (v/v) C 0 2  (Heraeus, Essex, UK) until 
completely confluent. Medium was changed twice weekly.
After confluency was reached, the cells were trypsinised (section 2.3.14) using 
a solution of 0.25% (w/v) trypsin in lxPE buffer (PBS containing ImM EDTA) and 
resuspended in fresh growth medium. Cells were lethally irradiated by exposure to 
60Gy of y-irradiation using a 60Co source. Following irradiation the feeder cells, now 
incapable of further cell division, were plated out immediately or stored for up to 
48 hours at 4°C without loss of feeding capacity. Feeder cells were plated at a density 
of lx l0 6  cell/90mm culture dish before addition of keratinocytes.
Feeder cells were removed from keratinocyte cultures by a process of selective 
trypsinisation; typsin solution was added to the mixed culture and after a 2 to 3 minute 
incubation at 37°C all feeders were detached from the culture plastic. Keratinocytes 
remained attached, requiring longer incubations in trypsin to be dislodged. Unwanted 
feeders were washed away using phosphate buffered saline (PBS:0.14M NaCl, 27mM 
KC1,1 OmM Na2HP04,15m M K2HP04)
2.3.1.2 Isolation of Primary Bovine Keratinocytes
A small section of palate tissue was taken from a bovine foetus which had 
completed no more than five months gestation. The palate tissue was immediately 
placed in a solution of PBS containing lOOpg/ml penicillin, 400pg/ml streptomycin,
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100pg/ml kanamycin and 2.5 fig/ml amphotericin. After washing a further two times 
in the PBS/antibiotic solution, the tissue was incubated overnight at 4°C in PBS 
containing 0.01% EDTA and 0.25% Worthington trypsin. Following a further 
30 minute incubation at 37°C, the trypsin was neutralised by the addition of foetal calf 
serum (FCS) to a final concentration of 10% (v/v). The tissue was transferred to a 
90mm tissue culture dish and keratinocyte (PalK) cells were separated from 
underlying mesenchyme by scraping along the surface of the tissue using a scalpel 
blade. The remaining solid tissue was placed in a second culture dish for further 
isolation of fibroblast cells (see section 2.3.1.3).
The freshly extracted PalK cells were suspended in 10ml keratinocyte medium, 
transferred to a 25ml universal tube and centrifuged at lOOOrpm for 5 minutes at room 
temperature. Primary Bovine Keratinocyte (PalK) growth medium comprises Special 
Liquid Medium supplemented with 4mM glutamine, 0.31% (w/v) sodium bicarbonate, 
2% (v/v) lOx Nutrient Mixture F-10, 10% (v/v) FCS, lOng/ml cholera enterotoxin, 
0.5pg/ml hydrocortisone, 5pg/ml insulin, 180pM adenine, lOng/ml EGF, 37.5pg/ml 
penicillin, lOpg/ml streptomycin and lOOpg/ml kanamycin.
The PalK cell pellet was gently resuspended as a single cell suspension in 
culture medium and counted (section 2.3.1.4). 5x10s viable cells were transferred 
onto a layer of irradiated Swiss 3T3 feeder cells (section 2.3.1.1) in a T175 tissue 
culture flask. The presence of the 3T3 feeder layer is necessary for keratinocytes to 
initiate colony formation (Rheinwald and Green, 1975a). Hydrocortisone in 
keratinocyte culture medium promotes orderly colony morphology and helps maintain 
an increased growth rate (Rheinwald and Green, 1975b). The addition of CET, by 
raising cAMP levels, appears to restrict keratinocyte enlargement (Green, 1978) and 
may thus prevent the onset of terminal differentiation (Sun and Green, 1976).
2.3.1.3 Isolation of Primary Bovine Fibroblasts
The isolation of fibroblasts from foetal bovine palate was described previously 
by Jaggar et al. (1990). Briefly, following removal of the keratinocyte layer (section 
2.3.1.2), the remaining tissue mass was cut into pieces approximately 2-4mm2  in size 
and placed into a 90mm dish with individual fragments being well spaced apart. 
Incubating the dish for five minutes at 37°C facilitated adhesion of the tissue pieces to
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the dish surface. Culture medium (Dulbecco’s Modified Eagles Medium (DMEM) 
supplemented with 10% foetal calf serum, 2mM glutamine, ImM pyruvate, 0.375% 
sodium bicarbonate, 37.5jig/ml penicillin and lOpg/ml streptomycin) was added 
slowly to the dish so as not to disturb the adherent samples. Medium was 
subsequently changed twice weekly. Following a two week period sufficient 
outgrowth of fibroblasts had occurred that the original tissue chips could be removed. 
The newly extracted fibroblasts were trypsinised and reseeded into a larger tissue 
culture flask. Cells were expanded until sufficient numbers were obtained for stocks 
to be made and stored in liquid nitrogen.
2.3.1.4 Maintenance, Counting and Passage of Cells in Culture
Cells were fed every three to four days with the appropriate culture medium 
and incubated at 37°C in a humid atmosphere containing 5% (v/v) C 0 2  (Heraeus, 
Essex, UK).
PalF cells were grown to approximately 90% confluence and then passaged.
PalK cells were grown to 80 to 90% confluence and then passaged (1 in 4 
split) or seeded into smaller culture dishes at a specified density. The background 
feeder layer was first removed by trypsinising for 3-4 minutes. After washing with 
PBS twice to remove the 3T3 cells, a second volume of trypsin was added which 
eventually dislodged the PalK cells. The feeder cells can be separated from PalK cells 
by this method of selective trypsinisation because they are less firmly attached to the 
culture plastic compared to the epithelial PalK cells.
Swiss 3T3 feeders were grown to 90% confluency before passaging or 100% 
confluency before irradiation.
To passage cells, spent medium was aspirated off and the cell monolayer 
washed two times with PBS pre-warmed to 37°C. After removing the second volume 
of PBS, trypsin solution (0.25% trypsin in lx PE; PBS containing ImM EDTA), also 
at 37°C, was added to the cells. The tissue culture flasks or plates were incubated at 
37°C until the cells detached from the culture plastic. Cells were resuspended in the 
appropriate growth medium, transferred to a sterile universal tube and centrifuged at 
lOOOrpm for 5 minutes at room temperature; serum present in the growth medium 
neutralised the trypsin. The cell pellet was resuspended in medium and the 
concentration determined.
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The concentration of a cell suspension was determined after cells were mixed 
with the dye napthalene black to enable the number of viable cells in the suspension to 
be evaluated. Living cells are impermeable to napthalene black whereas dead cells 
cannot exclude the dye and stain black (Kaltenbach et al, 1958). 20pl of a cell 
suspension was mixed with 80pl of staining solution ( 1 % (w/v) napthalene black in 
PBS). Stained cells were applied to the counting chamber of a covered 
haemocytometer slide (Improved Neubaer) and examined under a light microscope 
using a lOx objective lens. The number of living cells was counted and from the 
average of two separate counts the actual concentration of the cell suspension was 
calculated taking into account the sample area ( 1 mm2), depth of chamber and dilution 
factor. Cell concentrations were expressed as viable cells per millilitre. Cells were 
finally seeded at the required density.
2.3.1.5 Mycoplasma Screening
A 60mm dish of NRK (Newborn Rat Kidney) cells was provided by Marian 
Lacey (Beatson Institute, Glasgow). 2ml of growth medium, taken from cells being 
tested for the presence of mycoplasma, was added to the dish of NRK cells containing 
2ml fresh medium (SLM supplemented with 10% (v/v) FCS and mM glutamine) and 
incubated for 3-4 days in a humidified incubator at 37°C in an atmosphere of 5% CO2 . 
The growth medium from cells being screened must have been in contact with the 
cells for a minimum of 2 days. At the end of the incubation period all medium was 
removed and cells washed twice with PBS. 2.5ml of PBS followed by 2.5ml of 
fixative (75% (v/v) methanol, 25% (v/v) glacial acetic acid) was added to the dish.
This was removed and 5ml fixative only added. Fixative was aspirated off and a 
second 5ml volume of fixative added and then incuated at room temperature for 
10 minutes. Fixative was poured off and the dish placed at 37°C for 15 minutes to dry 
completely. 5ml of Heochst 33458 stain (0.05pg/ml in PBS) was added and the cells 
allowed to stain for 5 minutes at room temperature. When the staining solution was 
removed the plate was rinsed twice with distilled water and left to air dry. A drop of 
distilled water was added to the centre of the dish and covered with a clean glass cover 
slip. Cells were finally examined using a water immersion lens on a fluorescence 
microscope (Leitz Wetzlar) with a Mercury vapour lamp light source. Mycoplasma, if
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present, can be identified as extranuclear fluorescent specs against the dark 
background.
2.3.1.6 Long Term Cell Storage
To freeze cells stocks for storage, cells were trypsinised and pelleted as 
outlined above (section 2.3.1.4). The pellet was resuspended at a concentration of 
approximately 106  cell/ml in ice cold growth medium containing 10% (v/v) DMSO. 
The DMSO in the medium acts as a cryoprotectant but all solutions must be chilled as 
DMSO is toxic to cells at room temperature. The cells were transferred in 1ml 
aliquots into chilled Nunc cryotubes on ice. The cryotubes were transferred into a 
polystyrene rack, wrapped in cotton wool and frozen by placing in a -70°C freezer 
overnight. The insulation around of the cell ampoules ensures gradual cooling and 
eventual freezing of the cells which increases the viability of the cells. All cells were 
finally transferred to a storage rack and placed in liquid nitrogen (-195.8°C).
Frozen cells were recovered by placing an ampoule of cells directly from 
liquid nitrogen into a small, covered bucket of water at 37°C. Once thawed, the cells 
were added to 1 0 ml of the appropriate pre-warmed growth medium, centrifuged, 
resuspended in fresh medium and seeded into a tissue culture flask. PalK cells were 
plated out onto a layer of irradiated feeders (section 2.3.1.1).
2.3.1.7 Transient Transfection of Primary Bovine Fibroblasts
PalF cells were transiently transfected with a range of plasmid DNAs (see 
section 2.2.9) using the standard protocol for calcium phosphate-mediated 
transfection. Exponentially growing cells were trypsinised and l-2xl0 5  viable cells 
replated into each 60mm tissue culture dish containing 5ml of appropriate growth 
medium. Cell were replaced in a humidified incubator at 37°C containing 5% (v/v) 
C 0 2  for 24 hours.
For each 60mm monolayer of PalF cells to be transfected the following 
mixture was set up. These volumes can be multiplied according to the number of cells 
being transfected.
To 250jll1 of 2x  HEPES buffered saline (280mMNaCl, lOmM KC1, 1.5mM 
Na2 HP0 4 .2H2 0,12mM  D-glucose, 50mM HEPES), 250pl of a DNA solution (up to
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20(ig of total plasmid DNA(s) in 0.1 xTE pH8  containing 250mM CaC^) was added. 
The addition of the DNA solution to the 2xHBS must done very gradually with 
constant but gentle mixing. The mixture was left to stand at room temperature for 20 
to 30 minutes during which time a fine precipitate formed giving a slight blue/grey 
tinge to the transfection mix. At the end of the incubation, the mixture was gently 
pipetted up and down to resuspend the precipitate.
The calcium phosphate-DNA suspension was added directly into the medium 
above the cell monolayer. The dish was rocked slowly to disperse the transfection 
solution throughout the culture medium. All dishes of cell were incubated for 18-24 
hours in the presence of the transfection mixture.
Following this incubation, medium and precipitate were completely removed 
by aspiration. The monolayer was washed twice with pre-warmed PBS and fresh 
medium was added to each dish. Cells were returned to the incubator for a further 24 
hour after which time l-lOOpM quercetin or an equivalent volume of its diluent, 
ethanol, was added to the growth medium of the PalF cells. Incubation continued for 
a further 24 to 48 hours after which time the cells were harvested.
2.3.1.8 Transient Transfection of Primary Bovine Keratinocytes
PalK cells cannot be transfected using the calcium phosphate method of 
transfection because high concentrations of calcium in the cellular environment 
triggers terminal differentiation of keratinocytes (Boyce and Ham, 1983). Instead a 
procedure employing the use of the polycation Polybrene was found to give 
satisfactory transient transfection efficiency in PalK cells.
5xl0 5  PalK cells were seeded in 60mm dishes in the presence of the 
appropriate culture medium (section 2.3.1.2) but in the absence of an irradiated feeder 
layer. 18 hours later the medium was removed and 2 ml of transfection mix was added 
to each 60mm dish of cells. The transfection mix contained up to lOpg/ml of total 
plasmid DNA and 10p.g/ml Polybrene in PalK culture medium. The cells were 
incubated for 6  hours in the presence of the transfection medium with occasional 
rocking to enhance adsorption and prevent any area of the monolayer from drying out.
The transfection mix was aspirated off and 5ml of special liquid medium 
containing 35% (v/v) DMSO was added to each dish of cells and incubated for
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3 minutes at room temperature. After removal of the DMSO-shock volume, the cells 
were washed twice with warm PBS and refed with a fresh volume of growth medium. 
Cells were incubated overnight (16 to 24 hours) after removal of the transfection mix 
before quercetin at various concentrations or an equivalent volume of its solvent, 
ethanol, was added to the medium. Cells were incubated in the presence of quercetin 
or ethanol for a further 24 hours before being harvested.
2.3.1.9 Harvesting Cells
(a) For Reporter Gene Assays
At the end of the required incubation in the presence of quercetin or ethanol 
the culture medium was removed. Medium containing quercetin at any concentration 
was pipetted into a conical flask and detoxified by the addition of a PRESEPT* tablet; 
one PRESEPT* table is sufficient to disinfect 500j l i1 of medium containing any 
COSHH 3 chemical.
Cell monolayers were washed twice with PBS, the PBS was completely 
removed by aspiration and 300pl of lx Reporter Lysis Buffer (Promega) added to 
each 60mm dish. Following a 15 minute incubation at room temperature, cells were 
scrapped off the culture plastic and each lysate transferred to a 1.5ml eppendorf. Cell 
debris was pelleted by spinning lysates at 4°C in a microcentrifuge at 14,000rpm for 5 
minutes. The supernatant was transferred to a second eppendorf taking care not to 
disturb the cell pellet. The lysates were either assayed for reporter enzyme activity 
immediately or stored at -20°C.
(b) For Phosphotyrosine Analysis
PalF cells were grown in 90mm culture dishes in the presence of culture 
medium containing 20pM quercetin or an equivalent volume of ethanol. The duration 
of quercetin exposure and specific experimental conditions are given in detail in 
section 5.2.1.
Cells were harvested for total cellular protein under conditions designed to 
maintain the phosphorylation status of tyrosine-containing proteins at the time of lysis. 
Medium was removed from the cells and disposed of appropriately. Monolayers were
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washed twice with ice-cold PBS before the addition of 500|il of boiling lysis solution 
(1% SDS (w/v), lOmM Tris pH7.4) to each 90mm dish. Cells were scrapped from the 
culture dish, transferred to a microcentrifuge tube and boiled for 5 minutes. Samples 
were centrifuged for 5 minutes at 4°C at 14,000rpm in a microcentrifuge and the 
supernatant transferred to a chilled 1.5ml microfuge tube. Protease inhibitors PMSF 
and aprotinin were added to final concentrations of 2mM and lpg/ml respectively. 
Cell lysates were stored at -20°C.
(c) Preparation of Nuclear Extract from Cells in Culture
PalF cells were treated with quercetin or ethanol according to the schedule 
detailed in section 4.10.1. Following the appropriate treatment, medium was removed 
from the cells and the monolayer washed twice with ice-cold PBS. 5ml of PBS was 
added to the culture flask and the cells removed from the plastic surface using a cell 
scraper. The cell solution was transferred to a 50ml falcon tube and the flask rinsed 
with another 10ml PBS. The cells were pelleted by centrifugation at 2,000rpm for 5 
minutes at 4°C. The pellet was resuspended in 5ml of PBS and re-centrifuged as 
before. The PBS was removed and the pellet suspended in 160pl of freshly prepared 
hypotonic buffer (lOmM Tris-Cl (pH7.3), lOmM KC1, 1.5mM MgCl2, 2mM PMSF, 
4mM p-mercaptoethanol, 0.5mM benzamidine, lpg/ml leupeptin, lpg/ml aprotinin) 
and transferred to a clean eppendorf tube. The solution was spun in a microcentrifuge 
for 30sec at 14,000rpm at 4°C. The pellet was resuspended in 260pl fresh lysis buffer 
(0.4% (v/v) Nonidet P-40,10mM Tris-Cl (pH7.3), lOmM KC1, 1.5mM MgCl2, 2mM 
PMSF, 4mM P-mercaptoethanol, 0.5mM benzamidine, lpg/ml leupeptin, lpg/ml 
aprotinin) and left on ice for 1 0  minutes before spinning in a microcentrifuge 
(14,000rpm) for 5min at 4°C. The supernatant was removed and the pellet 
resuspended in 25pi of 0.02M KC1 buffer (20mM Tris-Cl (pH7.3), 25% (v/v) glycerol, 
1.5mM MgCl2, 0.2mM EDTA, 20mM KC1,2mM PMSF, 4mM P-mercaptoethanol, 
0.5mM benzamidine, lpg/ml leupeptin, lpg/ml aprotinin) followed by the drop-wise 
addition of lOOpl 0.6M KC1 buffer (20mM Tris-Cl (pH7.3), 25% (v/v) glycerol, 
1.5mM MgCl2, 0.2mM EDTA, 0.6M KC1, 2mM PMSF, 4mM P-mercaptoethanol, 
0.5mM benzamidine, lpg/ml leupeptin, lpg/ml aprotinin). The solution was 
incubated on ice for 30min then centrifuged in a microcentrifuge (14,000rpm) for
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15min at 4°C. The supernatant was aliquoted into clean cryotubes tubes, frozen on 
dry ice and stored at -70°C.
2.3.1.10 Growth Rate Analysis
Three separate methods were used to assess the effect of different 
concentrations of quercetin on the growth characteristics of PalF cells.
(a) Direct Cell Counting
Cells were trypsinised and replated at a density of 5x10s or 106  cells per 
90mm dish in the appropriate growth medium (section 2.3.1.3). After leaving the 
cells overnight to adhere to the culture plastic, old medium was aspirated off and fresh 
medium containing l-100pM quercetin or control medium containing ethanol was 
added to the appropriate dishes of cells. The volume of ethanol in control medium was 
equivalent (v/v) to the highest concentration of quercetin; quercetin or ethanol never 
exceeded 0.5% (v/v) in medium. Dishes of cells were set up in triplicate for each 
concentration of quercetin (1, 20, 50 and 100 pM), ethanol or medium alone.
Medium was changed every 24 hours to ensure that the active concentration of 
quercetin in the medium was maintained as constant as possible. Quercetin- 
containing medium must be properly disposed of (section 2.3.1.9a). Cell cultures 
were examined daily using a 4x and lOx objective lens on a light microscope. When 
monolayers reached approximately 90% confluency cells were trypsinised, removed 
from the culture dish and counted using a haemocytometer (section 2.3.1.4) before 
106  cells were reseeded. This procedure was continued over a period of nine days. At 
the end of the nine days all dishes of cells were trypsinised and the total number of 
cells in each counted. The cumulative number of cells was individually calculated for 
each dish of cells grown in the presence of a specific concentration of quercetin, 
ethanol or medium alone. The average number of cells from the three plates for each 
growth condition was plotted against time in days and graphically reproduced using 
Excel 5.0 spreadsheet software.
(b) MTT assay
MTT is a water soluble tetrazolium salt yielding a yellow coloured solution 
when dissolved in water or PBS. Soluble MTT can be converted to an insoluble
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formazan which is deep purple in colour. Active mitochondrial dehydrogenase 
enzymes will cause this conversion whereas dead cells will not. The water insoluble 
formazan can be solubilized in DMSO or other such solvents and measured 
spectrophotometrically (Carmichael et al, 1987). The absorbance read at 590nm is a 
function of concentration of dye converted.
1000-2500 PalF cells were added to each well in a 96 well tissue culture plate. 
One 96 well plate of cells was set up for each day in the growth curve duration 
including a plate for Day 0. The outer wells along the edge of the plate did not receive 
cells. Instead, 200pl of sterile distilled water was added to each of these wells to 
reduce evaporation from the inner cell-containing wells.
After an overnight incubation, during which time the cells attached to the 
bottom of each well, medium was changed. The fresh medium was supplemented 
with various concentrations of quercetin or ethanol present at the same dilution as the 
highest concentration of quercetin, i.e. 1% v/v. Five wells of cells received normal 
PalF medium only. The first plate, corresponding to Day 0, was incubated for four 
hours only after the addition of fresh medium then treated with MTT and assayed.
Each day thereafter one plate of cells was treated with MTT to determine the number 
of living cells in each well.
Treatment of cells with MTT was performed as follows; Medium from all cells 
in one 96 well plate was aspirated off using an 18 gauge needle. Any medium 
containing quercetin was disposed of in the appropriate manner (section 2.3.1.9a). 
Each well of cells was washed once with pre-warmed PBS before addition of 200jil 
medium containing 400pg/ml MTT. MTT was made from powder as a 5mg/ml stock 
solution in PBS. The plate was replaced in a humid incubator (37°C and 5% (v/v) 
C02) for 3 hours. MTT-medium was removed from each well into a COSHH 3 
conical flask using a 18 gauge needle and detoxified using PRESEPT* tablets as for 
quercetin medium. Following a single wash with PBS, lOOpl DMSO was added to 
each well and the plate placed on a horizontal shaking plateform for 1 0  minutes at 
room temperature. The absorbance in each well was read immediately at 590nm using 
a multiwell plate reader (Dynatech MR7000).
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(c) Thymidine incorporation
The uptake of tritiated thymidine applied to determining the number of viable 
cells in a culture population was first described by Elkind et al, (1963).
1000 or 2500 PalF cells were added to the inner wells of a 96 well plate. The 
wells along the edge of the plate contained sterile distilled water only which reduced 
the level of evaporation from the inner wells. After an overnight incubation, the 
medium was removed and replaced with medium containing increasing concentrations 
of quercetin ranging from l-100pM. Control wells of cells received either PalF 
medium alone or medium supplemented with ethanol, the solvent in which quercetin 
was dissolved.
The plate was incubated for three days in a humid 37°C incubator with an 
atmosphere of 5% (v/v) CO2 . The medium containing quercetin or ethanol was 
changed in the wells each day. On the fourth day medium was removed using an 18 
gauge needle and cells washed with PBS. 20pl of PalF medium containing 0.5 pCi of 
3 H-thymidine was added to each well of cells and incubated for a further 6  hours. The 
radioactive medium was removed into a conical flask containing DECON and 
disposed of down a designated radiochemical sink. 50pl of trypsin solution (0.25% 
trypsin in lx PE) was added to each well, the plate incubated at 37°C for 15 minutes 
and the cells harvested onto printed Filtermat A glass fibre filters using a multiwell 
harvester. Filters were left overnight at room temperature to dry completely before 
being sealed in sample bags with 15ml Betaplate Scint scintillant fluid and counted in 
a Beckman LS6000IC scintillation counter.
2.3.1.11 Luciferase Reporter Assay
Cells were lysed using lx Reporter Lysis Buffer (Promega) as detailed in 
section 2.3.1.9a. 50pl of cell lysate was aliquoted carefully into the bottom of a 
Clinicon disposable measuring cuvette. Luciferase activity in each sample was 
assayed using the Luciferase Assay System (Promega) according to the manufacturer’s 
instructions. The amount of luminescence produced was measured in a BioOrbit LKB 
1251 Luminometer for 30 seconds and readings expressed as millivolts per second.
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2.3.1.12 (3-Galactosidase Reporter Assay
The plasmid pCHl 10 was used in all transient transfections as an internal 
control against which the efficiency of transfection could be normalised. 
(3-galactosidase can catalytically convert colourless o-nitrophenyl-p-D- 
galactopyranoside (ONPG) to yellow o-nitrophenol. The level of activity of this 
enzyme can be assayed by measuring changes in light absorbance at 420nm.
Cells were lysed as detailed in section 2.3.1.9a. To 50pl of each cell lysate, 
lml of solution I (60mM Na2 HP04, 40mM NaH2 P 04, lOmM KC1, ImM MgCl2, 
50mM p-mercaptoethanol) and 0.2ml of solution II (60mM Na2 HP04, 40mM 
NaH2 P 0 4, 2mg/ml) was added. After mixing, all samples were incubated at 37°C for 
30-60 minutes or until a yellow colour change could be seen. Samples were 
transferred to plastic disposable cuvettes and the reactions stopped by the addition of 
0.5ml 1M sodium carbonate. The absorbance was read at 420nm using a Beckman 
DU 650 spectrophotometer.
2.3.1.13 Chloramphenicol Acetly Transferase (CAT) Reporter Assay
40pl of CAT assay master mix (250mM Tris pH7.5, 0.2jiCi
1 4 C- chloramphenicol, 0.5mg/ml acetyl CoA) was added to 5-50pi of each cell lysate 
sample and incubated at 37°C for 1 hour. After the addition of 400pl ethyl acetate, 
samples were mixed thoroughly by inverting the tubes several times and spun at room 
temperature for 30 seconds in a microcentrifuge to separate the aqueous and organic 
phases. The top solvent layer was transferred to a clean eppendorf taking care not to 
disturb the interface. All solvent was evaporated off by drying samples under vacuum 
in a speedivac. Each sample residue was resuspended in lOpl ethyl acetate, spotted 
onto a thin layer chromatography (TLC) plate and placed in a closed glass tank 
containing 95% (v/v) chloroform and 5% (v/v) methanol. As the solvent front moved 
up the TLC plate the various acetylated products of each sample were separated out. 
After 35 minutes, the plate was removed from the tank and placed on a sheet of 3MM 
Whatman paper to air dry. The dried plates were placed in a light tight lead cassette 
and exposed at room temperature to X-OMAT AR X-ray film overnight.
The film was automatically developed by passing it through a Kodak
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X-OMAT 480 RA Processor and placed on a light box. The TLC plates were placed 
on top of the film, aligned, and the position of the non-acetylated substrate and mono- 
acetylated products marked lightly with a pencil outline. These areas were cut out and 
placed in individual scintillation vials; the non-acetylated substrate was placed in a 
separate vial from its acetylated products. The vials were loaded into racks in a 
Beckman LS 6000 IC scintillation counter and readings for each sample obtained in 
Counts per minute (CPM). The percentage of substrate converted into acetylated 
product was calculated using the following formula;
CPM monoacetylated product 
% Conversion =   X 100
CPM non-acetylated product + CPM monoacetylated product
2.3.1.14 Flourescence Activated Cell Sorting (FACS) Analysis
Flourescence Activated Cell Sorting was used to analyse the cell cycling status 
of PalF cells in a particular population. Cells were grown in the presence or absence of 
quercetin according to the experimental conditions given in detail in section 3.3.1.
Cells were harvested by trypsinisation and pelleted at 4°C in growth medium 
as descibed previously in section 2.3.1.4. Each cell pellet was washed twice with ice 
cold PBS spinning cells, as before, between each wash. The second volume of PBS 
was aspirated off and the pellet was resuspended in a small residual volume of PBS 
(~ 200pl) before cells were fixed by the slow, drop by drop addition of 5ml ice cold 
70% ethanol. Samples were left on ice for 1 hour. Cells were either stored at -20°C 
under 70% ethanol for no longer than 1 month or stained immediately.
To stain cells for analysis, each cell suspension in 70% ethanol was pelleted at 
4°C for 5 minutes at 2000rpm. Ethanol was aspirated off and cells resuspended in 
500pl of staining solution (PBS containing 250pg/ml RNAse A, propidium iodide 
(lOpg/ml), 0.2% (v/v) Tween 20). Samples were left at room temperature for 30 
minutes to 1  hours before analysis.
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Stained cell samples were filtered through 70pm nylon gauze into Falcon 2054 
polystyrene round bottom tubes. Samples were assayed using a Becton Dickinson 
FACScan machine and analysed using the ‘Cell Quest’ software package.
2.3.2 Molecular Biology
2.3.2.1 Oligonucleotide synthesis
Single stranded oligonucleotides were synthesised on an Applied Biosystems 
392 DNA/RNA synthesiser using the manufacturers protocols and Cruachem reagents 
by Beatson Institute technical services staff. The final oligonucleotides were made 
with or without trityl group protection. All primers were deprotected after synthesis 
by incubating in a 55°C water bath overnight.
Oligonucleotides carrying the trityl moiety were detritylated using a Cruachem 
oligonucleotide purification (COP) cartridge according to manufacturers instructions. 
Each oligonucleotide was ultimately eluted from the COP cartridge minus the tritly 
group using 1 to 2ml of 20% (v/v) acetonitrile. The acetonitrile was evaporated off 
and the purified oligonucleotide was resuspended in 0.5 to 1ml sterile distilled water 
or TE pH8.0. The absorbance of each oligonucleotide solution was measuring at 
260nm and the concentration of the sample determined. An O.D. reading of 1 at 
260nm corresponds to an oligonucleotide concentration of ~33pg/ml.
Oligonucleotide solutions were stored at -20°C.
"Trityl off' oligonucleotides were provided in ammonia. The oligonucleotides 
were deprotected by heating to 55°C overnight then purified by precipitation with 
butan-l-ol. 1ml butan-l-ol was added to 150pl oligonucleotide solution and 
microcentrifuged at 13,000g for 20 minutes at room temperature. The butanol 
solution was carefully removed and the pellet dried by centrifugation under vacuum. 
The oligonucleotide was finally dissolved in an appropriate volume of sterile distilled 
water or TE pH8.0 and the concentration determined as described above.
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2.3.2.2 PCR-based Mutagenesis
Primers were designed to contain the appropriately altered base(s) plus a 
restriction enzyme site, e.g. Hind III. Single stranded oligonucleotide primers were 
generated and purified as detailed in section 2.3.2.1.
Appropriate primers were used to set up PCR reactions using a GeneAmp PCR 
Kit from Perkin Elmer according to the manufacturers instructions; the total volume 
of each reaction mix was lOOpl containing lng of template DNA plus 40pmol of each 
primer. Each reaction contained IX PCR buffer, 200mM each dNTP and 2.5 units 
AmpliTaq DNA polymerase. The final concentration of MgCl2  in each reaction was 
optimised in the range of l-4mM.
The PCR reaction volumes were contained in 0.5ml sterile eppendorf tubes. 
One drop of sterile mineral oil was added to each tube to cover the top of the reaction 
volume to prevent sample evaporation. The tubes were placed securely in a Perkin 
Elmer Cetus DNA thermal cycler 480. The samples were heated to 95°C for lmin 
(denaturing step), 55°C for lmin (annealing of primers step) and 72°C for 2min 
(elongation step). This cycle of denaturing, annealing and elongation was repeated a 
total of 30 times. The PCR products were phenol:chloroform extracted as detailed in 
section 2.3.2.4 before being digested with the appropriate restriction enzyme(s) 
(sections 2.3.2.3). After digestion, the PCR products were further extracted with 
phenolichloroform to remove any enzyme which may interfere with the ligation 
reaction of product into vector cut with compatible enzyme(s). Inserts were ligated 
into the appropriate vector as detailed in section 2.3.2.8 .
2.3.2.3 Restriction Enzyme Digests
Digestion of DNA was performed in small reaction volumes using enzymes 
and their appropriate concentrated buffer solutions according to the manufacturers 
instructions. 5-10 units of restriction enzyme were added per pg of DNA ensuring 
that the total volume of enzyme added did not exceed one tenth of the final reaction 
volume. Small quantities of plasmid DNA (<5pg) were routinely digested in a 20pl 
reaction volume for 1 to 2 hours at 37°C. Larger digests were carried out in 
proportionally larger reaction volumes. Digestion of DNA with more than one 
enzyme (double digestion) was performed either sequentially or in a single reaction
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providing the buffering conditions for the individual enzymes, as specified by the 
manufacturer, were compatible. When DNA was digested with different enzymes 
separately, the DNA was ethanol precipitated after the first round of digestion and 
resuspended in an appropriate volume of TE before the second reaction mix was set 
up. Reactions were terminated by the addition of 0.5M EDTA (pH 8.0) to a final 
concentration of lOmM. The digested DNA was finally ethanol precipitated and 
resuspended in an appropriate volume of TE.
2.3.2.4 DNA Extraction and Precipitation with Organic Solvents
DNA samples were purified by extraction with a mixture of phenol and/or 
chloroform to remove contaminants such as residual enzyme activities from a 
restriction reaction or detergents which may interfere with subsequent manipulations. 
In the first round of extraction, an equal volume of phenol:chloroform:isoamyl alcohol 
(24:24:1 v/v/v) was added to the DNA solution. The aqueous DNA and organic 
phases were mixed thoroughly by vortexing, then separated by centrifugation in a 
bench top microcentrifuge at 14,000rpm for 5min at room temperature. The upper 
aqueous phase was carefully removed, transferred to a clean microcentrifuge tube and 
the process repeated. Extraction with phenol:choloform:isoamyl alcohol was repeated 
until the interphase between the upper and lower phases was clear. The aqueous 
phase was then extracted with an equal volume of choloform:isoamyl alcohol 
(24:1 v/v) to remove any traces of phenol from the aqueous phase. After vortexing 
and centrifugation to separate the two phases, the upper aqueous DNA phase was 
removed to a fresh tube for ethanol precipitation.
Ethanol precipitation concentrated DNA samples and removed solute 
contaminants such as salt. To the aqueous solution of DNA, one tenth of the volume 
of 3M sodium acetate (pH 5.2) and 2-2.5 volumes of ice cold ethanol was added. The 
solution was mixed by inversion several times and then placed at -20°C for at least 30 
minutes to facilitate DNA precipitation. Precipitated DNA was recovered by 
centrifugation in a microcentrifuge at 14,000rpm for 15min at 4°C. The DNA pellet 
was washed with 70% ethanol to remove any traces of salt, dried under vacuum and 
resuspended in an appropriate volume of TE buffer (pH8.0). The concentration of the 
DNA solution was determined as detailed in section 2.3.2.5.
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2.3.2.5 DNA Quantification
The concentration of DNA in aqueous solutions was measured 
spectrophotometrically in a Beckman DU 650 spectrophotometer. Samples were 
diluted in TE buffer and transferred to a quartz cuvette with a path length of 1cm. The 
spectrophotometer was initially calibrated using TE buffer only as a blank. The 
optical density readings were obtained at 260nm and 280nm; an O.D. reading of 1 at 
260nm (A2 6 0  = 1) corresponds approximately to a concentration of 50pg/ml of double 
stranded DNA. The ratio between readings at 260nm and 280nm (A26o:A28o) 
provided an estimate of the DNA sample purity; a ratio of ~ 1.8 indicated that 
preparations contained essentially no protein or phenol contamination.
2.3.2.6 Agarose Gel Electrophoresis
Horizontal gel cast apparatus from Pharmacia was used. Agarose gels were 
generally 0.8% (w/v) in lxTAE buffer unless otherwise stated. The appropriate 
percentage (w/v) of agarose was dissolved in lxTAE buffer (40mM Tris base, 16mM 
acetic acid, ImM EDTA pH8.0) by heating the solution in a glass conical flask in a 
microwave until all the particles of agarose had dissolved. Ethidium bromide was 
added to the molten agarose to a final concentration of 0.5pg/ml just before the gel 
was poured. The gel was poured when the molten agarose was hand hot and a comb 
with the required number and size of teeth placed immediately into the gel to form the 
sample wells. The solidified gel was placed in the gel tank and submerged in lxTAE 
buffer containing 0.5p.g/ml ethidium bromide. Samples containing lx  loading buffer 
(lOx loading buffer; 0.45% (w/v) bromphenol blue, 1% (w/v) SDS, lOOmM EDTA, 
2.5% (w/v) Ficoll 400 in TE) were loaded into individual wells. An appropriate sized 
DNA marker was generally loaded into the first and/or last well in the gel. DNA 
markers used were;
• 1Kb DNA ladder (Suitable for sizing linear double-stranded DNA from 500bp to 12kb)
• X Hind III (Suitable for sizing linear double-stranded DNA from 125bp to 23kb)
• q>X174 Hae El (Suitable for sizing linear double-stranded DNA from 72 to 1,353 bp)
DNA was separated on the gel by running at 70-100 constant voltage usually until the 
samples' blue dye front was l-3cm from the end of the gel. The separated DNA was
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visualised by illimination on a short wave (312nm) UV light box and photographed 
onto videoprint paper using an Appligene Imager.
2.3.2.7 Isolation and Purification of DNA Restriction Fragments from Agarose Gels
DNA fragments to be used for cloning were separated from unwanted products 
of the restriction digest reaction by electrophoresis on 0 .6 % non-denaturing agarose 
gels and visualised as described in section 2.3.2.6. The fragment band was cut out of 
the gel using a clean scalpel blade and the gel slice placed in a sterile microcentrifuge 
tube. Extraction of the DNA fragment from the agarose was achieved using a 
QIAquick gel extraction kit (Qiagen) following the manufacturer's instructions. 
Alternatively, DNA fragments were purified from the gel slices using extraction with 
phenol:chloroform as detailed in section 2.3.2.4. First the gel slice was weighed then 
three volumes of TE buffer were added to the tube containing the gel fragment. The 
tube was place at 50°C until the gel had dissolved completely in the TE. Extraction 
with phenol:chloroform was performed as described earlier.
2.3.2.S Cloning DNA Fragments into Plasmid Vectors
Vector DNA and the DNA fragment to be inserted into the vector were 
separately digested according to conditions detailed in section 2.3.2.3. The DNA 
fragment to be cloned into the vector was prepared as described in section 2.3.2.7.
The cut ends of the vector DNA were dephosphorylated to prevent the vector 
from religating to itself. After the vector DNA had been linearized by digesting with 
the required enzymes in a 2 0 pl reaction volume, 2 .2 pl of lOx alkaline phosphatase 
buffer and 1 jlj.1 ( 1  unit) of alkaline phosphatase were added to the reaction mixture and 
incubated at 37°C for a further 35 minutes. All enzyme activity in the reaction was 
finally stopped by heating the reaction volume to 65°C for 5 minutes. Sterile distilled 
water was added to the inactivated reaction to a final volume of 60pl before 
undergoing phenol chloroform extraction (section 2.3.2.4).
The DNA fragment was inserted into dephosphorylated vector at a ratio of 3:1 
respectively. The vector (lOOng) and insert DNA were incubated together in a 
reaction containing lx  ligase buffer and lpl (4 units) of T4 DNA ligase and incubated
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overnight at 11°C. Dilutions of this reaction volume were used to transform 
competent bacterial cells (section 2.3.2.9).
2.3.2.9 Transformation of Competent Bacterial Cells
E.Coli DH5a competent cells obtained commercially were used for the 
propagation of plasmid DNAs. Stocks of competent cells were stored at -70°C. 
Bacteria were transformed according to the manufacturer's instructions.
Briefly, DH5a cells were thawed on wet ice and after gentle mixing, 20jal of 
the cell suspension was aliquoted into a chilled polypropylene tube (Falcon 2059).
Any unused bacterial cells were re-frozen rapidly in a dry-ice/ethanol bath and 
replaced in a -70°C freezer. Any one batch of cells should not be freeze-thawed more 
than once. l-2ng of plasmid DNA was gradually added to the cells while mixing 
gently. The cells were left on ice for 30 minutes. Cells were heat shocked by placing 
in a 42°C water bath for 40 seconds then immediately returned to ice for 2 minutes. 
80pl of sterile SOC (2% bactotryptone, 0.5% yeast extract, lOmMNaCl, 2.5mM KC1, 
lOmM MgC^, lOmM MgS04, 20mM glucose) was slowly added to the cells and the 
tube then placed securely in a shaking (225rpm) incubator at 37°C for 1 hour. Finally, 
the total transformation mix was spread onto a pre-warmed L-agar plate containing 
antibiotic at the appropriate concentration (eg. lOOpg/ml ampicillin), inverted and 
incubated at 37°C overnight. Colonies obtained were either picked immediately or the 
plates stored at 4°C up-side-down and wrapped in parafilm for up to two weeks.
2.3.2.10 Glycerol Stocks
Stocks of transformed bacterial cells were made by first picking a single 
colony of newly transformed cells with a sterile yellow pipette tip. This was used to 
inoculate a 5ml volume of warm L-broth containing the appropriate antibiotic. The 
5ml culture was incubated overnight at 37°C whilst shaken at 225rpm. 850p,l of the 
overnight culture, which contained exponentially growing cells, was added to 150pl of 
sterile glycerol in a 1.5ml Nunc cryotube. The mixture was vortexed to ensure that the 
glycerol was mixed throughout the bacterial cell suspension and frozen rapidly by 
placing the tube into a dry-ice/ethanol bath for 5 minutes. Glycerol stocks were stored 
at -70°C.
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2.3.2.11 Small Scale Preparation of Plasmid DNA (Miniprep)
Small amounts of plasmid DNA were simultaneously extracted from several 
individual, transformed bacterial colonies using either a QIAprep Spin plasmid 
miniprep kit following the manufacturer's instructions or the alkaline lysis method as 
described by Maniatis et al, 1989.
Briefly, a single colony of bacteria was picked from an agar+antibiotic plate 
using a sterile yellow pipette tip. This was used to inoculate a 5ml culture of L-Broth 
(1% (w/v) bactotryptone, 0.5% (w/v) yeast extract, 1% (w/v) NaCl). 20 to 40 separate 
colonies were generally picked for screening at any one time. The 5ml cultures were 
incubated at 37°C in a shaking incubator (225rpm) overnight. 1.5ml of each confluent 
bacterial culture was pelleted by spinning in a microcentrifuge (14,000rpm) for 30 
seconds at room temperature.
Each bacterial pellet was resuspended in lOOpl lysozyme solution (50mM 
glucose, 25mM Tris-HCl (pH8.0), lOmM EDTA, 2mg/ml lysozyme) and let stand at 
room temperature for 5 minutes. 200pl of freshly prepared solution 2 (0.2M NaOH, 
1% (w/v) SDS) was then added, mixed in gently and left at room temperature for 5 
minutes. 1 50j l x 1 of ice-cold 3M potassium acetate (pH4.8) was added, mixed 
thoroughly and the solution placed on ice for 5 minutes. The precipitate formed was 
pelleted by spinning the samples in a microcentrifuge (14,000rpm) for 3 minutes at 
room temperature and the supernatant removed to a clean eppendorf tube. The nucleic 
acids were precipitated by adding 2  volumes of ice-cold ethanol to the supernatant and 
standing the tube at room temperature for 5 minutes followed by centrifugation in a 
microcentrifuge (14,000rpm) for a further 10 minutes at 4°C. The pellet was washed 
with 70% ethanol before drying under vacuum for 5 minutes to remove all traces of 
ethanol. The pellet was dissolved in 20pl TE and stored at -20°C. Contaminating 
RNA in these samples can interfere with the detection of DNA fragments on an 
agarose gel. Hence RNA in these samples was destroyed by the addition of DNase- 
free RNase A (0.5mg/ml) to the digestion mixture.
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2.3.2.12 Large Scale Preparation of Plasmid DNA (Maxiprep)
lml of a 5ml overnight culture was used to inoculate 500ml of Super Broth 
(1.2% (w/v) bactotryptone, 2.4% (w/v) yeast extract, 0.8% (v/v) glycerol, 0.72M 
K2 HPO4 , 0.17M KH2 PO4 ) containing antibiotic (lOOpg/ml ampicillin) in a 2 litre 
glass conical flask. The culture was incubated at 37°C for 48 hours shaking at 
225rpm.
Bacterial cells were collected by centrifuging for 10 minutes at 6000g at 4°C. 
The bacterial pellet was weighted; 5g of bacterial pellet was resuspended in 20 ml 
GTE solution (50mM glucose, 25mM Tris-Cl (pH8.0), lOmM EDTA). When the 
pellet was completely resuspended, 5ml of 25mg/ml lysozyme in GTE solution was 
added, mixed thoroughly and the whole solution allowed to stand at room temperature 
for 10 minutes. 50ml of freshly prepared 0.2M NaOH / l%(w/v) SDS was added and 
stirred in gently with a pipette until the solution became homogenous and clear; this 
viscous solution was incubated on ice for 10 minutes. 37.5ml of 3M potassium 
acetate solution was added and the whole solution inverted sharply five times. The 
viscosity of the solution was reduced and a large, white precipitate formed. The 
solution was placed on ice for a further 1 0  minutes followed by centrifugation at 
20,000 x g at 4°C.
The supernatant was decanted through several layers of filter tissue and 
0.6 volumes of propan-2-ol added. The whole solution was mixed by inversion 
several times and left to stand at room temperature for 10 minutes. Nucleic acid was 
recovered by centrifuging for 10 minutes at 15,000 x g at room temperature. The 
pellet was washed with 70% ethanol, centrifuged briefly to collect the pellet, excess 
ethanol drained off and the pellet dried under vacuum.
The pellet was resuspended in 8 ml TE buffer. When completely dissolved, 
8 .8 g CsCl and 0.4ml lOmg/ml ethidium bromide were added. The refractive index of 
the solution was adjusted to 1.395. The solution was transferred to a 10ml 
polyallomer ultracentrifuge tube and the tube filled (if necessary) using CsCl/TE 
solution (with R.I.=1.395). The tube was sealed and placed in a T1270 rotor with a 
protective metal cap over the top of each tube. The plasmid DNA was banded by 
centrifuging at 55,000rpm for 24 hours at 20°C in a Sorvall OTD Combi 80 
ultracentrifuge.
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The tube was carefully removed from the centrifuge rotor and placed securely 
in a clamp on a retort stand. An 18 gauge needle was first inserted into the top of the 
tube to act as an air inlet and then a second needle attached to a 2 ml syringe was 
inserted into the side of the centrifuge tube ~lcm below the lower plasmid band. The 
plasmid DNA band was then carefully extracted and transferred to a clean 
ultracentrifuge tube. The tube was filled with CsCl/TE (RI=1.395) as before and a 
second round of ultracentrifugation at 50,000rpm (20°C) was performed for 48 hours.
The plasmid DNA band was removed from the tube as described above and 
the ethidium bromide in the solution removed by extracting with an equal volume of 
TE saturated butan-2-ol. The solution was mixed and the ethidium bromide separated 
with the upper organic phase which was carefully removed and discarded into 
appropriate waste bottles. The extraction with butanol was repeated until the lower 
aqueous phase was clear and colourless. The plasmid DNA was ethanol precipitated 
directly (section 2.3.2.2) or dialysed.
To dialyse, the plasmid DNA solution was transferred into a dialysis tube 
(Collodion Bag) and placed in a large beaker containing 2.5 litres of TE. Plasmid 
DNA was dialysed against the TE on a magnetic stirrer for 4 hours at room 
temperature. The TE buffer was changed and dialysis continued for a further 4 hours 
at room temperature or overnight at 4°C. After dialysis, plasmid DNA was ethanol 
precipitated as detailed in section 2.3.2.4.
2.3.2.13 DNA Sequencing
The sequence of all new plasmids was checked using Taq terminator 
sequencing on an Applied Biosystems 373A automated DNA sequencer which was 
performed by Beatson Institute technical servives staff.
The region to be sequenced first underwent PCR amplification. 0.5pg of 
template DNA was added to 12pl RQ grade H20 plus 3.2pmoles the appropriate 
primer. 8  pi of dye terminator cycle sequencing ready reaction premix was then added 
to each reaction volume contained in 250pl thin walled eppendorf tubes. The sample 
were placed in a PTC-100 programmable thermal controller (Genetic Research 
Instrumentation Ltd) and exposed to 25 cycles of 95°C for 30secs, 50°C for 15secs 
and 60°C for 4min. The PCR products were ethanol precipitated as detailed in section
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2.3.2.4, washed with 70% ethanol and finally dried under vacuum before being given 
to a member of technical services for loading onto the sequencing gel.
2.3.2.14 End Labelling Double Stranded Oligonucleotide
Single stranded oligonucleotides were synthesised using Cruachem chemicals 
and an Applied Biosystems 392 DNA/RNA automated oligonucleotide synthesising 
machine by Beatson Institute technical services. Oligonucleotides were deprotected 
by incubating at 55°C overnight, ethanol precipitated and resuspended in TE buffer. 
The concentration of oligonucleotide solutions was measured spectophotometrically at 
described in section 2.3.2.3. However, an optical density reading of 1 at 260nm 
(Abs260nm) f°r a single stranded oligonucleotide is roughly equivalent to a solution of 
33pg/ml compared to 50pg/ml for double stranded DNA.
Complementary single stranded oligonucleotides were mixed together in 
equimolar amounts, heated to 95°C for 5 minutes and then allowed to cool slowly to 
room temperature which enabled the two strands to anneal together into double 
stranded molecules. The concentration of the double stranded oligonucleotide 
solution was measured spectrophotometrically and diluted with TE buffer to give a 
final concentration of O.lmg/ml. Oligonucleotide solutions were stored at -20°C.
Double stranded oligonucleotides with sticky ends were end labelled as 
follows. Using a random primed labelling kit (Boehringer Mannheim), lpl (0.5nmol) 
dCTP, lpl (0.5nmol) dATP and 1 jlxI  (0.5nmol) dGTP solutions were added to 200ng 
of double stranded oligonucleotide. The reaction volume was made up to 12pl with 
distilled water. 2pl of lOx Klenow buffer (0.5M Tris-Cl (pH7.2), 0.1M MgSO^ ImM 
DTT, 0.5mg/ml bovine serum albumin (BSA - fraction V)) was added followed by 5pi 
[a-3 2 P]dTTP and lpl (2 units) Klenow enzyme (also taken from the random primed 
labelling kit). The contents of the reaction were mixed and incubated at 37°C for 30 
to 60 minutes. The radiolabelled oligonucleotide was separated from unincorporated 
nucleotides by polyacrylamide gel electrophoresis as described in section 2.3.2.15.
2.3.2.15 Purifying Radioactive Probe using Polyacrylamide Gel Electrophoresis
A 6 % non-denaturing polyacrylamide gel was made by adding 15% (v/v) 40% 
(w/v) acrylamide:2.1% (w/v) bisacrylamide solution to 0.5x TBE buffer (89mM Tris
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base, 89mM orthoboric acid, 2mM EDTA (pH8.0)). Polymerization of the gel was 
catalysied by the addition of 0.07% APS and 0.08% TEMED. After mixing 
thoroughly, the solution was poured between two glass plates which had been 
siliconized with repelcote, washed with detergent and cleaned with 70% ethanol prior 
to use. A comb forming sample wells was placed in the top of the gel immediately 
after pouring. The gel, 2mm thick, was left to polymerize in a verticle position for 
1  hour before use.
The gel spacer was removed and the gel, formed between the two glass sheets, 
was placed vertically into the electrophoresis tank (ATTO) containing 0.5x TBE and 
secured in place. 0.5x TBE buffer was added to the top reservoir of the tank to cover 
the top of the gel. The comb was removed carefully from the gel and each well rinsed 
out with 0.5x TBE buffer using a 20ml syringe. The gel was run for 15 minutes at 
150 volts to equilibrate the gel before any samples were loaded.
The radioactively labelled sample(s) was loaded into a single gel well. No 
loading dye was added to the sample, however lOpl of bromophenol blue loading 
buffer was added to the extreme wells to monitor the gels progress. The sample(s) 
was electrophoresed at 150 volts at room temperature until the blue dye front was 
approximately 5cm from the end of the gel. The position of each radiolabelled 
oligonucleotide was determined by exposing the gel, covered with cling film, to a 
sheet of Fuji RX medical X-ray film for 1-2 minutes. Using the X-ray film as a guide, 
the band containing the labelled probe was excised from the gel using a clean scalpel 
blade. The gel slice was transferred to a clean eppendorf tube and TE buffer was 
added to the tube sufficient to cover the gel slice. The tube was placed in a lead pot, 
sealed and left at room temperature overnight during which time the oligonucleotide 
eluted from the gel slice into the TE buffer. The polyacrylamide gel slice was 
removed from the solution and the radioactive oligonucleotide solution stored at 
-20°C.
2.3.2.16 Electrophoretic mobility Shift Assay (EMSA)
PalF cells were harvested for their nuclear extract as described previously in 
section 2.3.1.9c. Samples of nuclear extract were removed from storage at -70°C and 
thawed on wet ice. To 5pl (10-15pg) of nuclear protein extract, still on ice, 5pl lOx 
binding buffer (lOOmM HEPES (pH7.9), 2mM EDTA, 1M NaCl, lmg/ml BSA, 40%
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glycerol), 60|ug/ml polydldC and 4.4mM DTT was added followed by lpl (~lng) of 
radioactively labelled double stranded oligonucleotide DNA (section 2.3.2.14). 
lOOng of various unlabelled (cold) double stranded oligonucleotide was added to 
selected samples for competition analysis. The volume of each reaction mix was 
made up to 50pl with distilled water, mixed and incubated on ice for 30 minutes.
Each sample was loaded into a separate well on a 5% non-denaturing 
polyacrylamide gel prepared as described in section 2.3.2.17. 5 pi loading dye mixed 
with 45pl lx binding buffer was added to the end wells on the gel to allow migration 
of the samples down the gel to be monitored. Samples were electrophoresed at 150 
volts at 4°C until the blue dye front in the tracking wells was ~3cm from the end of 
the gel. The gel was transferred onto Whatman 3MM filter paper and dried down on a 
Biorad 583 gel drier at 80°C for 2 hours using a slow rise in temperature cycle. The 
dried gel was placed in a lead, light tight casette with intensifying screens, covered 
with a sheet of Fuji RX medical X-ray film and placed at -70°C overnight.
2.3.2.17 Non-denaturing Polyacrylamide Gel electrophoresis
A pair of 2mm ATTO glass plates were siliconized with repelcote, washed 
with detergent and cleaned with 70% ethanol prior to use. A 5% polyacrylamide gel 
was made by adding 12.6% (v/v) of 40% (w/v) acrylamide:2.1% (w/v) bisacrylamide 
solution to 0.5x TBE buffer (89mM Tris base, 89mM orthoboric acid, 2mM EDTA 
(pH8.0)). Polymerization of the gel was catalysied by the addition of 0.07% APS and 
0.08% TEMED. After mixing thoroughly, the solution was poured between two glass 
plates held securely together in the gel forming apparatus (ATTO). A comb to make 
the samples wells was placed in the top of the gel immediately after pouring. The gel 
was left to polymerize in a verticle position for 1  hour before use.
The gel spacer was removed and the gel, formed between the two glass sheets, 
was placed vertically into the electrophoresis tank (ATTO) containing 0.5x TBE and 
secured in place. The upper reservoir was filled with 0.5x TBE buffer, the comb was 
removed carefully from the gel and each well rinsed out with 0.5x TBE buffer using a 
20ml syringe. The gel was run for 15 minutes at 150 volts prior to use to equilibrate 
the gel.
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2.3.2.18 Electrophoretic mobility SuperShift Assay
Supershift assays provide a means of identifying a protein which shows 
binding affinity to a short sequence of DNA. The protocol employed in supershift 
assays was essentially identical to that detailed in section 2.3.2.16 except that antibody 
was added to the binding reaction before the addition of radiolabelled oligonucleotide. 
The antibody used is specific for a protein, or family of related proteins, which is 
suspected of binding to the oligonucleotide used in the EMSA assay.
2 pl (0 .2 ng) of antibody was added to a reaction mix containing 5pi (10-15ug) 
nuclear extract, lx binding buffer (lOmM HEPES (pH7.9), 0.2mM EDTA, 0.1M 
NaCl, 0.1 mg/ml BSA, 4% glycerol), 60pg/ml polydldC and 4.4mM DTT. This 
reaction mix was incubated on ice for 30 minutes after which time lpl (~lng) of 
radiolabelled double stranded oligonucleotide was added to the mix. The whole 
reaction was incubated on ice for a further 30 minutes. The samples were 
electrophoresed on a 5% non-denaturing polyacylamide gel (section 2.3.2.17) and 
after the gel was dried it was exposed to X-ray film as detailed in section 2.3.2.16.
2.3.3 Biochemistry
2.3.3.1 Determination of Protein Concentration in Cell Lysis Samples
Cells were harvested for total cellular protein as described in section 2.3.1.9b. 
The concentration of protein in a sample was determined by application of the 
BCA/CuS04  protein assay.
Proteins reduce alkaline Cu(II) to Cu(I) in a concentration-dependent manner. 
Bicinchoninic acid is a highly specific chromogenic reagent for Cu(I), forming a 
purple complex with an absorbance maximum at 562nm.
A small volume of each protein sample was diluted 1/10 and then lOpl of 
undiluted and diluted protein solution were placed in separate wells in a 96 well plate. 
200pl of developing solution (5ml BCA (Bicinchoninic acid) solution, lOOpl of 4% 
(w/v) CuS0 4  (copper II sulphate pentahydrate solution) was added to the diluted and 
undiluted protein samples and the plate incubated at 37°C for 1 hour.
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The absorbance of each sample was read at 590nm using a Dynatech MR7000 
automatic plate reader. The absorbance reading was converted to concentration in 
pg/pl for each sample using a standard curve generated from a series of control BSA 
solutions of known concentration. The actual concentration of each protein sample 
was calculated after multiply by the relevant dilution factor.
2.3.3.2 SDS-Polyacrylamide Gel Electrophoresis and Western Blotting
The resolving gel, containing 8-11% polyacrylamide in lx  resolving gel 
buffer-pH8 . 8  (4x RGB: 1.5M Tris, 0.4% SDS - pH to 8 . 8  with HC1) was poured 
between two glass plates siliconised and cleaned as described in section 2.3.2.17. 
0.08% TEMED and 0.07% APS were also added to the liquid resolving gel mixture, 
before the gel was poured, to catalyse polymerisation. The top of the gel was covered 
with water saturated butan-2-ol and allowed to polymerise for 1 hour. The butanol 
was poured off and the top of the gel washed with water and blotted dry. The stacking 
gel consisting of 5-7% polyacrylamide in 1 x stacking gel buffer-pH6 . 8  (4x SGB:
0.5M Tris, 0.4% SDS - pH to 6 .8 ) was poured on top of the resolving gel, a comb 
inserted and left to polymerise for at least 30 minutes before use. Again TEMED 
(0.08%) and APS (0.07%) were added to the gel mix to catalyse polymerisation. Due 
to the difference in pH between the stacking and resolving gels, the stacking gel 
should only be poured up to 1 hour before use to minimise merging of the pH's.
Equivalent amounts of each protein sample (20-40pg) was mixed with an 
equal volume of 2x SDS gel loading buffer (lOOmM Tris-Cl (pH6 .8 ), 2% (v/v) 
P-mercaptoethanol, 4% (w/v) SDS, 0.2% (w/v) bromophenol blue, 20% (v/v) 
glycerol), boiled for 3 minutes then placed immediately on ice. Samples were loaded 
into consecutive wells and 5 pi Rainbow™ protein molecular weight marker mix 
(molecular weight range 14.3KD-200KD) added to the first or last well on the gel.
The gel was run at 80mA (constant current) for several hours or at 25mA overnight in 
lx  Tris-glycine buffer (25mM Tris, 250mM glycine, 0.1% (w/v) SDS) at room 
temperature until the sample dye front was ~ l- 2 cm from the end of the gel.
The separated protein bands were visualised by placing the gel in 20-30ml 
staining solution (0.25% Coomassie Brilliant Blue (R250) dissolved in 45% (v/v) 
methanol, 45% (v/v) H2 0, 10% (v/v) glacial acetic acid) at room temperature on a 
slowly shaking platform for 2 0 min followed by destaining in the same solution
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without coomassie blue. Several changes of destain solution must be made for 
background staining to be minimised. The stained gel was dried down onto Whatman 
3MM paper using a Biorad 583 gel drier.
The gel was not stained with Coomassie blue if the proteins were to be 
Western blotted onto a nitrocellulose filter. Instead, one of the glass plates was 
removed and unused portions of the gel, including the stacking gel, were cut away and 
disgarded. The gel was rinsed twice in distilled water and placed on top of two sheets 
of Whatman 3 MM paper, cut to the same size as the gel, which had been soaked in 
Towbin buffer (0.3% (w/v) Tris, 0.19M glycine, 10% (v/v) methanol, 0.03% (v/v) 
conc. HC1) (Towbin et ol, 1979). A piece of nitrocellulose or Hybond Cextra 
membrane, cut to the same size as the gel, was soaked in Towbin buffer and placed 
carefully on top of the gel. Finally two more pieces of Towbin soaked Whatman 
3 MM paper cut to gel size were placed on top of the membrane and the whole 
assembly placed in a Bio-Rad cassette between two sponges which had been 
presoaked in Towbin. It is very important that no air bubbles exist between any of the 
paper, gel or membrane layers as these will interfer with transfer. The whole sandwich 
was placed in the Bio-rad wet transfer tank, the nitrocellulose side of the sandwich 
being positioned closest to the cathode. The tank was filled with Towbin buffer and 
the transfer performed overnight at 4°C at 30 volts.
After transfer the gel was stained with Coomassie blue staining solution as 
described above and the filter stained for 5 minutes in a solution of Ponseau S which 
allowed the fidelity of transfer and loading consistency to be checked. Ponseau S 
stain is a temporary stain which can be washed off the membrane with water. Proteins 
on the filter were detected using antibodies as described in section 2.3.3.3.
2.3.3.3 Phosphotyrosine Protein Detection on Western Blot
The filter was placed in 100ml blocking buffer (5% (w/v) Marvel (dried milk) 
in PBS-T (0.1% (v/v) in PBS)) and incubated at room temperature for 2 hours or at 
4°C overnight on a gently shaking platform. If the filter was blocked overnight, the 
blocking buffer was changed and the filter blocked at room temperature for 1  hour 
before addition of the primary antibody solution. The filter was placed in 25ml 
blocking buffer containing PY20 antiphosphotyrosine mouse monoclonal antibody at 
a 1/5000 dilution and incubated at room temperature for 1 hour with gentle agitation.
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The primary antibody solution was removed and filter rinsed in blocking buffer then 
washed 3 times, each for 15 minutes, in 100ml volumes of fresh blocking buffer. The 
filter was then incubated in 25ml blocking buffer containing a 1/1000 dilution of anti­
mouse IgG horse-radish peroxidase linked whole antibody for 1 hour at room 
temperature with gentle agitation.
The filter was rinsed, washed twice for 15 minutes in blocking buffer and 
finally washed for 15 minutes a further three times in PBS-T buffer only. Excess 
surface liquid was removed from the filter by briefly blotting with a piece of Whatman 
3 MM paper. Antibody was detected by immersing the filter in ECL detection reagent 
for 1 minute, the filter wrapped in cling film and exposed to Kodak X-OMAT S (fast) 
x-ray film at room temperature over a range of time intervals.
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Chapter 3
The Effect of Quercetin on the Growth 
Characteristics of PalF cells
Chapter 3 The effect of quercetin on the growth characteristics of PalF cells
3.1 Introduction
Quercetin (3,3’ ,4’ ,5,7-pentahydroxy flavone) is a member of a large class of 
natural substances called flavonoids which display a wide variety of biological actions 
(Gabor, 1988). Quercetin is one of the more extensively studied flavonoids and is 
present in most edible fruits and vegetables (Kuhnau,1976); humans are estimated to 
consume approximately 1  gram of mixed flavonoids each day as part of a normal diet, 
and of this amount quercetin is estimated to constitute 50 to 500mg (Jones and 
Hughes, 1982). Quercetin is classified as a weakly toxic drug and doses of lg per day 
per adult has been shown to have no serious side effects (Havsteen, 1983). It has been 
previously used therapeutically for the treatment of inflammation, allergy, bee sting 
and ulcer (Hofmann et a l, 1990).
Quercetin in the diet has been proposed to have beneficial qualities, namely as 
a chemopreventive agent (Verma et a l, 1988; Deschner et a l , 1991; Kato et a l , 1983) 
and as an inhibitor of tumour growth and invasion (Bracke et a l , 1988; Okada et a l, 
1990; Scambia et a l, 1990c, 1992; Ranelletti et a l, 1992). These positive qualities of 
quercetin have been related to its antioxidant and growth inhibitory properties. As an 
antioxidant quercetin displays free radical scavenging activity (Bors and Saran, 1987; 
Negre-Salvayre and Salvayre, 1992; Morel et a l, 1993). However, quercetin can also 
function as a prooxidant; auto-oxidation of quercetin has been shown to lead to the 
concomitant production of semiquinone radicals, superoxide anion radicals (0 2+), 
hydrogen peroxide (H2 0 2) and hydroxyl radicals ( OH) (Elliott et a l, 1992). The 
prooxidant actions of quercetin may contribute to the compound’s genotoxicity (Fazal 
et a l, 1990; Rahman et a l, 1990; Elliott et a l, 1992). Furthermore, the ability of 
quercetin to behave as a pro- or antioxidant appears to be dependent on the redox state 
of the cellular background (Plaumann et a l, 1996).
Quercetin has been shown to be a genotoxic agent (Bjeldanes and Chang,
1977; Brown, 1980; Nagao et a l, 1981); it can induce mutations in both prokaryotic 
and eukaryotic cells (Bjieldanes and Chang, 1977; MacGregor and Jurd, 1978; 
Amacher et a l, 1979; Maruta et a l, 1979; Nakayasu et a l, 1986; Ishikawa et a l,
1987) and cause clastogenic damage (Yoshida et a l, 1980; Ishidate et al., 1988).
Work by Suzuki et al (1991) revealed that quercetin could induce recombination of
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minisatellite sequences in a mouse fibrosarcoma cell line and in a mouse mammary 
tumour cell line in culture. The genotoxicity of quercetin correlates with its ability to 
complex with DNA and induce strand breaks in the presence of Cu(II) ions and 
oxygen (Rahman et a l , 1990; Fazal et a l , 1990). The free radicals generated by 
quercetin in the presence of Cu(II) can also lead to the fragmentation of proteins such 
as albumin (Said Ahmed et a l, 1994).
Compounds which are demonstrated to possess mutagenic properties are often 
shown to concurrently function as carcinogens. However, while the studies outlined 
above demonstrate that quercetin can act as a mutagen, few reports have identified 
quercetin to be carcinogenic. A study by Pamukcu and co-workers found that albino 
non-inbred male and female rats fed on a diet containing 0 .1 % quercetin for 
approximately one year developed multiple tumours of the ileal intestine and bladder 
(Pamukcu et al, 1980). In other long term animal feeding experiments, where 
quercetin was given at various concentrations in the diet to a number of different 
rodent species, quercetin was not found to be carcinogenic (Hirono, 1981; Hirono et 
a l, 1981; Morino et a l, 1982). The carcinogenicity of quercetin observed by Pamuku 
et al. (1980) may be partially attributable to the genetic background and/or microflora 
in the gut of the experimental animals used; Norwegian rats may be particularly 
sensitive to the carcinogenic effects of quercetin. The purity of quercetin use by 
Pamukcu et al (1980) was reported as >99% compared to >95% in other studies. It is 
possible, although unlikely, that the less pure quercetin preparations contained a 
potent inhibitor of quercetin-induced carcinogenesis.
An interesting report by Ishikawa et al (1987) showed that a mouse 
fibrosarcoma cell line (BMT-11 cl-9) treated with quercetin in vitro and then 
transplanted into C57B1/6 female mice, lead to the appearance of both regressing and 
progressing tumours. Thus, in these experiments, quercetin was shown to possess 
both a tumour promoting and anti-tumourigenic properties. The authors suggest that 
the fate of cells exposed to quercetin is determined by the specific spectrum of genes 
altered genetically, epigenetically or both. A later study by the same group suggested 
that tumour regression is associated with a decrease in prostaglandin E2  production 
(Okada etal., 1990).
The carcinogenicity of quercetin in the presence of other carcinogenic 
compounds has also been studied. The cooperative effects of 7,12-
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dimethylbenz[a]antracene (DMBA) and 12-0-tetradecanoylphorbol-13-acetate (TPA) 
in the production of skin tumours in mice has been extensively studied and well 
characterised (Balmain and Pragnell, 1983; Balmain et al., 1984). From such 
experiments TPA has been classified as a tumour promoter while DMBA has been 
shown to function as a tumour initiating agent. Quercetin has been observed to inhibit 
the promotive effects of TPA on skin tumours initiated by DMBA in a mouse skin 
model (Kato et a l, 1983). The ability of quercetin to inhibit TPA-induced tumour 
promotion has been associated with the concomitant inhibition of epidermal 
lipoxygenase activity (ibid.). Deschner and co-workers found that quercetin in the 
diet could inhibit azoxymethanol (AOM)-induced colonic tumours in CF1 female 
mice (Deschner et al., 1991); Verma et al. (1988) observed that DMBA and N- 
nitrosomethylurea-induce rat mammary cancers were similarly inhibited by dietary 
quercetin.
Finally, quercetin has further been shown to synergise with known anti­
proliferative drugs such as cisplatin (C-DDP), busulphan and adriamycin to inhibit 
tumour growth both in vitro (Hoffman et a l, 1988; Hofmann et al., 1989; Scambia et 
al., 1990a, 1994b) and in vivo (Hofmann et a l, 1990; Scambia et al., 1992).
In direct contrast to the results described above, quercetin given orally was 
shown to cause a dose-dependent enhancement of tumours induced by azoxymethane 
(AOM) in a rat colon model system (Pereira et al., 1996). In this setting, quercetin 
exhibits co-carcinogenic activity, functioning as a tumour promoting agent, analogous 
to the actions of TPA in the skin mouse model (Kato et al., 1983). It is particularly 
interesting to compare the work of Deschner et al 1991 and Pereira et al. 1996; in 
both studies, the duration of the experiment was very similar, as was the purity and 
concentration of quercetin in the diet. The inducer (AOM) and amount given was 
identical, however while both groups gave their animals 30mg AOM per kg body 
weight (30mg/kg) in total, Deschner et al. (1991) administered 3 separate sub­
cutaneous injections of lOmg AOM per kg body weight (lOmg/kg) compared to a 
single sub-cutaneous injection by Pereira et al. (1996). Perhaps the most notable 
difference between the two studies was that Deschner et al. (1991) used CF1 female 
mice whereas Pereira et a l (1996) used male Discher 344 rats. The age of the animals 
in both studies was very similar. In both experiments quercetin was shown not to 
inhibit the formation of aberrant crypt foci or nuclear aberrations, two alterations
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attributable to the actions of AOM. Hence, it would appear that quercetin does not 
inhibit the initiating effects of AOM.
In support of the results obtained by Pereira et al (1996), quercetin has further 
been demonstrated to modulate the mutagenic properties of aromatic amines and 
acetamides (Ogawa et a l , 1987a, 1987b), to enhance tumour induction by 
methylcholanthrene (Ishikawa et a l , 1985) and act as a tumour initiator in co­
operation with TPA in a two-stage transformation assay in mammalian cells in vitro 
(Sakai et al, 1990). Finally, quercetin was shown to transform normal primary PalF 
cells to a tumourigenic phenotype in nude mice in cooperation with BPV4 sequences 
and an activated ras gene (see section 1.7.2 for details; Pennie and Campo, 1992).
In keeping with the in vivo observations outlined above, quercetin has also 
been reported to have contradictory effects on various cell lines in vitro. The vast 
majority of work published however describes a growth inhibitory role of quercetin in 
a wide range of tumour cell lines derived from numerous cell types and anatomical 
sites. The growth of several leukaemic cell lines (Scambia et a l, 1990b; Yoshida et 
a l, 1992; Post and Varma, 1992) as well as acute myeloid leukaemia (AML) and 
acute lymphoid leukaemia (ALL) primary leukaemic blasts (Larocca et a l, 1990) has 
each been inhibited by quercetin. Furthermore quercetin was shown to inhibit AML 
and ALL progenitors in colony forming assays (Larocca et a l, 1991,1995). In 
addition to leukaemic cells, quercetin exerts growth inhibitory action on human 
mammary and breast cancer cell lines (Markaverich et a l, 1988; Scambia et a l, 1991, 
1993), human ovarian tumour and cultured cancer cells (Scambia et a l, 1990c, 1992, 
1994a), human meningiomas (Piantelli et a l, 1993), human melanoma cells (Piantelli 
et a l, 1995), and colon-cancer cell lines and primary colorectal tumours (Piantelli et 
a l, 1990; Hosokawa et a l, 1990a; Ranelletti et a l, 1992). In most of these studies, 
quercetin was seen to affect growth inhibition in a concentration-dependent manner.
In addition to assessing the general growth inhibitory action of quercetin, the effect of 
quercetin on cell cycle status in some cell lines has also been analysed.
Quercetin was seen to elicit a Gi/S phase arrest in human gastric cancer cells 
(IC50 of 32-55pM) (Yoshida et a l, 1990) and human colon cancer cells (Hosokawa et 
a l, 1990a). A late Gi arrest was observed when human leukaemic T-cells (70pM) 
(Yoshida et a l, 1992) and human peripheral blood lymphocytes (Gong et a l, 1994) 
were exposed to quercetin. In the latter experiments, cell cycle arrest followed the
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onset of cyclin E expression (Gong et a l , 1994). OVCA 433 cells (ovarian cancer 
cells)(Scambia et a l, 1990c) and colon cancer cell lines (Ranelletti et a l, 1992) were 
all blocked in the Go/Gi phase of the cell cycle by quercetin at concentrations ranging 
from lOnMto IOjjM.
However not all cells were induced to stop in the Gq/Gj to late Gi/S phase of 
the cell cycle. MDA-MB468 cells (human breast cancer cell line) arrested at the G2/M 
step in the cell cycle following a six day exposure to 30pg/ml (~89pM) quercetin 
(Avila et a l, 1994); arrest of the MDA-MB468 cells in G2/M correlated with the 
inhibition of translation of endogenous mutant p53. p53 mediated G2/M arrest was 
similarly observed in a non-tumour cell line C3H10T1/2CL8 (Plaumann et a l, 1996). 
In contrast to the results of Avila et a l (1994), this G2/M arrest was not observed in 
association with mutant p53 inhibition. Rather, quercetin was found to induce the 
accumulation of wild type p53. In addition to the G2/M arrest, quercetin further 
induced apoptosis in C3H10T1/2CL8 cells which occurred out of the G2/M phase.
The G2/M arrest and apoptosis observed in these cells following a 72hr exposure to 
120pM quercetin was determined to be p53 dependent as the same effects were not 
observed in p53 knockout fibroblasts (Plaumann et a l, 1996). Although p53 is 
generally associated with blocking the cells at the Gi/S transition point in the cell 
cycle, several reports have also identified a role for p53 in the establishment of a G2/M 
checkpoint later in the cell cycle (Agarwal et a l, 1995; Siegel et a l, 1995; Stewart et 
a l, 1995).
In relation to the cell cycle/growth inhibitory effects of quercetin, a number of 
cellular target molecules, in addition to p53 discussed above, have been implicated in 
mediating the actions of quercetin. Many reports identify the ability of quercetin to 
interact with estrogen type II binding sites (type-II EBS). Type-II EBS, originally 
described by Clark et a l, (1978) in the rat uterus, while displaying the same steroid 
and tissue specificity seen for the ‘true’ estrogen receptor (ER), occur at higher 
concentrations and exhibit a lower affinity for its ligand, estradiol, compared to ERs 
(Markaverich et a l, 1979; Syne et a l, 1982). Indeed, the binding affinity of type-II 
EBS for estradiol is so low, it is unlikely that these sites would be occupied by 
estrogens in vivo. Markaverich et al (1990) demonstrated that type-II EBS in normal 
and malignant cells are occupied by a flavonoid-like ligand which displays growth 
inhibitory activity. Furthermore, type-II EBS but not ERs in several human cancer
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cells lines bind flavonoids (Markaverich et a l, 1983) and inhibit cell growth possibly 
by mimicking the endogenous ligand (Markaverich et a l, 1984).
Quercetin has subsequently been shown to induce type-II EBS. Levels of type- 
II EBS is human breast-cancer cell lines were seen to increase following exposure to 
quercetin (Scambia et a l, 1993). The ability of quercetin to induce type-II EBS was 
well correlated with the relative binding affinity of quercetin for type-II EBS. More 
importantly, quercetin-induced enhancement of type-II EBS was accompanied by 
increased sensitivity of the breast cancer cell lines to the inhibitory effects of quercetin 
(Scambia et a l, 1993). Other reports further support a role for type-II EBS in 
mediating the actions of quercetin. The growth inhibitory potential and sensitivity of 
colon-cancer cell lines and primary tumours to quercetin correlated with the affinity 
for and number of type-II EBS per cell respectively (Ranelletti et a l, 1992). Type-II 
EBS have likewise been associated with the growth inhibiting actions of quercetin in 
primary and cultured ovarian cells (Scambia et a l, 1990b, 1990c), human menigiomas 
(Piantelli et a l, 1993) and melanoma (Piantelli et a l, 1995) as well as several myeloid 
and lymphoid leukaemic cells (Larocca et a l, 1990; Teofili et a l, 1992) and normal 
bone marrow (Larocca et a l, 1991).
Although the reports described above implicate type-II EBS in at least partially 
mediating the growth inhibitory effects of quercetin, the complete mechanism of 
action of quercetin is still poorly understood. TGFpi (transforming growth factor-p) 
has been presented as another potential candidate involved in quercetin-induced 
growth inhibition (Scambia et a l, 1994a; Larocca et a l, 1995). TGFpl is one 
member of a family of structurally related proteins (Keller et a l, 1992; Jacobsen et a l, 
1993). It has been isolated from normal and neoplastic cells (Roberts and Spom,
1985) and can significantly influence the growth and differentiation of numerous cell 
types. It can stimulate and/or inhibit the growth of myeloid progenitor cells depending 
on their differentiation status (Aglietta et a l, 1989; Hatzfeld et a l, 1991; Jacobsen et 
a l, 1991; Bursuker et a l, 1992; Keller et a l, 1992) and has further been shown to 
inhibit the growth of several human cancer cell lines (Knabbe et a l,  1987; Zugmaier 
et al, 1989; Berchuck et a l, 1990).
Quercetin has been shown to enhance TGFp 1 secretion from human ovarian 
cancer cells (Scambia et a l, 1994a). In this study, quercetin-induced growth 
inhibition was reversed by addition of a TGFpi neutralising antibody. Furthermore
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the induction of TGFpi following exposure to quercetin appeared to be specific as 
other anti-proliferative compounds were seen to have no effect on TGFpi secretion 
(ibid). In a second study, quercetin was found to induce TGFpi expression in 
leukaemic progenitor cells (Larocca et a l, 1995). Analogous to the work by Scambia 
et al (1994a), the use of TGFpi antisense oligonucleotides and neutralising 
monoclonal antibodies was shown to block the growth-inhibitory action of quercetin 
(ibid.).
It has been proposed that TGFpi expression is a consequence of type-II EBS 
induction. This is supported by experiments using other anti-proliferative drugs, such 
as tamoxifen, which like quercetin is known to bind type-II EBS. Tamoxifen, an anti­
estrogen used in the treatment of breast cancer, has been demonstrated to bind type-II 
EBS and subsequently induce TGFpi production (Knabbe et al., 1987; Colletta et a l, 
1990).
Type-II EBS and TGFp however are not the only possible mechanism(s) 
through which quercetin may be achieving growth inhibition. Quercetin is also 
reported to deregulate and/or inhibit the actions of a large number of enzymes 
including ATP-utilizing enzymes, such as protein kinase C (PKC) (Gschwendt et a l , 
1983), phosphatidylinositol 3-kinase (PI3-kinase) (Matter et a l, 1992), the Na,K- 
ATPase (Lang and Racker, 1974; Kuriki and Racker, 1976), the src encoded tyrosine 
kinase (Graziani et a l, 1983) as well as several other tyrosine kinases (Srivastava and 
Chiasson et a l, 1986) by competitive inhibition of ATP binding. Inhibition of 
enzyme activity, particularly kinases and phosphatases which mediate signal 
transduction signals, represents another way in which quercetin interferes with cellular 
proliferation. Quercetin can inhibit several other enzymes including cyclo-oxygenase 
and lipoxygenase (Kato et a l, 1983; Elia and Santoro, 1994). It has been suggested 
that lipoxygenase products are essential for tumour promotion (Fischer et a l, 1982), 
therefore inhibition of lipoxygenase by quercetin may constitute another putative 
mechanism by which quercetin prevents tumour promotion (Kato et a l, 1983; 
Nakadate et a l, 1984). In addition to the inhibition of specific enzyme activities, 
quercetin has also been shown to increase cyclic AMP levels (Graziani et a l, 1979), 
inhibit aerobic glycolysis, DNA, RNA and protein synthesis, and the transport of 
lactate, D-glucose and Ca (Hosokawa et a l , 1990b; Yoshida et a l , 1992 and
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references therein; Graziani et ah, 1983 and references therein; Uddin and Choudhry, 
1995).
The concentration of quercetin capable of inhibiting tumour cell growth in 
vitro is in the range of InM to lpM  (Scambia et ah, 1993; Piantelli et al., 1995). A 
quercetin concentration at this level has been shown to affect type-II EBS but is lower 
than the concentrations reported to inhibit many enzyme activities (>50pM) (Elliott et 
al., 1992; Lang and Racker, 1974; Monaham et al., 1975; Kuriki and Racker, 1976; 
Shoshan and MacLennam, 1981). This would suggest that the growth inhibitory 
effects of quercetin at concentrations <l\xM involves a mechanism mediated by type-II 
EBS. However not all cells will express type-II EBS and therefore higher local 
concentrations of quercetin may potentially be needed for significant growth 
inhibition to be realised. Notwithstanding, some enzymes, including lipoxygenase 
and PI3-kinase, and also certain cellular processes such as lactate transport and 
glycolysis, are more sensitive to quercetin and have been shown to be inhibited at 
quercetin concentrations similar to those sufficient to induced type-II EBS (Kato et 
al., 1983; Matter et ah, 1992; Belt et ah, 1979). Therefore, whatever the mechanism, 
it is quite probable that quercetin achieves growth inhibition by targeting several 
cellular mechanisms either individually or simultaneously. The specific cell type and 
local concentration of active quercetin will also dictate how quercetin will ultimately 
affect the cells’ normal activity.
Analysis of the anti-proliferative action of quercetin described above has been 
performed using, almost exclusively, tumourigenic cell lines or tumour material.
Even when non-oncogenic cell lines were used, the cells were nonetheless immortal. 
The effect of quercetin on primary, non-transformed cells of any origin has not been 
assessed in any detail. It is therefore not known if there is a differential response to 
quercetin by normal, primary cells compared to immortal or tumourigenic cells. 
Determining the sensitivity of various cell types at different stages of transformation 
would be very relevant and beneficial when considering the use of quercetin as an 
anticancer agent; it would naturally be very convenient to have an agent which 
exclusively or more specifically inhibited the growth of tumour cells in comparison to 
normal cells. Therefore, in light of the growth inhibitory activity of quercetin 
observed for a large number of tumour cell lines by several independent groups, we
103
wished to evaluate the effect of various concentrations of quercetin on the growth of 
normal, primary fibroblasts (PalF cells) originally derived from the soft palate of a 
bovine foetus. Furthermore, and more importantly, with respect to earlier results 
where quercetin was shown to act as a co-carcinogen in the BPV4 transformation 
system (Pennie and Campo, 1992; Caimey and Campo, 1995), we wished to 
determine if PalF cells continue to grow in the presence of quercetin particularly in 
concentrations which were effective at inducing cellular transformation in cooperation 
with BPV4 E7 and an activated ras.
3.2 Analysis of Growth Rate of PalF cells in the presence of quercetin
Earlier experiments demonstrated that quercetin, given at a concentration of 
20jiM, was able to synergise with BPV4 (or subgenomic fragments of BPV4) and ras 
in the transformation of PalF cells to a fully tumourigenic phenotype (Pennie and 
Campo, 1992; Caimey and Campo, 1995). In an attempt to evaluate the growth of 
normal PalF cells in the presence of quercetin, PalF cells were grown in medium 
containing increasing concentrations of quercetin. Three separate assays were used to 
characterise the growth response of PalF to a range of quercetin concentrations: these 
assays were MTT, tritiated-thymidine uptake and direct counting of viable cells (see 
section 2.3.1.10 for experimental details).
Why use three assays to analyse essentially the same characteristic of PalF 
cells’ behaviour in the presence of quercetin? By using three separate assays to look 
at the growth response of PalF cells quercetin, we would expect to find that the results 
from one assay generally confirmed or supported the results from the other assays, 
thus reinforcing that any effect of quercetin on PalF cell growth was genuine.
Each of the three assays used in the course of the work presented here have 
their own advantages. The manual counting of cells using a haemocytometer and 
visualising viable cells using dye exclusion and a light microscope (see section 
2.3.1.10a) has previously been the most direct and frequently used method for 
determining cellular growth rates. However, direct cell counting is slow and relies on 
personal assessment and accuracy in counting the number of viable cells. Also, larger 
culture dishes/flasks requiring greater volumes of medium are needed. Therefore it
104
would be beneficial to find an alternative method which was accurate and consistent 
with direct cell counting but which may be performed more rapidly and easily.
The MTT assay features several advantages in that it can be performed in 96- 
well plates which means fewer cells and less medium is needed in each well, multiple 
replicates can be set up for each quercetin concentration being analysed, a wide range 
of quercetin concentrations can be assessed using a single 96-well plate, and all 96 
wells can be read rapidly and simultaneously using a scanning multiwell spectrometer. 
The MTT assay is easy to do, convenient, quick and less labour intensive than the 
direct cell counting method. However, one disadvantage and important consideration 
when using the MTT assay with application to quercetin is that quercetin itself has 
been shown to directly reduce MTT (Habtemariam, 1995). Because this assay is 
dependent on the cellular reduction of MTT by the mitochondrial dehydrogenase of 
viable cells to the blue formazan product (Carmichael et a l , 1987), care had to be 
taken when quercetin was used in association with MTT. It was important, therefore, 
that all quercetin containing medium was removed from each well and that cell 
monolayers were washed with PBS before fresh medium containing MTT reagent was 
replaced (see section 2.3.1.10b for details of method employed). In this way the 
reduction of MTT could be attributed to the viable cells present per well and not to 
residual quercetin.
Like the MTT assay, the tritiated (H3)-thymidine uptake assay was performed 
in 96-well plates. However, thymidine-uptake was not used as a means of assessing 
the number of viable cells on a daily basis. Rather, this assay provided information 
relating to the specific concentration of quercetin which produced a 50% reduction in 
the uptake of H -thymidine relative to control cells, that is, cells which were not 
exposed to quercetin. The concentration of quercetin (or any compound) which 
inhibits the uptake of H3-thymidine by 50% is called the I.C.50 value. Indirectly, the
I.C.50 reading can be related to the proliferation rate of cells as the uptake of 
thymidine is generally proportional to cell number.
By employing these three separate assays for assessing the proliferative 
response of PalF cells to quercetin in culture medium, it was hoped that comparisons 
could be made whereby the results of one assay would be supported by the results of 
the other two. Furthermore, by comparing the results of the MTT assay with those
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obtained from direct cell counting, the accuracy and applicability of the MTT assay as 
a more convenient and rapid method of assessing the growth rate of PalF cells may be 
considered.
3.2.1 Experimental Procedure
Normal, low passage PalF cells were used in all three assays detailed below. 
Figure 3.1 shows photographs of normal, sub confluent PalF cells as viewed using a 
light microscope.
For direct cell counting, cells were seeded at 5xl0 5  or 106  cells per 90mm 
tissue culture dish as detailed in section 2.3.1.10a. Triplicate dishes were set up for 
each concentration of quercetin (1,20, 50 and lOOpM). Control dishes were also set 
up in triplicate where cells were incubated in medium alone or medium supplemented 
with 0.5% ethanol (0.5% v/v ethanol was equivalent to the volume of quercetin 
dissolved in ethanol which was added to medium to give final quercetin concentration 
of IOOjjM). Fresh medium, with or without quercetin/ethanol, was replenished in 
each dish every 24 hours in an attempt to keep the effective concentration of quercetin 
in the culture medium constant. Cell monolayers were trypsinised and counted, 
according to the procedure detailed in section 2.3.1.10a, when cells reached 
approximately 90% confluence. The growth of PalF cells was assayed according to 
this method over a 9 day time interval.
In the MTT assay, 1000 or 2500 cells were plated into each well in 96-well 
plates as indicated in section 2.3.1.10b. Following an overnight incubation during 
which time the cells adhered to the bottom of each well, the medium was changed. 
Where appropriate the medium was supplemented with quercetin to a final 
concentration of 0.1,1,10, 15, 25, 35, 50, 75, 100 or 200pM. Five wells of cells were 
exposed to each of the quercetin concentrations (quintuplicate wells). In addition to 
the specific quercetin concentrations, two control groups of five wells were each 
incubated in either medium alone or medium supplemented with 1 % v/v ethanol ( 1 % 
v/v ethanol was equivalent to the volume of quercetin in ethanol added to wells to 
give a final quercetin concentration of 200pM). Medium was replenished in all wells
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Figure 3.1 Photographs of Normal Primary PalF cells
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every 24 hours. PalF cell proliferation rates were assayed using MTT for a period of 7 
days.
Similar to the conditions set for the MTT assay, for the H3-thymidine uptake 
assay PalF cells were seeded into separate wells in 96-well plates at a density of 1000 
or 2500 cells per well (see section 2.3.1.10c). Plates were incubated overnight to 
allow cells to adhere to the culture plate’s surface. The following day, old medium 
was removed and replaced with either fresh medium alone, medium + 1 % v/v ethanol, 
or medium containing quercetin at the appropriate concentration (0.1, 1,10, 15, 25,
35, 50, 75, 100 or 200pM). Quintuplicate wells were set up for each culture medium 
condition. Medium (+/- quercetin or ethanol) was changed every 24 hours for the next 
three days. On the fourth day, H3-thymidine in PalF medium was added to each well 
and the plates incubated in the appropriate atmosphere for a further 6  hours, as detail 
in materials and methods (section 2.3.1.10c).
3.2.2 Results
(a) Direct cell counting
Figure 3.2 shows the growth curves for PalF cells which were cultured in 
medium containing quercetin over a nine day period. The cell doubling time for 
untreated PalF cells was shown to be 36 to 48 hours. Quercetin present at 1 pM has no 
significant effect on the growth of PalF cells. However, when quercetin was present 
at concentrations of 20pM and higher, the doubling time for PalF cells was increased. 
The higher the concentration of quercetin in the culture medium, the greater the 
inhibitory effect on PalF cell growth rate. Cell proliferation was almost totally 
inhibited when quercetin was present at concentrations > 50pM. From the graphs,
20|liM was the concentration of quercetin which was seen to inhibit the growth rate of 
PalF cells by more than 50%.
(b) MTT assay
Figure 3.3 corresponds to the second set of growth curves for PalF cells 
cultured in the presence of quercetin over a six day period. The absorbance readings 
are proportional to cell number. Consistent with the results shown in figure 3.2,
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quercetin was seen in inhibit the growth rate of PalF cells in a concentration 
dependent manner. A quercetin concentration of 10 to 15pM was seen to inhibit the 
growth rate of PalF cells by approximately 50%.
(c) Tritiated thymidine uptake
Figure 3.4 illustrates the effect of increasing concentrations of quercetin on the 
uptake of H -Thymidine by PalF cells. A quercetin concentration of 25 to 35pM was 
effective at inhibiting the uptake of thymidine by PalF cells by approximately 50% 
(I.C.50 = 25-35pM). This is consistent with results obtained by other workers (Dr. 
Judith Brown, personal communication). The I.C.50 is slightly greater than the 
concentrations of quercetin which were found to inhibit the growth rate of PalF cells 
as indicated in the results shown in figure 3.2 and 3.3. One explanation for this is 
that the thymidine uptake assay involved treating PalF cells with quercetin for only 
three days compared to nine and six days in the growth rate assays described above.
Nevertheless, the results from each of the three independent assays showed 
that quercetin inhibited the growth of, and uptake of thymidine by, normal PalF cells 
in a concentration-dependent manner. The concentration of quercetin which inhibited 
the growth of PalF cells by approximately 50%, as determined by direct cell counting 
(~20pM) (Figure 3.2) and MTT (10-15pM) (Figure 3.3), correlated relatively closely 
with the I.C.50 value obtained from the H3-thymidine uptake assay (25-35pM) (Figure 
3.4). The results indicate that all three assays yield similar results. Furthermore, the 
results support the use of the MTT assay as a attractive alternative to direct cell 
counting as a rapid and convenient method of analysing the growth rate of PalF cells. 
Hence the MTT assay may be applied in future studies to analyse the growth response 
of PalF, PalF transfected cells or other similar cell types to quercetin and/or other test 
compounds. Finally, it must be stressed that care must always be taken when using 
quercetin in conjunction with MTT due to the potential of quercetin to independently 
reduce MTT.
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Figure 3.3 MTT assay results illustrating the growth rates of 
PalF cells cultured in increasing concentrations of quercetin.
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Figure 3.4 H3-Thymidine uptake by PalF cells exposed to increasing
concentrations o f quercetin.
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3.3 Cell cycle analysis of PalF cells exposed to quercetin
As outlined above in section 3.1, quercetin has been shown to induce cell cycle 
arrest in several tumour cell lines and tumour material. The results from the growth 
analysis (section 3.2) showed that quercetin inhibited the growth of PalF cells in a 
concentration dependent manner. However, the growth curves gave no indication as 
to how quercetin was affecting proliferation; it was not clear whether the inhibition of 
cell growth was due to an increase in the rate of apoptosis, such that the rate of cell 
death was equal to the rate of proliferation, or if quercetin was inducing growth arrest 
at a specific or random stage in the cell cycle. As a means of addressing these 
questions, cell cycle analysis was performed on PalF cells cultured in medium 
containing increasing concentrations of quercetin.
3.3.1 Experimental Procedure
5xl05 low passage PalF cells were seeded into 90mm tissue culture dishes. 
After an overnight incubation during which time the cells adhered to the culture 
plastic, the medium was changed. Cells were cultured in either medium alone, 
medium + 0.5% ethanol, or medium supplemented with 1,20, 50 or 100pM quercetin. 
Medium was replenished in all dishes every 12 hours. Duplicate dishes were set up 
for each culture condition. Cells were grown in the appropriate medium for 12, 24, 36 
or 48 hours. Following treatment cells were harvested and the percentage of cells in 
each phase of the cell cycle was determined using fluorescence activated cell sorting 
(FACS) as detailed in section 2.3.1.14.
The effect of quercetin on the cell cycle was not studied for a period longer 
than 48 hours. Within the context of earlier experiments, PalF cells treated with 
quercetin for 48 hours was shown to be sufficient to induce transformation to 
tumourigenicity in co-operation with BPV4 and an activated ras oncogene (Pennie 
and Campo, 1992; Cariney and Campo, 1995). We therefore only wished to analyse 
the cell cycle status of PalF cells exposed to quercetin within a 48 hour time interval.
3.3.2 Results
The photographs of PalF cells exposed to a variety of quercetin concentrations 
for 48 hours (figure 3.5) show that quercetin can induce certain morphological
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Figure 3.5
Figure 3.5 Photographs of PalF cells taken after exposure to various
concentrations of quercetin for 48 hours
Panel A, B and C: Cells exposed to lxDMEM medium only 
Panel D, E and F: Cells exposed to lxDMEM supplemented with 0.5% ethanol 
Panel G,H and I: Cells exposed to medium supplemented with lpM quercetin
Panel J, K  and L: Cells exposed to medium supplemented with 20pM quercetin 
Panel M, N and O: Cells exposed to medium supplemented with 50pM quercetin 
Panel P, Q and R: Cells exposed to medium supplemented with lOOpM quercetin
Panels A, D, G, J, M and P: Bright field images; final magnification x20 
Panels B, E, H, K, N and q: Phase contrast images: final magnification x50 
Panels C, F, I, L, O, and R: Phase contrast images: final magnification xlOO
Figure 3.5
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changes particularly when present at concentrations as high as lOOpM (Figure 3.5). In 
addition to an obvious reduction in cell density, cells were flatter and the cytoplasm 
was more vacuolar in appearance when grown in medium containing higher levels of 
quercetin. Nevertheless, the number of floating cells in the medium did not appear to 
be dramatically increased when cells were cultured in higher quercetin concentrations 
(personal observation). This would suggest that the concentrations of quercetin used 
were not sufficiently cytotoxic to induce significant cell death within 48 hours after 
first addition. However, no specific assay to accurately assess the level of apoptosis 
was performed. Therefore, the ability of quercetin to induce apoptosis in PalF cells 
has not yet been determined.
As the line plots in figure 3.7 illustrate, 12 hours after the addition of 50 or 
lOOpM quercetin to culture medium, the proportion of cells in the Go/Gi phase of the 
cell cycle was seen to fall dramatically. Simultaneously, the proportion of cells in S 
phase was seen to increase accordingly. A similar drop in the percentage of cells in 
G2 /M phase was also observed 12 hours after quercetin was first added to the culture 
medium; the fall in the proportion of cells in G2 /M was again only observed for cells 
treated with 50 or IOOjiM quercetin. These observations suggest that quercetin, at 
concentrations of 50 and IOOjiM, can stimulate cells in G0 /G 1 to enter S phase and 
cells in G2 /M to progress through mitosis (M phase) and on into Gj. An alternative 
explanation is that cells’ exit from S phase was delayed in the presence of quercetin. 
Whether quercetin is stimulating cells to enter S and M phases of the cell cycle or 
delaying their exit into successive phases, this effect of quercetin appears to be an 
early and transient event only. By 24 hours the accumlation of cells in S was no 
longer evident.
As the growth rate studies indicate (figures 3.2, 3.3 and 3.4), quercetin inhibits 
the growth of PalF cells when constantly present in the culture medium. Therefore, 
the effects of quercetin on PalF cells appears to be incompatible with normal cell 
proliferation. Indeed, cell cycle analysis of PalF cells treated with quercetin for longer 
time periods suggests quercetin can induce a proportion of cells to arrest.
A partial arrest in the G2 /M phase of the cell cycle was observed in cells 
exposed to quercetin for 48 hours (Figure 3.6 and 3.7). The percentage of cells 
arrested in G2 /M was proportional to the concentration of quercetin in the
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Figure 3.7 Plots showing the percentage of PalF cells in each phase 
of the cell cycle following exposure to increasing concentrations 
of quercetin over a 48 hour period
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culture medium. Furthermore, the percentage of cells arresting in G2 /M in response to 
quercetin increased steadily over the 48 hours of the experiment (Figure 3.6 and 3.7).
It was observed in early, preliminary cell cycle experiments that if quercetin 
was added only once to each culture dish, that a similar G2 /M arrest began to appear 
within 24 hours after quercetin was first added to the medium. Consistent with the 
results above, the percentage of cells arresting in G2 /M was dependent on and 
proportional to the concentration of quercetin in the medium. However, over the next 
24 hours, the percentage of cells in G2 /M steadily declined rather than continuing to 
increase as expected. The apparent recovery of PalF cells from this quercetin-induced 
arrest suggested that the effect of quercetin on the cell cycle was merely transient. 
Nevertheless, results from the later experiments where quercetin was replenished in 
the medium every 12 hours (Figures 3.6 and 3.7), showed that the proportion of cells 
arresting in the G2 /M phase of the cell cycle increased steadily over the 48 hour assay 
period. Quercetin in culture medium appears to undergo a process of gradual 
inactivation or degradation: hence the effective concentration of active quercetin in 
medium seeems to decline over time. Thus in all subsequent experiments, quercetin 
was replenished every 12 to 24 hours in an attempt to maintain the active 
concentration of quercetin as constant as possible.
As mentioned above, the cell cycle arrest of PalF cells in response to quercetin 
exposure was concentration dependent. The extent of the growth arrest observed was 
greatest for the highest concentrations of quercetin (> 50pM). However, it is evident 
from the DNA histogram plots (figure 3.6) and from the line plots illustrating the 
percentage of cells in each phase of the cell cycle (figure 3.7) that quercetin, even 
when present at a concentration lOOfiM, did not induce a complete G2 /M arrest in 
PalF cells. This is consistent with observations made by Hosokawa et a l (1990a) and 
Plaumann et al (1996).
One explanation for this may be that concentrations of quercetin greater than 
IOOjiM are necessary to induce a complete G2 /M phase arrest in PalF cells. Indeed, a 
quercetin concentration of 120pM was required to induce a significant growth arrest 
in C3H10T1/2CL8 cells (Plaumann et a l , 1996).
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A further explanation is that the experiment was not continued long enough to 
allow all cells to arrest in G2 /M. From the growth rate analyses (section 3.2), PalF 
cells in these experiments have been shown to have a cell doubling time of 36 to 48 
hours. Because the cell cycle analysis was only observed over a 48 hour period, it is 
possible that not enough time had elapsed for all susceptible cells to arrest in any 
particular stage of the cell cycle.
A third possibility may be that quercetin can induce cells to arrest in more than 
one phase of the cell cycle. Indeed, as the results in figure 3.7 indicate, the level of 
cells in the Go/Gi phase of the cell cycle peaked 24 hours after quercetin was first 
added to the culture medium and dispite a drop by 36 hours, the proportion of cells in 
the Go/Gi phase of the cell cycle remained relatively high. Thus the results suggests 
that quercetin can simultaneously induce a G2 /M and a Gi arrest in PalF cells
PalF cells can be induced to arrest largely in Gq/Gj . This was confirmed when 
PalF cells were cultured in medium containing low serum concentrations (0.5% serum 
compared to a normal concentration of 10%). After 48 hours, 86.56% of cells were in 
G0 /Gi, 11.56% of cells were in G2/M and 1.91% of cells were in S phase (Figure 3.8). 
For normal, untreated PalF cells, 64.34%, 13.47%, and 22.19% of cells were in Go/Gi, 
G2/M and S phase respectively. This suggests that the ability of quercetin to induce a 
G2/M arrest is a specific effect of quercetin and not merely a consequence of PalF 
cells’ inability to arrest in Go/Gj.
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Figure 3.8 DNA profiles o f PalF cells grown in (A) high (10%) and 
(B) low serum (0.5% )lxD M EM  medium for 48 hours
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Chapter 4
Analysis of the Effects of Quercetin 
on BPV4 transcription
Chapter 4 Analysis of the effects of quercetin on BPV4 transcriptional activity
4.1 Introduction
As discussed in detail in earlier chapters, the bioflavonoid quercetin can 
synergise with BPV4 DNA sequences, in the presence of an exogenous activated ras 
gene, and induce several characteristics of transformation in bovine foetal palate 
fibroblast (PalF) cells including tumorigenicity (Pennie and Campo, 1992; Caimey 
and Campo, 1995) (see section 1.7.2). The mechanism(s) involved in this 
transformation system is not known. The principle aim of this thesis was to attempt to 
identify possible mechanisms by which quercetin contributes to the cellular 
transformation of PalF cells in association with BPV4.
4.2 The effect of quercetin on the transcriptional activity of the wild type, full 
length BPV4 LCR acting in a promoter configuration
We hypothesised that quercetin may contribute to the transformation of PalF 
cells, in co-operation with BPV4, by altering the level of viral transcription; an 
increase in viral transcription may give rise to higher levels of viral proteins which 
could contribute to the transformation observed. To tests this hypothesis, PalF cells 
were treated with 20|iM quercetin for 48 hours both before and after transfection with 
a plasmid carrying the entire BPV4 LCR cloned upstream and driving expression of a 
luciferase reporter gene. Cells were exposed to 20pM quercetin as this was the 
concentration of quercetin which was sufficient to transform PalF cells, in co­
operation with BPV4 viral sequences and an activated ras gene, as detailed in earlier 
experiments (Pennie and Campo, 1992; Caimey and Campo, 1995).
4.2.1 Experimental procedure
Quercetin solid (powder) was dissolved in ethanol to give a stock solution of 
20mM. A fresh stock solution of quercetin was made every week and stored at 
-20°C.
105  low passage PalF cells were seeded into 60mm tissue culture dishes as 
specified in section 2.3.1.7. Following an overnight incubation, during which time the 
cells adhered to the tissue culture dish, the culture medium was removed and replaced 
with either fresh medium supplemented with 20p,M quercetin or medium
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supplemented with an equivalent volume of ethanol. Cells were incubated in the 
appropriate medium for 48 hours. At the end of 48 hours, the cells were co­
transfected with either 7.5pg pLCRLuc plus 2.5pg pCHl 10 vectors or 7.5pg pOLuc 
plus 2.5pg pCHl 10 vectors according to the protocol detailed in section 2.3.1.7. The 
plasmid vector pCHl 10 contains the lacZ gene; this second reporter vector was 
included in all transfections as an internal control providing a means of determining 
and correcting for the efficiency of each transfection.
After transfection, cells which had initially been exposed to quercetin before 
transfection received medium supplemented with ethanol, while cells which were 
previously cultured in ethanol containing medium were given medium plus quercetin; 
quercetin was present at a final concentration of 20pM. Each dish of cells was 
incubated in the appropriate medium for a further 48 hours. At the end of the 48 
hours, cells were harvested (see section 2.3.1.9a) and assayed separately for luciferase 
and p-galactosidase enzyme activities, as detailed in sections 2.3.1.11 and 2.3.1.12.
Table 4.1 summarises the various incubation and transfection conditions which 
were used in this experiment. Conditions #1 and #2 correspond to control sets in 
which cells were not exposed to quercetin. In each experiment, duplicate cell samples 
were set up for each of the 6  conditions.
The luciferase reading for each sample was corrected for efficiency of 
transfection using the p-galactosidase readings according to the following equation;
(Sample’s luciferase reading - background luciferase reading (lysis buffer 
only)) x (average of all p-gal. readings -r sample’s P-gal reading)
Background transcription, attributable to the empty vector (pOLuc) alone, was 
corrected for by subtracting the average luciferase readings from condition #1, #3 and 
#5 from the average luciferase readings from condition #2, #4 and # 6  respectively.
The ‘No quercetin’ reading was then set =1 and the ‘Quercetin before’ and ‘Quercetin 
after’ readings were subsequently normalised to the ‘No quercetin’ reading. Once 
normalised, the results from all the separate experiments were amalgamated; the 
average luciferase reading, and the standard error of the mean (S.E.M), were 
calculated for each condition (quercetin before transfection, quercetin after
122
transfection and no quercetin) using the results from all experiments combined. The 
Student’s t-Test was used to calculate p; p provides a measure of how statistically 
significant is the difference between two values, or how likely it may be that the 
difference between two values may have occurred by chance. A p value less than or 
equal to (<) 0.05 is taken as being statistically significant.
Table 4.1 Summary of the experimental conditions used when PalF cells were 
transfected with the BPV4 LCR present in a promoter configuration, and treated 
with or without quercetin.
Condition
#1
Condition
#2
Condition
#3
Condition
#4
Condition
#5
Condition
#6
Before transfection Med + 
EtOH
Med + 
EtOH
Med + 
Quer.
Med + 
Quer.
Med + 
EtOH
Med + 
EtOH
Transfected with pOLuc + 
pCHl 10
pLCRLuc 
+ pCHl 10
pOLuc + 
pCHl 10
pLCRLuc 
+ pCHl 10
pOLuc + 
pCHl 10
pLCRLuc 
+ pCHl 10
After transfection Med + 
EtOH
Med + 
EtOH
Med + 
EtOH
Med + 
EtOH
Med + 
Quer.
Med + 
Quer.
Abbreviations used: Med = medium (IX DMEM)
Quer. = quercetin (to final concentration of 20pM)
EtOH = ethanol (a volume equivalent to the volume of
quercetin added in other conditions, ie. 0 . 1 % v/v)
4.2.2 Results
Figure 4.1 shows the results obtained from 8  separate experiments. Quercetin 
was shown to increase the transcriptional activity of the BPV4 LCR by an average of 
2.67 fold over untreated control cells. Exposure of cells to quercetin before 
transfection had no apparent effect on the activity of the LCR. The p values obtained 
were as follows;
• Quercetin before transfection compared to no quercetin; p=0.48
• Quercetin after transfection compared to no quercetin; p=0.0036**
• Quercetin after transfection compared to quercetin before; p=0.0024**
* significant p value, ** very significant p value
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Figure 4.1
Figure 4.1 Full length BPV4 LCR acting as a promoter driving a luciferase 
reporter gene in PalF cells
Top panel shows a scatter plot which represents the results from each of 8  separate 
experiments.
Bottom panel shows the results from all 8  experiments combined. The vertical bars 
correspond to the standard error of the mean (S.E.M).
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As the p values indicate, the increase in transcription of the BPV4 LCR in 
response to quercetin treatment after transfection was significant compared to cells 
either not treated with quercetin or treated with the same concentration of quercetin 
(20pM) before transfection.
The observation that the activity of the LCR is only altered if quercetin is 
added to culture medium after cells have been transfected with the LCR suggests 
quercetin and the LCR must be present simultaneously for an alteration in LCR 
activity to be achieved. It further suggests that any epigenetic changes which may 
occur as a consequence of quercetin treatment are relatively short lived.
4.3 The effect of quercetin on the transcriptional activity of the full length, 
wild type BPV4 LCR functioning in an enhancer configuration
As the results in figure 4.1 demonstrated, quercetin was seen to increase the 
transcriptional activity of the BPV4 LCR approximately 2.5-3 fold when the LCR was 
present in a promoter orientation. We wished to determine if quercetin could induce a 
similar effect on the activity of the BPV4 LCR if functioning as an enhancer.
PalF cells were transfected as described in section 4.2.1. A different set of 
plasmid vectors was used in place of those described in the previous experiment. The 
plasmids used were p41X-PINT and p41X, again in conjunction with the pCHl 10 
vector. p41X-PINT carries the entire BPV4 LCR cloned upstream of the herpes 
simplex virus thymidine kinase (TK) promoter and together these control the 
expression of the bacterial chloramphenicol acetyltransferase (CAT) reporter gene . 
p41X is the same vector as p41X-PINT but without the BPV4 LCR sequences.
4.3.1 Experimental procedure
105  PalF cells were treated as described in section 4.2.1. Briefly, PalF cells 
were exposed to either quercetin at 20pM or an equivalent volume of ethanol for 48 
hours before transfection. Cells were then co-transfected with either 7.5pg p41X plus 
2.5pg pCHl 10 plasmids or 7.5pg p41X-PINT plus 2.5jig pCHl 10 plasmids as 
detailed in section 2.3.1.7.
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After transfection, cells which were previously exposed to medium containing 
ethanol were given medium plus 20pM quercetin, and cells which were originally 
treated with quercetin were given medium supplemented with an equivalent volume of 
ethanol. Cells were cultured in the appropriate medium for a further 48 hours after 
which time all cells were harvested as described and section 2.3.1.9a and assayed for 
P-galactosidase and CAT enzyme activities (see sections 2.3.1.12 and 2.3.1.13).
Table 4.2 summarises the experimental rationale used.
Table 4.2 Summary of the experimental conditions used when PalF cells were 
transfected with the BPV4 LCR present in an enhancer configuration, and 
treated with or without quercetin.
Condition
# 1
Condition
# 2
Condition
# 3
Condition
# 4
Condition
# 5
Condition
# 6
Before transfection Med + 
EtOH
Med + 
EtOH
Med + 
Quer.
Med + 
Quer.
Med + 
EtOH
Med + 
EtOH
Transfected with p41X + 
pCHl 10
p41X-PINT 
+ pCHl 10
p41X + 
pCHl 10
p41X-PINT 
+ pCHl 10
p41X + 
pCHl 10
p41X-PINT 
+ pCHl 10
After transfection Med + 
EtOH
Med + 
EtOH
Med + 
EtOH
Med + 
EtOH
Med + 
Quer.
Med + 
Quer.
Abbreviations used: Med = medium (IX DMEM)
Quer. = quercetin (to final concentration of 20pM)
EtOH = ethanol (a volume equivalent to the volume of 
quercetin added in other conditions, ie. 0 .1 % v/v)
Each CAT reading was corrected for the efficiency of transfection using the 
corresponding P-galactosidase reading and applying the equation given in section 
4.2.1. The effect of the empty vector (p41X) on transcription was further corrected for 
as described in section 4.2.1. Within each experiment, the results were normalised to 
the ‘No quercetin’ condition which was set =1. Using the combined results from all 
experiments, the average CAT reading and the S.E.M for each condition was 
calculated and the Student’s t-Test was applied to determine statistical significance 
between the various conditions.
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4.3.2 Results
Figure 4.2 illustrates the results obtained from 5 separate experiments. 
Quercetin, given before or after transfection, had no significant effect on the 
transcriptional activity of the BPV4 LCR when acting as an enhancer. The p values 
obtained were as follows;
• Quercetin before transfection compared to no quercetin; p=0.06
• Quercetin after transfection compared to no quercetin; p=0.33
• Quercetin after transfection compared to quercetin before; p=0.25
This result suggests that the effect of quercetin on the activity of the full length 
BPV4 LCR in PalF cells is promoter specific and is not observed if the LCR is present 
in enhancer mode.
4.4 Comparison of the effect of quercetin and/or TPA on the transcriptional 
activity of the Collagenase TRE and the BPV4 LCR in high and low serum 
culture conditions
Sequence analysis of the BPV4 LCR identified binding motifs for several 
known transcription factors both viral and cellular in origin. These include sites for 
BPV4 E2, C/EBPp, PEBP2, putative NFl-like binding sites and a TRE-like element. 
Figure 4.3 presents a schematic illustration of these various binding motifs as they 
appear within the BPV4 LCR. Although three separate NFl-like motifs have been 
identified, binding of NF1 to these sites has not yet been investigated.
TRE (TPA responsive elements) or API-binding motifs are known to bind the 
well characterised transcription factor APl(Angel et al., 1987; Lee et al., 1987). API 
is a general term to describe a transcription factor which can comprise a selection of 
different protein subunits coming together to form either homo- or heterodimers. 
Purified preparations of API have shown that API can constitute a homodimer of Jun 
or Jun-related proteins; alternatively API can incorporate a heterodimer of Jun and 
cFos as well as several Fos-related proteins called Fras (Fos-related antigens) 
(Halazonetis et al., 1988; Latchman, 1991). Homodimers of the Fos protein are 
unable to bind API-binding sites (Latchman, 1991). Increased levels of Jun and Fos 
have been detected in cells after treatment with phorbol esters such as TPA
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Figure 4.2
Figure 4.2 Full length BPV4 in enhancer configuration in PalF cells
Top panel shows a scatter plot which represents the results from each of 5 separate 
experiments.
Bottom panel shows the results from all 5 experiments combined. The vertical bars 
correspond to the standard error of the mean (S.E.M).
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Figure 4.3
Figure 4.3 Schematic representation of the BPV4 LCR highlighting the positions 
of several transcription factor binding sites
The sequence along the bottom of the figure corresponds to nucleotides 275 to 331 of 
the LCR. The TATAA box and the TRE-like motifs are highlighted in grey boxes. 
The sequence below the TRE-like motif corresponds to the consensus sequence which 
binds the transcription factor A PI.
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(Lamph et al., 1988). Likewise, Jun and Fos have also been induced in quiescent 
cells after treatment with serum or growth factors (Lamph et al, 1988; Rauscher et 
al., 1988). Jun and Fos have both been identified as potential oncoprotein as 
uncontrolled expression of these proteins leads to cellular transformation (Cooper, 
1990).
As mentioned above, the BPV4 LCR contains a TRE-like element. The 
nucleotide sequence at this site is identical to an API-consensus binding motif except 
for a single base difference.
• TRE-like element sequence: TGAGGCAG
• API consensus binding site sequence: TGAGTCAG
API-binding sites are generally located in enhancers or upstream to promoter 
elements. In this respect the location of the TRE-like element within the BPV4 LCR 
is rather unusual, being located within the 3’ extreme end of the promoter region and 
lying downstream of the TATAA box.
Despite the single base change and its location with the LCR, the TRE-like 
element remains a potential target site through which quercetin may be mediating a 
increase in transcription. We therefore decided to test whether quercetin was perhaps 
altering the transcriptional activity of the BPV4 LCR through AP-1 activation.
Firstly, as a control, a plamid containing five copies of the collagenase TRE 
was transfected into PalF cells in both high and low serum culture conditions. Cells 
were treated with TPA which is known to induce API.
API in normal, cycling cells is constitutively expressed. In order to best 
visualise an induction of API, background API levels must first be reduced. This 
can be achieved by driving cells into a quiescent state. Removal or marked reduction 
of serum from the cells' culture medium can force cells into quiescence. Against a 
backdrop of depleted API levels, the effect of a treatment(s) which may induce API 
expression can then be observed to maximum effect. In light of this, cells were 
precultured in a low serum environment before treating with TPA
Cells transfected with the collagenase TRE plasmid were also treated with 
quercetin in high and low serum containing medium to see if quercetin could induced 
a similar effect on API expression.
The same experimental rationale was also applied using a plasmid carrying 
the BPV4 LCR. The transcriptional activity of the LCR in PalF cells in response to
1 3 0
treatment with quercetin, TPA or both was determined as for the collagenase TRE- 
containing plasmid.
4.4.1a Experimental procedure
TPA (12-O-tetradeconolyphorbol 13-acetate) was dissolved in ethanol to give 
a stock solution of lOOpg/ml. This stock solution was stored at -20°C when not in 
use.
105  PalF cells were seeded into the appropriate tissue culture dish as specified 
in section 2.3.1.7. The following day cells were transfected with either 7.5 pg 
p5xTRECAT plus 2.5 pg pCHl 10 or 7.5pg pTKCAT plus 2.5 pg pCHl 10. After 
transfection, cells were fed with a fresh volume of medium containing either high 
(10% v/v) or low (0.5% v/v) serum. All cells were cultured in the appropriate serum- 
containing medium for a period of 48 hours after which time the medium was 
replenished. The fresh medium contained the same concentration of serum as before 
but was now supplemented with either ethanol, quercetin (20pM), TPA (lOOng/ml) or 
quercetin plus TPA; fresh medium was added to the appropriate dishes of cells 
according to the protocol summarised in table 4.3. The volume of ethanol added to 
cells in conditions #1 and #2 was equivalent to the total volume of quercetin plus TPA 
which was added to cells in conditions #7 and #8 . Cells were cultured in the new 
supplemented medium for a further 24 hours. At the end of this time, all cells were 
harvested (section 2.3.1.9a) and the resultant cell lysates assayed for both CAT and P- 
galactosidase enzyme activities (section 2.3.1.12 and 2.3.1.13).
Each CAT assay reading was corrected for efficiency of transfection and the 
contribution of empty vector (pTKCAT) on transcription was removed. The final 
readings were normalised to the ‘No quercetin’ reading set = 1, as described in detail 
in section 4.3.1.
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Table 4.3 Summary of the experimental conditions used when PalF cells were 
transfected with the Collagenase TRE and treated with or without quercetin
and/or TPA
Cond.
#1
Cond.
# 2
Cond.
# 3
Cond.
#4
Cond.
#5
Cond.
#6
Cond.
# 7
Cond.
# 8
Transfected with pTKCAT
+
pCHl 10
p5xTRE
+
pCHl 10
pTKCAT
+
pCHl 10
p5xTRE
+
pCHl 10
pTKCAT
+
pCHl 10
p5xTRE
+
pCHl 10
pTKCAT
+
pCHl 10
p5xTRE
+
pCHl 10
Serum content 
(%)
H
(10)
L
(0.5)
H
(10)
L
(0.5)
H
(10)
L
(0-5)
H
(10)
L
(0.5)
H
(10)
L
(0.5)
H
(10)
L
(0.5)
H
(10)
L
(0.5)
H
(10)
L
(0-5)
Treated with E E Q Q Q+T Q+T
Abbreviations: E = ethanol
Q = quercetin (20pM)
T = TPA - 12-O-tetradecanoylphorbol 13-acetate (lOOng/ml)
H = high serum (10%)
L = low serum (0.5%)
*In each of the conditions given in the table 4.3, cells were incubated in either high 
(10%) or low (0.5%) serum containing medium for a period of 48 hours after 
transfection and before the addition of ethanol, quercetin and/or TPA. For all 
conditions, duplicate dishes of cells were used.
4.4.1b Experimental procedure
The experimental procedure described in section 4.4.1a was simultaneously 
repeated with PalF cells but using a different set of plasmid vectors. PalF cells were 
alternatively transfected with either 7.5pg pLCRLuc plus 2.5pg pCHl 10 or 7.5pg 
pOLuc plus 2.5pg pCHl 10. After transfection, cells were cultured for 48 hours in 
lxDMEM containing either a high (10%) or low (0.5%) serum content. At the end of 
the 48 hour incubation a fresh volume of medium containing the same concentration 
of serum as before, but freshly supplemented with either ethanol alone, quercetin (2 0 p 
M), TPA (lOOng/ml), or quercetin plus TPA, was added to the appropriate dishes in 
each experimental conditions, as indicated in table 4.4. All cells were cultured in 
supplemented medium for a further 24 hours. At the end of the incubation, all dishes
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of cells were harvested and assayed for luciferase and P-galactosidase enzyme 
activities (section 2.3.1.11 and 2.3.1.12). Table 4.4 summarises the protocol followed 
in this particular experiment.
Each luciferase assay reading was corrected for efficiency of transfection, the 
contribution of empty vector (pOLuc) on transcription was removed, and the final 
readings were normalised to the ‘No quercetin’ reading set = 1, as described in detail 
in section 4.3.1.
Table 4.4 Summary of the experimental conditions used when PalF cells were 
transfected with the BPV4 LCR functioning as a promoter and treated with or 
without quercetin and/or TPA.
Cond.
#1
Cond.
#2
Cond.
#3
Cond.
# 4
Cond.
# 5
Cond.
# 6
Cond.
# 7
Cond.
# 8
Transfected
with
pOLuc
+
pCHl 10
pLCRLuc
+
pCHl 10
pOLuc
+
pCHl 10
pLCRLuc
+
pCHl 10
pOLuc
+
pCHl 10
pLCRLuc
+
pCHl 10
pOLuc
+
pCHl 10
pLCRLuc
+
pCHl 10
Serum 
content (%)
H
(10)
L
(0.5)
H
(10)
L
(0.5)
H
(10)
L
(0.5)
H
(10)
L
(0.5)
H
(10)
L
(0.5)
H
(10)
L
(0.5)
H
(10)
L
(0.5)
H
(10)
L
(0.5)
Treated with E E Q Q Q+T Q+T
Abbreviations: E = ethanol
Q = quercetin (20pM)
T = TPA - 12-O-tetradecanoylphorbol 13-acetate (lOOng/ml) 
*A11 cells were incubated in either high (10%) or low (0.5%) serum containing 
medium for a period of 48 hours after transfection and before the addition of ethanol, 
quercetin and/or TPA. For each condition given in table 4.4, duplicate dishes of cells 
were used.
4.4.2 Results
Figure 4.4 illustrates the results obtained from 3 separate experiments. TPA 
increased the activity of the collagenase TRE. As expected, this was more clearly 
observed when cells were preincubated in low serum containing medium
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(see figure 4.4, panels A and B). Quercetin had a small effect on the transcriptional 
activity of the collagenase TRE and, like TPA, the increase in transcriptional activity 
was more obvious in cells cultured in a low serum environment. Quercetin and TPA, 
when present in the culture medium simultaneously, appeared to have antagonistic 
effects on the transcriptional activity of the collagenase TRE; the activity of the 
collagenase TRE was reduced to a level below that observed for either quercetin or 
TPA alone. This would suggest that the pathway(s) which is activated by TPA is 
inhibited by quercetin and vice versa.
TPA was unable to induce an increase in the activity of the BPV4 LCR when 
added to cells incubated in either high or low serum containing medium (figure 4.4, 
panels C and D). The effect of quercetin on the upregulation of the BPV4 LCR’s 
transcriptional activity was most strikingly observed for cells cultured in medium 
containing 10% serum (panel C). This suggests that quercetin requires certain serum 
factors, perhaps serum growth factors, to achieve the increase in LCR activity. 
Alternatively, the observed increase in transcription as a result of quercetin exposure 
may reflect the need for carrier proteins present in serum, such as albumin, for 
quercetin to gain access to the cell. Notwithstanding, effects of quercetin are not 
abolished in a low serum environment. This is exemplified by the observed reduction 
in response of the collagenase TRE to TPA in low serum when quercetin is also 
present. The mechanism of interference or antagonism between TPA and quercetin is 
not known.
Similar to the results described for the collagenase TRE, the effect of quercetin 
on the BPV4 LCR was not observed when TPA was simultaneously present in the 
culture medium. This supports the earlier suggestion that quercetin and TPA have a 
competitive or antagonistic effect on particular cellular function(s).
4.5 Analysis of the effect of a 21 base pair 3’ truncation of the BPV4 LCR on 
transcriptional activity of the LCR acting as a promoter
Results from the previous experiments suggested that quercetin did not induce 
an increase in the transcriptional activity of the BPV4 LCR via activation of an API 
transcription factor. Nevertheless, it was not clear if the TRE-like element, or another 
as yet unidentified site within the 3’ 21 base pair sequence of the BPV4 LCR 
(nucleotides 311-331), was mediating the effect of quercetin on the LCR’s
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transcriptional activity. Therefore, a plamid carrying a 21 base pair deletion from the 
3’ end of the BPV4 LCR, a region which included the TRE-like element, was 
introduced into PalF cells and the transcriptional activity of this LCR deletion mutant 
was assayed.
4.5.1 Experimental procedure
A 21 base pair, 3’ truncated form of the BPV4 LCR was contained in the 
p41X-PIN plasmid vector. However in p41X-PIN, the LCR was present as an 
enhancer element lying upstream of a TK promoter. This truncated form of the LCR 
was cut out of p41X-PIN using an appropriate restriction enzyme and sub-cloned into 
the BamHl site of the pOLuc vector as a promoter element, thus generating the 
psLCRLuc vector (see sections 2.2.9 and 2.3.2 for details).
105  low passage PalF cells were seeded in the appropriate tissue culture dish 
and incubated overnight as indicated in section 2.3.1.7. The culture medium was 
removed and replaced with a fresh volume of medium supplemented with either 
20pM quercetin or an equivalent volume of its diluent, ethanol. Cells were cultured 
for 48 hours in this fresh medium. At the end of the 48 hours, the medium was 
changed to a fresh volume of lxDMEM and the cells transfected with a combination 
of either 7.5pg psLCRLuc plus 2.5pg pCHl 10 or 7.5pg pOLuc plus 2.5pg pCHl 10. 
After an overnight incubation (section 2.3.1.7) the cells were re-fed with fresh 
medium supplemented with 20pM quercetin or an equivalent volume of ethanol; cells 
which previously were cultured in quercetin received ethanol containing medium, 
whereas cells which were previously grown in the presence of ethanol received 
quercetin medium. Control cells which were cultured in ethanol-containing medium 
before transfection were again given a fresh volume of medium containing ethanol.
Cells were incubated in the appropriate conditions for a further 48 hours after 
which time all cells were harvested. The cell lysates obtained were assayed for 
luciferase and p-galactosidase enzyme activities (section 2.3.1.11 and 2.3.1.12). All 
results were corrected for efficiency of transfection and normalised to the ‘No 
quercetin’ condition as described in section 4.2.1. The results from each of the 
experiments were combined and used to calculate the average fold increase in reporter 
gene expression, also detailed in section 4.2.1.
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Table 4.5 Summary of the experimental conditions used when PalF cells were 
transfected with a 3’ truncated BPV4 LCR present as a promoter and treated 
with or without quercetin.
Condition
#1
Condition
#2
Condition
#3
Condition
#4
Condition
#5
Condition
#6
Before transfection Med + 
EtOH
Med + 
EtOH
Med + 
Quer.
Med + 
Quer.
Med + 
EtOH
Med + 
EtOH
Transfected with pOLuc + 
pCHl 10
psLCRLuc 
+ pCHl 10
pOLuc + 
pCHl 10
psLCRLuc 
+ pCHl 10
pOLuc + 
pCHl 10
psLCRLuc 
+ pCHl 10
After transfection Med + 
EtOH
Med + 
EtOH
Med + 
EtOH
Med + 
EtOH
Med + 
Quer.
Med + 
Quer.
Abbreviations used: Med = medium (IX DMEM)
Quer. = quercetin (to final concentration of 20pM)
EtOH = ethanol (a volume equivalent to the volume of
quercetin added in other conditions, ie. 0 . 1 % v/v)
4.5.2 Results
Quercetin produced a smaller increase in the level of transcription from the 
3’truncated BPV4 LCR compared to the response of the full length LCR. This 
reduced effect of quercetin on the transcriptional activity of the 3’ truncated LCR was 
only seen in cells which were treated with 20jiM quercetin for 48 hours after 
transfection. This is similar to the observation described for the full length LCR 
(section 4.2.2). Also in keeping with observations described in section 4.2.2, the same 
concentration of quercetin had no effect on short-LCR activity when added to the 
culture medium before transfection.
Despite the removal of nucleotides 311 to 331 from the BPV4 LCR, a slight 
increase the transcriptional activity of the LCR in response to quercetin exposure was 
observed (see figure 4.5). The response of this truncated form of the BPV4 LCR to 
quercetin however was less than that seen for the full length LCR (see section 4.2.2). 
Furthermore, the increase in transcription observed for the shortened LCR in cells 
treated with quercetin after transfection was found not to be statistically significant, 
according to Student t-Test analysis, p values obtained indicate no significant 
difference in the relative luciferase activity for cells treated with quercetin
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Figure 4.5 Activity of the 3’truncated BPV4 LCR acting as a promoter driving a 
luciferase reporter gene in PalF cells
Top panel shows a scatter plot which represents the results from each of 3 separate 
experiments.
Bottom panel shows the results from all 3 experiments combined. The vertical bars 
correspond to the standard error of the mean (S.E.M).
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after transfection compared to cells either not exposed to quercetin or exposed to 
quercetin before transfection.
• Quercetin before transfection compared to no quercetin; p=0.95
• Quercetin after transfection compared to no quercetin; p=0.11
• Quercetin after transfection compared to quercetin before; p=0.08
4.6 Analysis of the effect of a 21 base pair 3’ truncation of the BPV4 LCR on the 
transcriptional activity of the LCR acting as an enhancer
Results from the experiment described in section 4.5.2 indicated that removal 
of 21 base pairs from the 3’ end of the BPV4 LCR acting as a promoter correlated 
with a reduction in the response of the LCR to quercetin. Similar to the procedure 
presented in section 4.3.1, and as an extension of the results in section 4.5.2, we 
wished to determine if this shortened LCR showed similar activity, with relation to 
quercetin treatment, when the LCR was present in an enhancer orientation.
4.6.1 Experimental procedure
The experimental procedure employed was identical to that described in 
section 4.5.1. Briefly, 105  low passage PalF cells were seeded in 60mm tissue culture 
dish and incubated overnight as indicated in section 2.3.1.7. Cells were grown for the 
next 48 hours in medium supplemented with either quercetin (20pM) or an equivalent 
volume of ethanol. Following this the cells were transfected with a combination of 
plasmid vectors comprising either 7.5pg p41X-PIN plus 2.5pg pCHl 10 or 7.5pg 
p41X plus 2.5pg pCHl 10. After transfection (section 2.3.1.7), the medium was 
changed. Cells which were initially cultured in the presence of quercetin were given 
medium supplemented with ethanol, while cells which were previously treated with 
ethanol before transfection received medium supplemented with 20pM quercetin. 
Control cells were cultured in ethanol-containing medium for 48 hours both before 
and after transfection. At the end of the 48 hours, all dishes of cells were harvested 
and their cell lysates assayed for CAT and p-galactosidase enzyme activities (section 
2.3.1.12 and 2.3.1.13).
Each CAT assay reading was corrected for efficiency of transfection, the 
contribution of empty vector (p41X) on transcription was removed, and the final
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readings were normalised to the ‘No quercetin’ reading set = 1, as described in detail 
in section 4.3.1.
Table 4.6 Summary of the experimental conditions used when PalF cells were 
transfected with the 3* truncated BPV4 LCR present as an enhancer and treated 
with or without quercetin.
Condition
# 1
Condition
# 2
Condition
# 3
Condition
# 4
Condition
# 5
Condition
# 6
Before transfection Med + 
EtOH
Med + 
EtOH
Med + 
Quer.
Med + 
Quer.
Med + 
EtOH
Med + 
EtOH
Transfected with p41X + 
pCHllO
p41X-PIN 
+ pCHl 10
p41X + 
pCHllO
p41X-PIN 
+ pCHllO
p41X + 
pCHllO
p41X-PIN 
+ pCH110
After transfection Med + 
EtOH
Med + 
EtOH
Med + 
EtOH
Med + 
EtOH
Med + 
Quer.
Med + 
Quer.
Abbreviations used: Med = medium (IX DMEM)
Quer. = quercetin (to final concentration of 20pM)
EtOH = ethanol (a volume equivalent to the volume of
quercetin added in other conditions, ie. 0 . 1 % v/v)
4.6.2 Results
The p values obtained using the Student’s t-Test are given below;
• Quercetin before transfection compared to no quercetin; p=0.23
• Quercetin after transfection compared to no quercetin; p=0.15
• Quercetin after transfection compared to quercetin before; p=0.02*
The enhancer activity of 21 base pair 3’ truncated form of the BPV4 LCR was 
not significantly altered by exposure to 20pM quercetin (see figure 4.6). The 
relatively poor response of the LCR as an enhancer to quercetin was independent of 
whether quercetin was added to the culture medium before or after transfection with 
p41X-PIN. The p-value obtained when comparing cells treated with quercetin before 
and after transfection appears significant. Nevertheless, results from the other 
experiments detailed in earlier sections indicate that the effect of quercetin on the 
activity of the BPV4 LCR is generally limited to cells treated with quercetin after
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Figure 4.6
Figure 4.6 Activity of the 3’truncated BPV4 LCR in enhancer configuration in
PalF cells
Top panel shows a scatter plot which represents the results from each of 5 separate 
experiments.
Bottom panel shows the results from all 5 experiments combined. The vertical bars 
correspond to the standard error of the mean (S.E.M).
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transfection. The p-value obtained when comparing untreated cells with cells treated 
with quercetin after transfection is not significant therefore it is more likely that 
quercetin has relatively little to no effect on the activity of the LCR when present as an 
enhancer. This result in very similar to that described in section 4.3.2.
Hence, it would appear that the BPV4 LCR, either full length or 3’ truncated, 
does not respond to quercetin when present as an enhancer in PalF cells.
A review of the results described in sections 4.2.2,4.3.2,4.5.2 and 4.6.2 
suggest that the response of the BPV4 LCR to quercetin exposure is only observed if 
the LCR is present as a promoter and quercetin is added to the culture medium after 
cells have been transfected with the BPV4 LCR.
4.7 Time course experiment to determine the optimum length of quercetin 
treatment before cells are harvested, to detect the maximum increase in LCR 
activity
The results presented in sections 4.2.2 and 4.5.2 showed that the 
transcriptional activity of the BPV4 LCR in PalF cells was increased only when cells 
were treated with 20jiM quercetin for 48 hours after transfection with a reporter vector 
carrying the BPV4 LCR. Cells were treated with quercetin for 48 hours as this was in 
keeping with the experimental protocol described by Caimey and Campo (1995); 
treatment of PalF cells with 20pM quercetin for 48 hours after transfection with BPV4 
DNA (and ras) was sufficient to induce full cellular transformation.
However, it had not been established if treating cells with quercetin for 48 
hours was the optimum incubation interval to achieve or observe the maximum 
increase in the LCR’s transcriptional activity. For this reason, a time course 
experiment was performed in order to determine the duration of quercetin treatment 
which would produce in the greatest fold activation, as determined by reporter protein 
levels.
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4.7.1 Experimental procedure
Approximately 2xl0 5  PalF cells were transfected with either 7.5 pg pLCRLuc 
plus 2.5pg pCHl 10 or 7.5pg pOLuc plus 2.5pg pCHl 10. After transfection cells 
were treated with 20pM quercetin for either 1.5, 3, 6 ,12, 24, 32,40 or 48 hours. 
Control cells were treated with an equivalent volume of ethanol for 48 hours. After 
cells had been exposed to quercetin for the required time interval, cells were harvested 
(section 2.3.1.9a) and assayed for luciferase and p-galactosidase activities (sections 
2.3.1.11 and 2.3.1.12).
Each luciferase assay reading was corrected for efficiency of transfection as 
described in section 4.3.1. The contribution of empty vector (pOLuc) on transcription 
was removed by subtracting the corrected luciferase reading for the pOLuc transfected 
cells treated with ethanol from the corresponding reading for cells transfected with 
pLCRLuc and treated with ethanol; the luciferase reading for pOLuc transfected cells 
treated with quercetin was likewise subtracted from the luciferase readings obtained 
for cells transfected with pLCRLuc and treated with quercetin. The average luciferase 
reading for the duplicate plates from each culture condition was calculated and the 
readings normalised to the ‘No quercetin’ reading set = 1, as described in detail in 
section 4.3.1.
4.7.2 Results
Results from the time course experiment are given in figure 4.7. The biggest 
increase in LCR transcriptional activity was observed when PalF cells were incubated 
in 20pM quercetin for 24 to 32 hours after transfection. In keeping with this 
observation, and in an attempt to optimise any potential response to quercetin 
treatment, exposure of cells to quercetin in all subsequent experiments was performed 
for a duration 24 hours.
4.8 Comparing the difference in response to quercetin treatment between full 
length and 21 base pair 3’ truncated BPV4 LCRs in PalF cells
The activity of both the full length and truncated BPV4 LCRs cloned into the 
pOLuc vector is not very high in PalF cells. The reasons for this may be two fold. 
Firstly, the pOLuc vector is not a particularly strong expression vector in PalF cells. 
Secondly, PalF cells are not the natural host cell for a BPV4 infection; BPV4 is
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naturally tropic for keratinocytes, therefore it is reasonable to expect the activity of the 
LCR to be less than optimum in fibroblasts.
As a means of improving the level of reporter gene expression, the full length 
and 21 base pair truncated BPV4 LCRs were cloned into the Bgl II site of the pGL3 
expression vector (Promega) by Dr Iain Morgan (Beatson Institute, Glasgow). In 
addition to sub-cloning the BPV4 LCRs into a more efficient expression vector, 
quercetin treatment of cells was observed for 24 hours, rather than 48 hours as in 
previous experiments, in keeping with the results of the time course experiment 
(section 4.7.2).
The following experiments compared the expression of the full length and 
short LCRs, present as promoter elements in the pOLuc and pGL3 vectors, in response 
to quercetin exposure in PalF cells.
4.8.1 Experimental procedure
Quercetin was only given after transfection as no appreciable alteration to the 
level of transcription was detected when cells were treated with quercetin before 
transfection, as observed from the experimental results detailed above (section 4.2.2 
and 4.5.2).
2xl0 5  PalF cells were seeded into 60mm tissue culture dishes. The following 
day, cells were transfected with either 7.5pg of pOLuc/pGL3 plus 2.5pg pCHl 10 
(condition #1), 7.5pg pLCRLuc/pGL3-PINT plus 2.5fig pCHl 10 (condition #2), or 
7.5p.g psLCRLuc/pGL3-PIN plus 2.5pg pCHl 10 (condition #3) according to the 
schedule detailed in section 2.3.1.7. After transfection, two dishes of cells from each 
condition (duplicate dishes) were given medium supplemented with either 20pM 
quercetin or an equivalent volume of ethanol. All cells were cultured for a further 24 
hours and then harvested as described in section 2.3.1.9a. The resultant cell lysates 
were assayed for luciferase and p-galactosidase enzyme activities (sections 2.3.1.11 
and 2.3.1.12).
Each luciferase assay reading was corrected for efficiency of transfection (see 
section 4.3.1). The contribution of empty vector (pOLuc or pGL3) on transcription 
was removed by subtracting the luciferase reading for pOLuc/pGL3 transfected cells 
treated with ethanol or quercetin from the luciferase reading for cells transfected with 
pLCRLuc/pGL3-PINT or psLCRLuc/pGL3-PIN similarly treated with ethanol or
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quercetin respectively (ethanol readings are subtracted from ethanol readings and 
quercetin readings are subtracted from quercetin readings). The final readings were 
normalised to the ‘No quercetin’ reading set = 1, as described in detail in section 
4.3.1.
Table 4.7a Summary of the experimental conditions used when PalF cells were 
transfected with the pOLuc vectors, carrying the full length and truncated BPV4 
LCRs present as a promoter, and treated with or without quercetin.
Condition # 1 Condition # 2 Condition # 3
Transfected with pOLuc + 
pCHl 10
pLCRLuc + 
pCHl 10
psLCRLuc + 
pCHl 10
Treated with E Q E Q E Q
Table 4.7b Summary of the experimental conditions used when PalF cells were 
transfected with the pGL3 vectors, carrying the full length and truncated BPV4 
LCRs present as a promoter, and treated with or without quercetin
Condition # 1 Condition # 2 Condition # 3
Transfected with pGL3 + pCHl 10 pGL3-PINT + 
pCHl 10
pGL3-PIN + 
pCHl 10
Treated with E Q E Q E Q
4.8.2 Results
Figure 4.8 illustrates the response of the full length and 3’ truncated BPV4 
LCRs in pOLuc (panel A) and pGL3 (panel B) vectors to quercetin. Removal of 21 
base pairs from the 3’ end of the BPV4 LCR correlated with a significant decrease in 
response to quercetin treatment. A significant decrease in response to quercetin 
treatment was observed independent of whether the truncated LCR was cloned in the 
pOLuc (p=0.025) or pGL3 based vector (p=0.037). Nevertheless, the response of the 
truncated LCR to quercetin treatment in either vector was not totally abolished
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Figure 4.8 The transcriptional response of the full length  
and 3 ’ truncated BPV4 LCRs in (A) pOLuc and 
(B) pGL3 vectors in PalF cells 
treated with 20|iM  quercetin
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Figure 4.9 The basal transcriptional activity of the full length  
and 3 ’ truncated BPV4 LCRs in (A) pOLuc and 
(B) pGL3 vectors in PalF cells
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suggesting that other regions of the LCR are involved in mediating the transcriptional 
effects of quercetin.
Figure 4.9 shows the basal activity of the full length and 3’ truncated forms of 
the BPV4 LCR in pOLuc (panel A) and pGL3 (panel B) vectors. The truncated BPV4 
LCR appears more active in PalF cells compared to the full length LCR, when cloned 
in pOLuc based vectors (panel A). This difference appears to be significant according 
to a Student’s t-Test analysis (p=0.005). In the pGL3 based vectors however, the short 
LCR appears less active compared to full length LCR (figure 4.9 - panel B). The 
difference in basal activities of the full length and truncated forms of the BPV4 LCR 
in pGL3 vectors, unlike that observed for the pOLuc vectors, was found not to be 
significant according to the Student’s t-Test analysis (p=0.17).
These apparently contradictory results indicate that the activity of the truncated 
LCR in these two vectors is different. Alternatively, the variant activities observed 
may reflect fundamental differences in the vector constructs directly, independent of 
the BPV4-specific sequences also present. There are noticeable differences in the 
basal activities of the LCRs in these two vectors (figure 4.9) which is reflected in their 
respective relative luciferase activities; the activity of the full length and truncated 
LCRs in greater in the pGL3 based vectors compared to corresponding activities in the 
pOLuc base vectors. Nevertheless, the fold increase in transcriptional activity in 
response to quercetin for the full length and truncated forms of the BPV4 LCRs is 
roughly the same irrespective of which vector they are cloned into.
4.9 Comparing the difference in response to quercetin treatment between full 
length and 21 base pair 39 truncated BPV4 LCRs in PalK cells
As mentioned in previous sections, BPV4 does not naturally infect fibroblast 
cells. Rather the virus infects keratinocytes in vivo. For this reason we wished to 
determine the activity of the BPV4 LCR, both full length and truncated, in a more 
physiologically relevant cell type and to this end primary bovine keratinocyte cells 
explanted from the soft palate of a bovine foetus (PalK cells) were used in a series of 
transient transfection experiments. Figure 4.10 contains photographs of PalK cells 
viewed at two magnifications as seen with a light microscope. Similar to the protocol 
described in section 4.8, both the pOLuc and pGL3 vectors, containing the full length
149
Figure 4.10 Photographs of PalK cells
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and 21 base pair truncated LCRs, were transfected into bovine keratinocytes. The cells 
were treated with quercetin or ethanol for 24 hours after transfection only.
4.9.1 Experimental procedure
The procedure followed in these experiments was essentially identical to that 
detailed in section 4.8.1. However, in place of PalF cells , 5xl0 5  primary bovine 
foetal palate keratinocyte (PalK) cells were seeded in the appropriate tissue culture 
dishes, in the absence of a feeder layer, and transfected as described in section 2.3.1.8. 
All cells were transfected with a total of lOpg of DNA as indicated in tables 4.8a and 
4.8b; cells in condition #1 received 7.5pg pOLuc/pGL3 plus 2.5pg pCHl 10, condition 
#2 received 7.5pg pLCRLuc/pGL3-PINT plus 2.5pg pCHl 10 and condition #3 
received 7.5pg psLCRLuc/pGL3-PIN plus 2.5pg of pCHl 10. The appropriate dishes 
of cells were subsequently treated with either 20pJM quercetin or an equivalent volume 
of ethanol for 24 hours after transfection according to the schedules summarised in 
table 4.8a and 4.8b. All dishes of cells were harvested at the end of the 24 hour 
incubation period (2.3.1.9a). Each cells lysate was then assayed for luciferase and p- 
galactosidase enzyme activities (sections 2.3.1.11 and 2.3.1.12).
Each luciferase assay reading was corrected for efficiency of transfection using 
the corresponding P-galactosidase reading as described in section 4.3.1. The 
contribution of empty vector (pOLuc/pGL3) on transcription was removed by 
subtraction, as detailed in section 4.8.1. Each reading was finally normalised to the 
‘No quercetin’ reading set = 1 (section 4.3.1).
Table 4.8a Summary of the experimental conditions used when PalK cells were 
transfected with the pOLuc vectors, carrying the full length and truncated BPV4 
LCRs present in a promoter configuration, and treated with or without 
quercetin.
Condition # 1 Condition # 2 Condition # 3
Transfected with pOLuc + 
pCHl 10
pLCRLuc + 
pCHl 10
psLCRLuc + 
pCHl 10
Treated with E Q E Q E Q
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Table 4.8b Summary of the experimental conditions used when PalK cells were 
transfected with the pGL3 vectors, carrying the full length and truncated BPV4 
LCRs present in a promoter configuration, and treated with or without 
quercetin
Condition # 1 Condition # 2 Condition # 3
Transfected with pGL3 + pCHl 10 pGL3-PINT + 
pCHl 10
pGL3-PIN + 
pCHl 10
Treated with E Q E Q E Q
4.9.2 Results
Figure 4.11 shows the response to quercetin treatment of the full length and 3’ 
truncated BPV4 LCRs, cloned in both pOLuc (panel A) and pGL3 (panel B) vectors, 
following transfection into PalK cells. Removal of 21 base pairs from the 3’ end of 
the BPV4 LCR correlated with a decrease in the transcriptional response to quercetin 
for the psLCRLuc vector only. A similar decrease was not observed for the truncated 
LCR cloned in the pGL3 vector (pGL3-PIN). For both vectors, the response of the 
truncated LCR to quercetin treatment was not significantly different from the response 
of the full length LCR; p values comparing the quercetin response of the truncated 
versus the full length LCR in the pOLuc- and pGL3-based vectors were 0.098 and 
0.78 respectively. As was observed for the same vectors transfected into PalF cells 
(section 4.8.2), the response of the truncated LCR to quercetin treatment in either 
vector was not abolished. This further supports the suggestion that other regions of 
the LCR are involved in mediating the transcriptional effects of quercetin.
Figure 4.12 represents the basal activity of the full length and 3’ truncated 
forms of the BPV4 LCR, in pOLuc (panel A) and pGL3 (panel B) vectors, in PalK 
cells. In contrast to the results obtained with the pOLuc vectors in PalF cells (section 
4.8.2), the 3’ truncated BPV4 LCR was less active in PalK cells compared to the full 
length LCR (panel A). The fall in the basal level of transcriptional activity observed 
for the psLCRLuc (truncated LCR) vector as compared to the pLCRLuc (full length 
LCR) was determined not to be significant according to a Student’s t-Test analysis 
(p=0.2). The basal activities for psLCRLuc described in this section and in section
4.8.2 highlight that the same vector can display contrasting activity in different cell 
types.
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Figure 4.11 The transcriptional response of the full length 
and 3 ’ truncated BPV4 LCRs in (A) pOLuc and 
(B) pGL3 vectors in PalK cells 
treated with 20pM  quercetin
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Figure 4.12 The basal transcriptional activity of the full length  
and 3 ’ truncated BPV4 LCRs in (A) pOLuc and 
(B) pGL3 vectors in PalK cells
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The truncated LCR in the pGL3 based vector in PalK cells also showed a decrease in 
the basal level of transcription with respect to the full length LCR, however unlike the 
pOLuc-based vector, the observed drop in response to quercetin was found to be very 
significant (p=0.0016) (figure 4.12 - panel B).
Results from the experiments described in sections 4.8 and 4.9 show that a 
sequence of the BPV4 LCR can display varying activities, both at a basal level and in 
response to quercetin treatment, depending on the vector into which the sequence is 
cloned. Furthermore, the cell type into which the vector is transfected can also affect 
the levels of activity observed. Notwithstanding, results from sections 4.8 and 4.9 
indicate that nucleotides 311-331 of the BPV4 LCR are at least partially involved in 
mediating the increase in transcriptional activity of the BPV4 LCR in response to 
quercetin treatment. In addition, the drop in basal reporter gene activity upon removal 
of these nucleotides from the 3’ end of the BPV4 LCR suggests that this stretch of the 
LCR is also important in terms of the basal activity and regulation of viral 
transcription.
4.10 Identification of a factor, QX1, which binds within the 3’ terminal 21 base 
pair sequence of the BPV4 LCR
Results from the transfection experiments detailed above have shown that the 
increase in transcription, in response to quercetin treatment, was less for the truncated 
form of the LCR when compared to the response of the full length LCR. This 
suggested that a site(s) within or adjacent to nucleotides 311-331 of the BPV4 LCR 
was mediating, at least in part, the effect of quercetin on the LCR’s transcriptional 
upregulation. We therefore decided to use an oligonucleotide corresponding to the 
last 25 base pair sequence from the BPV4 LCR in a series of electrophoretic mobility 
shift assays (EMSA), in an attempt to identify any factor(s) which has the potential to 
bind within this region of the LCR.
4.10.1 Experimental procedure
The experimental protocol which was used is given in detailed in section 
2.3.2.14-2.3.2.17. Briefly, 106  low passage PalF cells were seeded in each of 8xT175 
tissue culture flasks. The cells were left overnight to adhere to the tissue culture 
plastic. The following day, cells were re-fed with a fresh volume of lxDMEM
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medium. Cells were incubated for 24 hours under normal conditions. After 24 hours, 
the medium in 4 of the T 175 flasks was supplemented with 20jliM quercetin; medium 
in the 4 remaining T175 flasks was supplemented with an equivalent volume of 
ethanol (0.1% v/v). Cells were cultured in the presence of 20pM quercetin or ethanol 
for 24 hours. At the end of the incubation period, the cells were harvested for nuclear 
extract as detailed in section 2.3.1.9c.
Approximately lOpg of nuclear extract from the quercetin and ethanol treated 
PalF cells was mixed with the appropriate radioactively labelled oligonucleotide 
containing the binding site of interest, plus non-radioactively labelled competitor 
oligonucleotide where specified. Details of the oligonucleotides used as labelled 
probes and unlabelled competitors in this and other EMSAs is given in figure 4.13. 
The reaction mixtures were incubated as described in section 2.3.2.16 and then 
separated on a polyacrylamide gel as detailed in section 2.3.2.17.
4.10.2 Results
As illustrated in figure 4.14, two complexes were detected binding to the 
labelled 3’wtLCR oligonucleotide. Both complexes were detected in nuclear extract 
from PalF cells independent of whether the cells were exposed to quercetin or its 
diluent ethanol prior to harvesting.
The lower band corresponds to a complex which binds non-specifically to the 
labelled probe, as indicated by the lack of competition with any of the unlabelled 
oligonucleotides which were used.
The second complex, indicated by the arrows, was designated QX1. Exposure 
of PalF cells to 20pM quercetin for 24 hours prior to harvesting had no apparent effect 
on the binding of QX1 (figure 4.14 - lane 5); the EMSA performed with an identical 
amount of nuclear extract from cells similarly treated with ethanol before harvesting 
showed no change in the binding of QX1 (figure 4.14 - lane 2). The QX1 band was 
competed away with unlabelled 3’wtLCR oligonucleotide or with an unlabelled 
oligonucleotide corresponding to the sequence of the collagenase TRE which 
contained a consensus API-binding site. The competition observed indicates that the 
binding of QX1 to a region of the LCR between nucleotides 311 and 331 is specific. 
Binding probably involves the nucleotides in or adjacent to the TRE-like element; this
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Figure 4.13 Oligonucleotides used in Electrophoretic  
M obility Shift Assays (EM SA)
3’wt LCR: 5 ’ - GGATTTGGTGCATGAGGCAGTAGCT - 3 ’
M utant #1: 5 ’ - T C G A G G A TTTG G TG C A TG A G TC A G T A G C TTC C A T C  - 3 ’
M utant # 2 : 5 ’ - TCGAGGATTTGGTGCAAAAGGCAGTAGCTTCCATC - 3 ’
M utant #3: 5 ’ - TCGAGGATTTGGAACATGAGGCAGTAGCTTCCATC - 3 ’
Col. TRE: 5’ - AAGCATGAGTCAGACACCTC - 3’
Myc: 5 ’ - CCCCCACCACGTGGTGCCTGA - 3’
• Shaded region in 3 ’w t (wild type) LCR sequence highlights the TRE-like 
elem ent
• Shaded bases in m utants #1, #2 and #3 indicate nucleotide changes com pared to 
3 ’wt LCR
• Shaded region in Col. TR E (collagenase TR E) sequence highlights the AP1- 
binding m otif
• The sequence for the M yc oligonucleotide was taken from Blackw ood and 
Eisenm an, 1991
All o ligonucleotide sequences used in the binding assays were double stranded and 
end labelled with 22P, as detailed in sections 2.3.2.1 and 2.3.2.14. Only the sequence 
o f the leading strand o f  each double stranded oligonucleotide is show n above.
The 3 ’ w ild type (wt) LCR, m u tan t#  1, m utant # 2 and m utant # 3 oligonucleotides 
were synthesised by Beatson Institute technical services. Each strand o f the 
oligonucleotide was generated separately and then annealed in equim olar quantities 
after purification (see section 2.3.2.1 for details).
The collagenase TR E and M yc double stranded oligonucleotides were kindly 
provided by Dr. David G illespie and Dr. Kevin Ryan (Beatson Institute) 
respectively.
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Figure 4.14 EM SA showing the binding o f factor QX1 to a 
BPV4 LCR oligonucleotide (nucleotides 308-331) using 
nuclear extract from PalF cells treated with or without quercetin
1 2 3 4 5 6 7
QXl >  >
Lane 1 contain no nuclear extract
Lanes 2-4 each contain ~10 |ig  nuclear extract from  PalF cells exposed to 
O . W t  v/v ethanol for 24 hours before cells were harvested 
Lane 5-7 each contains ~10pg nuclear extract from  PalF cells exposed to 
20pM  quercetin for 24 hours before cells were harvested
Lane 1: 3 'w tL C R  probe alone (no extract)
Lane 2: 3 'w tL C R
Lane 3: 3 'w tL C R  probe + cold 3 'w tL C R  com petitor (self)
Lane 4: 3 'w tL C R  probe alone + cold Col.TR E com petitor 
Lane 5: 3 'w tL C R  probe
Lane 6: 3 'w tL C R  probe + cold 3 'w tL C R  com petitor (self)
Lane 7: 3 'w tL C R  probe alone + cold Col.TR E com petitor
Each com petitor was added to the lanes as indicated in a 100 fold 
excess with respect to labelled probe
158
Fi gur e  4.15 E M S A  s h o wi n g  a fac tor ,  Q X I ,  b inds  wi th i n  the 3 ' terminal  21 bp 
s e q u e n c e  of  the B P Y 4  L C R  and that  QX1  is present  in both chick  
e m b r y o  f i brobl as t s  and bovi ne  foetal  pa late  f ibroblas t s
I  « Q X i
L a n e s  1-4  c o n t a i n  w h o l e  c e l l  e x t r a c t  f r o m  c h i c k  e m b r y o  f i b r o b l a s t s  ( C E F )  
L a n e s  5 - 8  c o n t a i n  n u c l e a r  e x t r a c t  f r o m  b o v i n e  f o e t a l  p a l a t e  f i b r o b l a s t s  ( P a l F )
L a n e  1: 3 ’w t L C R  p r o b e
L a n e  2:  3 ' w t L C R  p r o b e  + C o l d  3 ' w t L C R  c o m p e t i t o r  ( S e l f )
L a n e  3:  3 ’w t L C R  p r o b e  + C o l d  C o l . T R E  c o m p e t i t o r
L a n e  4:  3 ' w t L C R  p r o b e  + C o l d  M y c  c o m p e t i t o r
L a n e  5:  3 ’w t L C R  p r o b e
L a n e  6:  3 ’w t L C R  p r o b e  + C o l d  3 ' w t L C R  c o m p e t i t o r  ( S e l f )
L a n e  7:  3 ' w t L C R  p r o b e  + C o l d  C o l . T R E  c o m p e t i t o r
L a n e  8:  3 ’w t L C R  p r o b e  + C o l d  M y c  c o m p e t i t o r
Q X  1: F a c t o r  w h i c h  is s e e n  to b i n d  b e t w e e n  n u c l e o t i d e s  3 1 0  a n d  3 3 1  o f  B P V 4  L C R
2 3 4 5 6 7
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is supported by the similar degree of competition observed with the collagenase TRE 
and 3'wtLCR oligonucleotides alike.
Figure 4.15 shows that QX1 is not specific to PalF cell nuclear extract. A 
band, apparently identical to QX1, was similarly detected in nuclear extract from 
chick embryo fibroblasts (CEF) (see QX1 band in lane 1). The QX1 band detected in 
CEF extract was competed away with unlabelled 3'wtLCR and unlabelled collagenase 
TRE oligonucleotides (lanes 2 and 3 respectively). An unlabelled oligonucleotide 
carrying the binding site for the c-myc protein was unable to compete for the binding 
of QX1. The pattern of binding and competition of QX1 observed with CEF extract 
was the same as that obtained when using PalF nuclear extract. This supports the 
conclusion that the two bands correspond to the same factor, namely QX1, and that 
QX1 is present in fibroblast cells both bovine and chick in origin.
4.11 Factor QX1 is not classical AP-1
It was not clear if  the QX1 band, identified in figures 4.14 and 4.15, was a 
novel factor or if  this band corresponded to an API factor. API was a potential 
candidate factor for binding to the BPV4 LCR oligonucleotide considering the high 
degree of homology between the TRE-like element and the API-binding site (see 
section 4.4 for sequence comparison).
To address this question it was first necessary to determine the level of API in 
PalF cells. This was done in an EMSA using an oligonucleotide containing the 
canonical API-binding site from the collagenase gene. Secondly, we wish to 
determine if QX1 and API were the same factor; if QX1 and API were indeed the 
same, then the bands for QX1 and API should display similar mobility in an EMSA.
4.11.1 Experimental procedure
Approximately 10pg of chick embryo fibroblast (CEF) or PalF nuclear extract 
was incubated with a radiolabelled oligonucleotide probe containing either the 
collagenase API-binding site or the TRE-like element found in the BPV4 LCR. 
Competitor oligonucleotides were included in reaction mixes where specified (see 
figure 4.16 and 4.17 for details of competitors used). Binding to the radiolabelled 
oligonucleotides was determined by running the reaction samples in individual lanes
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on a non-denaturing polyacrylamide gel and exposing the dried gel to X-ray film at - 
70°C, as described in sections 2.3.2.16 and 2.3.2.17.
4.11.2 Results
PalF cells contain readily detectable levels of API (see figure 4.16). The level 
of API detected in PalF cells was roughly identical to that observed for CEF extracts 
(figure 4.16). The API band was completely competed away using the same 
unlabelled TRE oligonucleotide (self competition) for both CEF and PalF extracts 
(lanes 3 and 8 ). Addition of unlabelled 3’wtLCR oligonucleotides to the reaction 
mixes resulted in only a small degree of competition. This indicates that the 
interaction between API and the 3’wtLCR sequence is not as specific as API for the 
collagenase TRE (lanes 4 and 9). The unrelated c-myc oligonucleotide had no affect 
on the binding of API to the collagenase TRE (lane 5 and 10).
As is illustrated in figure 4.17, the QX1 and API bands appear at very 
different position on the same gel. This indicates that the two factors are not the 
same. An unlabelled collagenase TRE oligonucleotide was able to compete well with 
the 3’wtLCR for the binding of QX1 (figure 4.17 - lane 4). Conversely, the 3’wtLCR 
competed poorly with the collagenase TRE for the binding of API.
Other complexes in addition to API and QX1 were detected in the EMSAs 
presented in figures 4.16 and 4.17. These other complexes however displayed a non­
specific pattern of binding or were not consistently detected in every assay and are 
thus not discussed further here or in following sections.
4.12 Analysis to determine if QX1 and API share any common structural 
components
Although it would appear from the results in section 4.11.2, that QX1 and API 
are not the same, this does not rule out the possibility that the two factors each contain 
a common structural component(s), particularly when considering the similarity 
between their individual binding motifs. As mentioned in section 4.4, API may exist 
as a homo- or heterodimer; Jun proteins may combine to form homodimers, or Jun 
may combine with Fos (or Fras) to produce the heterodimer form of API. We 
therefore used antibodies to the cJun and cFos to test if QX1 contained either of these 
two proteins as structural subunits.
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F i g u r e  4 . 1 6  E M S A  to d e t e c t  A P I  in n u c l e a r  e x t r a c t s  f r o m  C h i c k  
e m b r y o  f i b r o b l a s t s  a n d  B o v i n e  f o e t a l  p a l a t e  f i b r o b l a s t s
1 2  3 4 5 6 7 8 9 10
tf V #  * « # < »
L a n e s  2 - 5  c o n t a i n  w h o l e  c e l l  e x t r a c t  f r o m  c h i c k  e m b r y o  f i b r o b l a s t s  ( C E F )  
L a n e s  7 - 1 0  c o n t a i n  n u c l e a r  e x t r a c t  f r o m  b o v i n e  p a l a t e  f i b r o b l a s t s  ( P a l F )
L a n e  1: C o l . T R E  p r o b e  a l o n e  ( n o  e x t r a c t )
L a n e  2: C o l . T R E  p r o b e
L a n e  3 :  C o l . T R E  p r o b e  + C o l d  C o l . T R E  c o m p e t i t o r  ( S e l f )
L a n e  4: C o l . T R E  p r o b e  + C o l d  3 ' w t L C R  c o m p e t i t o r
L a n e  5: C o l . T R E  p r o b e  + C o l d  M y c  c o m p e t i t o r  
L a n e  6: C o l . T R E  p r o b e  a l o n e  ( n o  e x t r a c t )
L a n e  7: C o l . T R E  p r o b e
L a n e  8: C o l . T R E  p r o b e  + C o l d  C o l . T R E  c o m p e t i t o r  ( S e l f )
L a n e  9: C o l . T R E  p r o b e  + C o l d  3 ' w t L C R  c o m p e t i t o r
L a n e  10: C o l . T R E  p r o b e  + C o l d  M y c  c o m p e t i t o r
C o m p e t i t o r  o l i g o n u c l e o t i d e s  w e r e  p r e s e n t  in 1 00  f o l d  e x c e s s  
w i t h  r e s p e c t  to l a b e l l e d  p r o b e
1 6 2
Figure 4.17 EMSA with nuclear extract from Bovine Foetal Palate 
Fibroblasts to determine if QX1 and API are the same factor
1 2 3 4 5 6 7  8 9  10 11 12
4 API
Lane 1 and 6 contain no cellular extract 
Lanes 2-5. 7-10 contain extract from  PalF cells
Lane 11 and 12 contain whole extract from  chick em bryo fibroblasts (CEF)
Lane 1: 3 ‘wtLCR probe alone (no extract)
Lane 2: 3* w tLCR probe
Lane 3: 3 'w tL C R  probe + Cold 3 ‘wtLCR com petitor (Self)
Lane 4: 3 ‘wtLCR probe + Cold Col.TRE com petitor 
Lane 5: 3 ‘wtLCR probe + Cold Myc com petitor 
Lane 6: Col.TRE probe alone (no extract)
Lane 7: Col.TR E probe
Lane 8: Col.TR E probe + Cold Col.TRE com petitor (Self)
Lane 9: Col.TRE probe + Cold 3 ‘wtLCR com petitor 
Lane 10: Col.TRE probe + Cold Myc com petitor
Lane 11: Col.TRE probe alone
Lane 12: Col.TRE probe + Cold Col.TR E com petitor
Each com petitor oligonucleotide used was present in 100 fold excess 
with respect to labelled probe
I.
Q X l ^  I t  « i
163
4.12.1 Experimental procedure
For details of the basic experimental procedure followed, see section 2.3.2.18. 
The supershift assay was performed first with chick embryo fibroblast (CEF) nuclear 
extract and subsequently with PalF nuclear extract. The CEF extract was used to 
determine if the antibodies were producing a supershift of the API band as expected. 
The CEF extract was also used to assess if similar disruption or shift could be 
obtained for the QX1 band. The antibodies used were known to shift the CEF API 
band (personal communication by Dr. David Gillespie), however it was not known if 
the same antibodies would bind to and shift the bovine proteins with the same 
efficacy. Therefore the supershift experiment using the CEF extract functioned 
primarily a positive control, to confirm that the antibodies were able to produce the 
desired supershift of API. Furthermore, if the antibodies did induce change in the 
QX1 band, this may be more evident with CEF extract, particularly if the antibodies 
recognise the CEF proteins more specifically than the bovine proteins.
4.12.2 Results
Figure 4.18 shows the supershift EMSA result obtained using CEF extract.
The complex in lane 1 indicated by the first blue arrow corresponds to API. The API 
complex was competed away with an unlabelled collagenase TRE oligonucleotide 
(lane 2). Addition of either the cJun or cFos antibodies resulted in a shift of the API 
band up the gel (lanes 3 and 4 respectively). Addition of pre-immune serum to the 
reaction mix had no effect on the mobility of the API band.
The complex in lane 6 , indicated by the second blue arrow, corresponds to 
QX1. QX1 was successfully competed away by addition of a 100 fold excess of 
unlabelled 3’wtLCR oligonucleotide to the reaction mix (lane 7). Inclusion of the 
cJun antibody to the reaction mix had no effect on the position of the QX1 band (lane 
8 ). Although a weak complex was detected at the top of the gel (see arrow at the top 
of lane 8 ), a similar complex was also detected with pre-immune serum (lane 1 0 ).
The cFos antibody, while not producing a clear band shift as in lane 4, disrupted the 
binding of QX1 to the 3’wtLCR oligonucleotide, which is reflected in the reduced 
band intensity (lane 9). As observed in lane 5, addition of pre-immune serum had no 
effect on the binding of QX1 to the 3’wtLCR oligonucleotide (lane 10). These results 
indicate that QX1 in CEF may comprise API components. The absence of a clear
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F i g u r e  4 . 1 8  E l e c t r o p h o r e t i c  m o b i l i t y  S u p e r  S h i f t  a s s a y  u s i n g  n u c l e a r  
e x t r a c t  f r o m  C h i c k  e m b r y o  f i b r o b l a s t  ce l l s  ( C E F )  a n d  a n t i b o d i e s  
to c o m p o n e n t s  o f  t h e  A P I  c o m p l e x  ( c J u n  a n d  c F o s )
1 2 3 4 5 6 7 8 9 10
A l l  l a n e s  c o n t a i n  ~ 1 O u s  o f  n u c l e a r  e x t r a c t  f r o m  c h i c k  e m b r y o  f i b r o b l a s t  c e l l s  ( C E F )
L a n e  1 
L a n e  2 
L a n e  3 
L a n e  4 
L a n e  5 
L a n e  6 
L a n e  7 
L a n e  8 
L a n e  9 
L a n e  1
C o l . T R E  p r o b e
C o l . T R E  p r o b e  + C o l d  C o l . T R E  c o m p e t i t o r  ( S e l f )  
C o l . T R E  p r o b e  + A n t i - c J u n  a n t i b o d y  
C o l . T R E  p r o b e  + A n t i - c F o s  a n t i b o d y  
C o l . T R E  p r o b e  + p r e - i m m u n e  s e r u m  
3 ' w t L C R  p r o b e
3 ' w t L C R  p r o b e  + C o l d  3 ' w t L C R  c o m p e t i t o r  ( S e l f )  
3 ' w t L C R  p r o b e  + A n t i - c J u n  a n t i b o d y  
3 ' w t L C R  p r o b e  + A n t i - c F o s  a n t i b o d y  
3 ' w t L C R  p r o b e  + p r e - i m m u n e  s e r u m
B l u e  a r r o w s  i n d i c a t e  p o s i t i o n  o f  A P I  ( l a n e  
a n d  Q X  1 ( l a n e  6 )  c o m p l e x e s
R e d  a r r o w s  i n d i c a t e  b a n d s  w h i c h  h a v e  b e e n  s h i f t e d  u p  t h e  g e l  
( o r  d i s r u p t e d )  a s  a c o n s e q u e n c e  o f  a n t i b o d y  b i n d i n g
1 6 5
shift with cJun suggest that cJun is probably not a component of QX1. 
Notwithstanding, a different cJun-related protein, which is perhaps not well 
recognised by the specific cJun antibody which was used in this experiment, may be 
involved. Likewise, cFos or one of the other fos related proteins (Fras) may be a 
constituent of the QX1 factor.
Figure 4.19 illustrates the Supershift EMSA results obtained using PalF 
extract. The results obtained with the PalF extract are very similar to those observed 
with CEF extract. The cJun and cFos antibodies shifted or disrupted the API band 
(lanes 3 and 4 respectively). The supershift obtained upon addition of the cJun 
antibody to the reaction mix with PalF nuclear extract was not as efficient as that 
observed with CEF extract. The incompleteness of the shift may simply reflect a drop 
in specificity of the cJun antibody for the bovine cJun protein. The same argument 
could apply to the banding pattern observed in lane 4; the cFos antibody had less of an 
effect on the bovine API band compared to the supershift profile observed with the 
CEF extract (figure 4.18 - lane 4).
The cJun and cFos antibodies had little or no effect on the binding of QX1 to 
the 3’wtLCR with PalF extract. The cJun antibody appeared to have no effect on the 
position of QX1. A weak band was detected at the top of lane 8  but, as was observed 
with CEF extracted, a similar band was produced when pre-immune serum was added 
to the reaction mix. (see lane 10). Addition of cFos to the reaction mix also appeared 
to have no effect on the position or intensity of the QX1 band (lane 9). As was 
suggested earlier, the antibodies which were used in the respective reaction mixes are 
probably more specific for chicken proteins. The structure of the bovine proteins may 
be sufficiently diverse in structure from those of chicken origin so as not to be 
efficiently recognised.
As the results from figure 4.18 indicate, it is probable that QX1 is not 
composed of either cJun or cFos. This however does not exclude the involvement of 
proteins related to either cJun, cFos or both. Failure therefore to achieve a clear 
supershift of the QX1 band with either the cJun or cFos antibodies when using PalF 
extract may be partially attributable to potential diversity in the constituent proteins 
between species. In addition to this, the level of relatedness of the QX1 proteins to 
cJun and/or cFos even within each cell species probably further influenced the 
sensitivity the assay.
166
F i g u r e  4 . 1 9  E l e c t r o p h o r e t i c  m o b i l i t y  S u p e r  S h i f t  a s s a y  u s i n g  
n u c l e a r  e x t r a c t  f r o m  B o v i n e  f o e t a l  p a l a t e  f i b r o b l a s t  ce l l s  ( P a l F )  
a n d  a n t i b o d i e s  to c o m p o n e n t s  o f  t he  A P I  c o m p l e x  ( c J u n  a n d  c F o s )
1 2  3 4 5 6 7 8 9 10
A l l  l a n e s  c o n t a i n  ~ 1 0 u g  o f  n u c l e a r  e x t r a c t  f r o m  B o v i n e  f o e t a l  p a l a t e  f i b r o b l a s t s  t P a l F )
L a n e  1 C o l . T R E  p r o b e
L a n e  2 C o l . T R E  p r o b e  + C o l d  C o l . T R E  c o m p e t i t o r  ( S e l f )
L a n e  3 C o l . T R E  p r o b e  + A n t i - c J u n  a n t i b o d y
L a n e  4 C o l . T R E  p r o b e  + A n t i - c F o s  a n t i b o d y
L a n e  5 C o l . T R E  p r o b e  + p r e - i m m u n e  s e r u m
L a n e 6 3 ' w t L C R  p r o b e
L a n e  7 3 ' w t L C R  p r o b e  + C o l d  L C R  c o m p e t i t o r  ( S e l f )
L a n e  8 3 ' w t L C R  p r o b e  + A n t i - c J u n  a n t i b o d y
L a n e  9 3 ' w t L C R  p r o b e  + A n t i - c F o s  a n t i b o d y
L a n e  10: 3 ’w t L C R  p r o b e  + p r e - i m m u n e  s e r u m
►B l u e  a r r o w s  i n d i c a t e  p o s i t i o n  o f  A P I  ( l a n e  a n d Q X l  ( l a n e  6 )  c o m p l e x e s
R e d  a r r o w s  i n d i c a t e  b a n d s  w h i c h  h a v e  b e e n  s h i f t e d  u p  t h e  g e l  
( o r  d i s r u p t e d )  a s  a c o n s e q u e n c e  o f  a n t i b o d y  b i n d i n g
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4.13 Analysis of the effect of mutations within or adjacent to the TRE-like 
element in the BPV4 LCR on the binding of QX1
Sequence comparison between the TRE-like element and the API-binding site 
revealed a single base difference between the two sites. We were interested to know if 
mutating the TRE-like element to a consensus API-binding site would alter the 
binding profile of this 3’ terminal stretch of the BPV4 LCR. We were also interested 
in trying to abolish QX1 binding by means of mutating nucleotides adjacent to the 
TRE-like element; by altering or disrupting QX1 binding, it may be possible to 
identify critical residues within the QX1 binding motif.
4.13.1 Experimental procedure
Three oligonucleotides were synthesised which contained a single or double 
base pair change with respect to the wild type sequence of the LCR (nucleotides 311 
to 331) - see figure 4.13 for nucleotide sequences of the mutant LCR oligonucleotides 
used. Mutant #1 harbours a G-T transversion which changes the TRE-like element to 
a consensus API-binding site. Mutants #2 and #3 contain changes in nucleotides 
which are at the 5’end of or are immediately adjacent to the TRE-like element.
The mutant oligonucleotides were mixed with ~10pg of PalF nuclear extract as 
described in section 2.3.2.16. Unlabelled oligonucleotides were added as competitors, 
as specified in figure 4.20 and 4.21.
4.13.2 Results
Figure 4.20 illustrates the effect of a single base change within the BPV4 TRE- 
like element on the binding of QX1 and API. The G-T mutation introduced at 
nucleotide 317 of the BPV4 LCR, which converted the TRE-like element to a 
consensus API-binding motif, facilitated the binding of API to this mutated 
oligonucleotide. In addition to the de novo binding of API, this mutant 
oligonucleotide retained the ability to bind QX1. Furthermore, the level of QX1 
binding to mutant oligonucleotide #1 appeared to be enhanced. It would appear 
however that API and QX1 can not bind simultaneously to the 3’wtLCR sequence as 
a third complex corresponding to both complexes bound was not detected above the 
API band on the gel. Both the API and QX1 complexes were competed away by 
addition of unlabelled mutant#! oligonucleotide. Addition of unlabelled 3’wtLCR
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oligonucleotide competed away QX1 more efficiently than API. Conversely, 
unlabelled collagenase TRE oligonucleotide competed away API more specifically 
than QX1. Addition of an unlabelled myc-binding oligonucleotide had no effect on 
the binding of API or QX1 to the mutant# 1 oligonucleotide sequence. These 
observations highlight the significance of this single nucleotide base with respect to 
both QX1 and API binding.
The effect of the two other mutant LCR oligonucleotides on the binding of 
QX1 was less dramatic. As the results in figure 4.21 demonstrate, QX1 was seen to 
bind to mutant #2 and mutant #3 oligonucleotides with an efficacy similar to that 
observed for the wild type LCR. Because the binding of QX1 to mutant 
oligonucleotides #2 and #3 was apparently unaffected by the respective nucleotide 
changes, it may be concluded that the residues which were mutated are not critical for 
the binding of QX1 to this region of the BPV4 LCR.
4.14 The effect of mutations within the 3’ terminal 21 base pairs of the BPV4 
LCR on the transcriptional activity of the LCR
In figure 4.20, a dramatic change in the binding profile of the EMSA was 
observed when a single nucleotide within the 3'wtLCR oligonucleotide was mutated to 
generate a consensus API-binding site (figure 4.13). This single base pair change 
within the TRE-like motif was sufficient to allow API to bind a sequence within 
nucleotides 311-331 of the BPV4 LCR. As an extension of the experiment and results 
described in section 4.13, mutant variants of BPV4 LCR were created and cloned into 
the pGL3 expression vector. The basal transcriptional activity and response to 
quercetin treatment of these newly generated mutant LCR-containing plasmids was 
then assessed.
4.14.1 Experimental procedure
Four new plasmid vectors were generated using a PCR based method (see 
section 2.3.2.2 for details). Mutations were introduced into the LCR by designing 
specific PCR primers which contained the desired mutation. On the end of each of the 
PCR primers, a separate recognition site for a restriction enzyme was included. This 
facilitated subsequent cloning of the new LCR inserts into the appropriate expression 
vector and in the correct orientation. The sequences of the oligonucleotide primers
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Figure 4.21 EMSA showing the effect of BPV4 LCR mutants #2
and #3 on the binding of factor QX1
1 2 3 4 5 6 7 8 9 10 11 12
All lanes, except lanes 1 and 7. contain ~10ug nuclear extract from  
bovine foetal palate fibroblasts (PalF)
Lane 1: BPV4 LCR m utant #2 probe alone (no extract)
Lane 2: M utant #2 probe
Lane 3: M utant #2 probe + Cold m utant #2 com petitor (self)
Lane 4: M utant #2 probe + Cold 3 ’w tLC R  com petitor
Lane 5: M utant #2 probe + Cold C ol.TR E com petitor
Lane 6 : M utant #2 probe + Cold M yc com petitor
Lane 7: BPV4 LCR M utant #3 probe alone (no extract)
Lane 8 : M utant #3 probe
Lane 9: M utant #3 probe + Cold m utant #3 com petitor (self)
Lane 10: M utant #3 probe + Cold 3 ‘w tLC R com petitor 
Lane 11: M utant #3 probe + Cold Col.TR E com petitor 
Lane 12: M utant #3 probe + Cold M yc com petitor
Q X I ^  *  k *
used to generate the LCR mutants are given in figure 4.22. The forward primer 
annealed to the bottom strand at the 5’ end of BPV4 LCR (at nucleotide 6710); the 
reverse primers, which carried the particular point mutations, annealed to the top 
strand at the 3’ end of the BPV4 LCR (at nucleotide 310 (sLCR) or nucleotide 331 
(wt, API and random). The same forward primer was used in all PCR reactions.
The API primer was designed to change the TRE-like element in the LCR to a 
classic API-binding site. This involved a single base change at nucleotide 317; the 
remainder of the LCR sequence was unchanged. The random primer was designed to 
replace nucleotides 311-331 with a string of 21 random nucleotides. This was to 
address the question of whether the specific sequence of nucleotides 311-331 is 
important with respect to the basal activity and response to quercetin of the BPV4 
LCR.
The PCR products, corresponding to the various mutant LCR inserts, were 
separated from unwanted by products of the PCR reaction by electrophoresis through 
an agarose gel. The mutant LCR inserts were purified from the gel and their ends cut 
with the appropriate restriction enzymes. The pGL3 expression vector was linearised 
with the same enzymes used to cut the ends of the mutant LCR PCR products; the 
enzymes chosen allowed the mutant LCRs to be inserted into the vector in the correct 
orientation. After being linearised, the vector was incubated with alkaline 
phosphatase to prevent the vector from religating to itself. The mutant LCR PCR 
products were ligated into the pGL3 vector and subsequently transformed into 
competent DH5a bacterial cells. Transformed colonies were screened for vectors 
which contained the BPV4 LCR inserts. Positive colonies were picked and cultured 
in 500ml or 1 litre volumes of LB broth containing the appropriate selection 
antibiotic. The mutant LCR vectors were purified from the bacterial cultures and the 
sequence of each of the mutant LCRs checked using an automated sequencing 
machine. Details of all the methods used in the process described above can be found 
in section 2.3.2
2xl0 5  low passage PalF cells or 5x105  PalK cells were seeded into 60mm 
tissue culture dishes. The following day, cells were transfected with either 7.5 pg 
pGL3 plus 2.5pg pCHl 10, or 7.5pg pGL3-wtLCR plus 2.5pg pCHl 10, or 7.5pg 
pGL3-sLCR plus 2.5pg pCHl 10, or 7.5pg pGL3-randLCR plus 2.5pg pCHl 10,
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or 7.5pg pGL3-APlLCR plus 2.5pg pCHl 10 as described in section 2.3.1.7 (for PalF 
cells) or section 2.3.1.8 (for PalK cells). After transfection, a fresh volume of 
medium, supplemented with 20pM quercetin or an equivalent volume of ethanol, was 
added to the appropriate dishes of cells, as summarised in table 4.9. Cells were 
cultured in this medium for 24 hours and finally harvested as described in section 
2.3.1.9a. The cell lysates were assayed for P-galactosidase and luciferase enzyme 
activities (section 2.3.1.11 and 2.3.1.12).
Each luciferase assay reading was corrected for efficiency of transfection using 
the corresponding p-galactosidase reading, as described in section 4.3.1. The 
contribution of empty vector (pGL3) on transcription was removed by subtraction, as 
detailed in section 4.8.1, and the final readings were normalised to the ‘No quercetin’ 
reading set = 1 (section 4.3.1).
Table 4.9 Summary of the experimental conditions used when PalF and PalK 
cells were transfected with pGL3 vectors, carrying mutant BPV4 LCRs present 
in a promoter configuration, and treated with or without quercetin
Condition
#1
Condition
#2
Condition
# 3
Condition
# 4
Condition
# 5
Transfected with pGL3 + 
pCHl 10
pGL3- 
wtLCR + 
pCHl 10
pGL3- 
sLCR + 
pCHl 10
pGL3- 
randLCR + 
pCHl 10
pGL3- 
AP1LCR + 
pCHl 10
Treated with E Q E Q E Q E Q E Q
4.14.2 Results
Figure 4.23 illustrates the response to quercetin exposure and the basal 
transcriptional activity of four newly generated BPV4 LCR-containing plasmids. 
Similar to observations detailed in earlier results sections, the transcriptional activity 
the wild type BPV4 LCR was increased approximately 2 fold when PalF cells were 
treated with 20pM quercetin for 24 hours after transfection (figure 4.23 - panel A). 
Also in keeping with earlier observations, the activity of the 21 base pair truncated 
form of the BPV4 LCR was increased in response to quercetin treatment
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Figure 4.23 Bar charts showing the basal activities and 
response to quercetin treatment for a range o f  
BPV4 LCR mutants
2.5 
2
1.5 
1
0.5
0
WT sLCR Random AP1-
LCR
A
PalF cells
Response to Q uercetin
500
WT sLCR Random AP1- 
LCR
B
PalF cells
Basal activity
2
1.5
1
0.5
0
PalK  cells
Response to Q uercetin
WT sLCR Random AP1-
LCR
100000
■ rti
. r
• mm
M . m .
WT sLCR Random AP1-
LCR
D
PalK  cells
Basal activity
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(~1.5 fold increase), but the level of the response was less in comparison to the wild 
type LCR. The random-LCR plasmid showed a response to quercetin similar to that 
observed for the truncated LCR. The response to quercetin treatment of the LCR 
plasmid which carried an API-binding site was similar to that seen for the truncated 
and random LCRs but less than the response of the wild type LCR sequence.
The response of the same four vectors to quercetin exposure after transfection 
into PalK cells was essentially the same as that seen with PalF cells (see figure 4.23 - 
panel C). The largest response to quercetin was observed with the wild type LCR, 
although the level of the response was slightly less than the response seen for the same 
vector in PalF cells. The truncated LCR again showed a slightly reduced response 
with respect to the wild type LCR however the level of the response was very similar 
to that achieved by the same vector in PalF cells. The random LCR, as in PalF cells, 
showed the smallest response to quercetin treatment. It would appear that replacing 
nucleotides 311 to 331 of the BPV4 LCR with a stretch of random nucleotides has a 
greater effect on response to quercetin than simply deleting the same bases.
The activity of the API-LCR was increased in response to quercetin. The fold 
increase observed was similar to that seen for the truncated LCR but less than 
response of the wild type LCR. This result indicates that a single base substitution, 
which changes the TRE-like motif to a canonical API-binding site, directly affects the 
response of the LCR to quercetin treatment.
The basal transcriptional activities of the four vectors was more varied than 
their individual responses to quercetin treatment (figure 4.23 - panels B and C). In 
both PalF and PalK cells, the API-containing LCR displayed the strongest 
transcriptional activity. Thus, by replacing the TRE-like element in the BPV4 LCR 
with a canonical API-binding site, by virtue of a single base pair change, the basal 
level of transcription was increased. Hence the TRE-like element must contribute to 
the normal activity of the BPV4 LCR.
The wild type LCR showed good activity in both PalF and PalK cells. The 
activity of the truncated LCR was less than that seen for either the wild type or AP1- 
containing LCR. The difference in activity between the wild type and truncated LCR 
was more evident in PalK cells; the activity of the truncated LCR was only slightly 
less than the activity of the wild type LCR in PalF cells.
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The basal transcriptional activity of the random LCR was dramatically less 
than the wild type LCR in both PalF and PalK cells. In the random-LCR vector, 
nucleotides 311-331 of the BPV4 LCR were replaced with a stretch of random 
nucleotides; these nucleotides are situated down stream of and did not directly involve 
the TATAA box. Nevertheless, it seems clear that the specific sequence of 
nucleotides 311 to 331 of the BPV4 LCR is important for maintaining the basal level 
of transcription from the viral LCR and this sequence cannot simply be replaced by 
any sequence of random nucleotides.
One very clear observation was that the activity of all four vectors was 
considerable higher in PalK cells in comparison to their corresponding activities in 
PalF cells. Each of the vectors was approximately 40 to 50 times more active in PalK 
than in PalF cells. This difference in the basal level of transcriptional activity strongly 
reflects the natural tropism of BPV4 for epithelial cells.
4.15 Identification of other potential regions in the BPV4 LCR which may 
mediate the effects of quercetin on the LCR’s transcriptional activity
The results from experiments with the full length and 3’ truncated forms of the 
BPV4 LCR indicated that, although the sequence between nucleotides 311 and 331 
may be partially mediating the effect of quercetin on levels of transcription, other 
regions of the LCR also appear to be involved. A panel of 5’ truncated BPV4 LCR 
mutants was generated by Dr. Iain Morgan (Beatson Institute). Figure 4.24 is a 
schematic representation of the BPV4 LCR sequences which are included in each of 
the mutant LCR plasmids. By transfecting these mutants into PalF cells, it was 
possible to screen for other regions of the BPV4 LCR which may be contributing to 
the upregulation of transcription in response to quercetin exposure.
4.15.1 Experimental procedure
2x105  low passage PalF cells were plated into 60mm tissue culture dishes. 
After an overnight incubation, the cells were transfected with one of the following 
plasmid DNA combination;
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Figure 4.24 pGL-3 basic vector map
(taken from  the Prom ega biological research products catalogue, 1997)
(for background
pGL3-Basic
Vector
(4818bD)
2010
2004
Sal I 
BamH l
Synthetic poly(A) signal / 
transcriptional pause site 
reduction)
Kpn  1 5
S ac  1 11
Mlu 1 15
Nhe 1 21
Sma 1 28
Xho 1 32
Bgl II 36
Hind III 53
N co  I 86 
Nar I 121
1742
SV 40 late poly(A ) s ig n a l 
(for luc* reporter) 
Hpal 1 9 0 2
XPa I
The follow ing BPV4 LCR deletion mutants were cloned into the site 
o f pGL-3 basic vector (see section 2.2.9 for details)
GL3-PINTI B  AB ♦ ♦ ♦  1  » V I  nt 6710-331
GL3-PINI g  A l  W  nt 6710-310
GL3-A10I A i  f f i  ■  ■
GL3-A36I 7TB 1  —
G L 3-A 17 0  [ B B Q E Z B I  nt 44-310
G L 3 - A 1 5 l H _ f L - H  nt 149-310
G L 3 -A 1 1 4  C M
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• 7.5(Ig pGL3 + 2.5 pg pCHl 10 • 7.5(lg pGL3-PINT + 2.5 jag pCHl 10
• 7.5pg pGL3-A57.1 + 2.5 |Llg pCHl 10
• 7.5pg pGL3-A36 + 2.5pg pCHl 10
• 7.5|IgpGL3-A151 +2.5  pg pCHl 10
• 7.5pg pGL3-PIN + 2.5 pg pCHl 10
• 7.5pg pGL3-A10 + 2.5 fig pCHl 10
• 7.5pgpGL3-A170 + 2.5 pgpCHllO
• 7.5pgpGL3-Al 14 + 2.5 pgpC H l 10
Cells were transfected according the protocol detailed in section 2.3.1.7. After 
transfection, the cells were treated with a fresh volume of medium supplemented with 
either 20pM quercetin or an equivalent volume of ethanol (see table 4.10 for details). 
Cells were cultured in the appropriate supplemented medium for 24 hours. At the end 
of the incubation period, all cells were harvested as described in section 2.3.1.9a and 
the cell lysates obtained were assayed for P-galactosidase and luciferase enzyme 
activities (see sections 2.3.1.11 and 2.3.1.12).
Each luciferase assay reading was corrected for efficiency of transfection using 
the corresponding p-galactosidase reading, as described in section 4.3.1. The 
contribution of empty vector (pGL3) on transcription was removed by subtraction, as 
detailed in section 4.8.1, and the final readings were normalised to the ‘No quercetin’ 
reading set = 1 (section 4.3.1).
4.15.2 Results
Figure 4.25 -panel A illustrates the response of each the 5’ deletion mutants to 
quercetin exposure. As expected the full length, wild type LCR displayed the greatest 
response to quercetin treatment. Removal of nucleotides 311-331 from the LCR 
correlated with a drop in response to quercetin treatment to approximately 1.5 fold. 
Deletion of 421 nucleotides from the 5’ end of the LCR had no effect on the response 
of the vector to quercetin exposure. Deletion of a further 82 nucleotides from the 
5’end of the LCR however resulted in a drop in the response to quercetin back to a 
level comparable with the empty vector. This would indicate that nucleotides in this 
region of the LCR may be involved in mediating part of the response of the BPV4 
LCR to quercetin. More extensive 5’ deletions of the BPV4 LCR had little further 
effect on response of the LCR to quercetin.
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Table 4.10 Summary of the experimental conditions used when PalF cells were 
transfected with pGL3 vectors carrying various 5’ and 3’terminal truncated 
mutants of the BPV4 LCRs present in a promoter configuration, and treated 
with or without quercetin
Transfected with Treated with
Condition #1 7.5pg pGL3 + 
2.5pg pCHl 10
E (2 dishes) 
Q (2 dishes)
Condition #2 7.5pg pGL3PINT + 
2.5pg pCHl 10
E (2 dishes) 
Q (2 dishes)
Condition #3 7.5pg pGL3-PIN + 
2.5pg pCHl 10
E (2 dishes) 
Q (2 dishes)
Condition #4 7.5pg pGL3-A57.1 
+ 2.5pg pCHl 10
E (2 dishes) 
Q (2 dishes)
Condition #5 7.5pg pGL3-A10 + 
2.5pg pCHl 10
E (2 dishes) 
Q (2 dishes)
Condition #6 7.5pg pGL3-A36 + 
2.5pg pCHl 10
E (2 dishes) 
Q (2 dishes)
Condition #7 7.5pg pGL3-A170 
+ 2.5pg pCHl 10
E (2 dishes) 
Q (2 dishes)
Condition #8 7.5pgpGL3-A151 
+ 2.5pg pCHl 10
E (2 dishes) 
Q (2 dishes)
Condition #9 7.5pgpGL3-A114 
+ 2.5pg pCHl 10
E (2 dishes) 
Q (2 dishes)
Figure 4.25 - panel B illustrates the basal transcriptional activities of each of 
the LCR deletion mutant plasmids. The activity of the full length BPV4 LCR (pGL3- 
PINT) is approximately 35 fold greater than the empty vector. Removal of 
nucleotides 311-331 from the 3 ’end of the LCR resulted in a decrease in the basal 
level of activity. This is in keeping with observations from earlier experiments 
(sections 4.8.2 and 4.9.2). Sequential deletion of nucleotides from the 5’ end of the 
LCR correlated with a steady decline in the basal transcriptional activity of the LCR. 
This suggests that a number of regulatory elements which influence the activity of the
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LCR are located at different sites along the length of the LCR. A significant drop in 
activity was observed with pGL3-A36 when nucleotides 7131 to 7212 were deleted 
(figure 4.24). Deletion of these residues was also associated with a drop in response 
to quercetin treatment (figure 4.25 - panel A). Therefore, the region of the BPV4 LCR 
encompassing nucleotides 7131-7212 appears to contains sequences which are 
important in terms of both basic levels of transcriptional activity and response to 
quercetin treatment.
4.16 Analysis of the effect of quercetin treatment on the transcriptional activity 
of the Moloney Murine Long Terminal Repeat (MoMuLTR) acting as a 
promoter element
Experiments described by Caimey and Campo (1995) demonstrated that 
transfection of PalF cells with the BPV4 E7 gene and an activated ras gene, followed 
by a 48 hour exposure to 20pM quercetin, was sufficient to induce cellular 
transformation of PalF cells. The same degree of transformation was not observed 
however when the same cells were similarly transfected but not treated with quercetin. 
In these experiments, expression of the BPV4 E7 coding sequence was not controlled 
by the viral LCR but rather the Moloney Murine long terminal repeat (MoMuLTR). 
The MoMuLTR is a strong viral promoter. It had not been determined if the activity 
of the MoMuLTR could be altered by exposure to quercetin as has been observed for 
the BPV4 LCR. We therefore transfected PalF cells with a plasmid carrying the CAT 
reporter gene under the transcriptional control of the MoMuLTR. The cells were 
treated with 20pM quercetin for 24 hours after transfection and ultimately screened 
for any changes in reporter protein levels.
4.16.1 Experimental procedure
2x105  low passage PalF cells were plated into the appropriate tissue culture 
dishes and incubated overnight as described in section 2.3.1.7. The following day the 
cells were transfected with one of the following plasmid DNA combinations;
• 7.5pg pCAT + 2.5pg pCHl 10
• 7.5pg pMoMuLTR-CAT + 2.5pg pCHl 10
• 2pg pMoMuLTR-CAT + 2.5fig pCHl 10 + 5.5pg salmon sperm DNA
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• 1 pg pMoMuLTR-CAT + 2.5pg pCHl 10 + 6.5pg salmon sperm DNA
• 0.2pg pMoMuLTR-CAT + 2.5pg pCHl 10 + 7.3pg salmon sperm DNA
Salmon sperm DNA was added to transfection reactions as indicated above to
act as carrier DNA and to bring the total amount of DNA in each reaction to a total of 
1 0 ng.
After transfection, a fresh volume of medium, supplemented with either 20pM 
quercetin or an equivalent volume of ethanol, was added to the appropriate dishes; 
two dishes in each transfection condition were treated with quercetin while the other 
two were treated with ethanol. The cells were incubated in this medium for 48 hours 
and then harvested as detailed in section 2.3.1.9a. The cell lysates were assayed for 
CAT and P-galactosidase enzyme activities as described in sections 2.3.1.12 and 
2.3.1.13.
Each CAT assay reading was corrected for efficiency of transfection using the 
corresponding p-galactosidase reading, as described in section 4.3.1. The contribution 
of empty vector (pCAT) on transcription was removed by subtraction, as detailed in 
section 4.8.1, and the final readings were normalised to the ‘No quercetin’ reading set 
= 1 (section 4.3.1). The results from 3 separate experiments are presented in figure 
4.26a and b.
4.16.2 Results
The Molony Murine LTR was found to be a very strong promoter 
element. The results in figure 4.26a show that when 7.5pg of plasmid vector 
containing the MoMuLTR was transfected into PalF cells, expression of the CAT 
reporter gene was high. This was reflected in the level of conversion of 
chloramphenicol substrate to mono-and even diacetylated products; 2 pl of each cell 
lysate, from a total lysis volume of 350pl, was sufficient to convert almost 100% of 
the chloramphenicol substrate. Usually 50pl of a 350pl cell lysate is used in each 
CAT assay reaction and even then such a high conversion level is often not observed. 
No difference was seen in the percentage conversion for cells which had been exposed 
to 20pM quercetin for 48 hours after transfection. From the results shown in figure 
4.26a, no conclusion as to the response of the MoMuLTR to quercetin can be made as
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any effect of quercetin on the activity of the MoMuLTR has probably been obscured 
by the high basal level of expression for this promoter element.
Figure 4.26b shows the results from two separate experiments in which the 
amount of MoMuLTR reporter vector had been sequentially reduced in an attempt to 
identify any change in activity of the MoMuLTR in response to quercetin treatment.
As the average percentage conversion values given in each table show, quercetin 
appeared to actually inhibit the activity of the MoMuLTR. This is in contrast to the 
response of the BPV4 LCR to quercetin treatment. The effect of quercetin on the 
activity of the BPV4 LCR has not been assessed using nanogram amounts of a BPV4 
LCR-containing vector, as was done with the MoMuLTR (as detailed in section 
4.16.1). Nevertheless, it would appear from the results with the MoMuLTR and the 
BPV4 LCR that the response of different promoters to quercetin treatment is not the 
same.
Although the results in figure 5.26b suggest that quercetin treatment can 
partially inhibit the activity of the MoMuLTR, this effect was only observed when 
small amounts of the reporter vector were transfected into the host cells and less than 
usual amounts of the cell lysate samples were used in the assay reactions. It is very 
clear that the MoMuLTR is a very powerful promoter even in the presence of 
quercetin. In relation to the experiments described by Caimey and Campo (1995), it is 
unlikely that a crucial role of quercetin was to alter the level of transcription of viral 
genes which were under the transcriptional control of the MoMuLTR. Nevertheless, 
quercetin is known to affect a wide range of cellular functions. It is very possible that 
the effect of quercetin on one or more other cellular targets synergised with the high 
level of viral gene expression from the MoMuLTR and thus contributed to cellular 
transformation in PalF cells.
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Figure 4.26a Transcriptional activ ity of the 
M oloney M urine Long Terminal Repeat (LTR) in PalF cells
D iacetylated !
*  #  *[ i i  #  iM onoacetylated \
U nacetylated { ®
1 2 3 4 5 6 Blank
Lane 1. 2. and 3 4. 5. and 6
Transfected with 7 .5pg pM oM uLTR- 
C A T + 2 .5 |ig  p C H l l O
7.5ug pM oM uLTR- 
C A T + 2.5pg p C H l l O
Treated with Ethanol Quercetin
Average 7c conversion 91.927c 91.697c
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Chapter 5
The Effect of Quercetin on 
Protein Phosphotyrosine Levels 
in PalF cells
Chapter 5 The effect of quercetin on Protein Phosphotyrosine levels
5.1 Introduction
Quercetin is known to affect a number of different cellular functions. Many of 
the quercetin-induced effects have been attributed to the ability of quercetin to inhibit 
or alter the activity of a large number of cellular enzymes. The inhibition of enzymes 
such as mitochondrial succinoxidase, NADH-oxidase, enzymes involved in 
arachidonic acid metabolism, aldose reductase and several other oxido-reductases 
(Elliott et a l , 1992 and references therein) account for the ability of quercetin to 
inhibit various metabolic processes including lactate transport and glycolysis (Belt et 
a l , 1979). The inhibition of several kinases including pp60src (Graziani et a l , 1983), 
casein kinase II (Cochet et a l , 1982), protein kinase C (Gshwendt et a l , 1983), 
phosphorylase kinase (Srivastava, 1985), phosphatidylinositol-3-kinase (Matter et a l , 
1992) and several tyrosine kinases associated with mammary tumours (Levy et a l , 
1984), suggest a role for quercetin in the inhibition and/or de-regulation of a number 
of different signal transduction pathways.
The extensive repertoire of enzymes which can be inhibited by quercetin is 
undoubtedly a critical aspect of quercetin’s ability to induce such a large number of 
varied and sometimes contradictory effects.
5.2 Determining the phosphotyrosine status of proteins in PalF cells after 
quercetin treatment
In chapter 4, the ability of quercetin to modulate the level of transcription from 
the BPV4 LCR was analysed. In spite of the observed increase in transcription from 
the LCR, it was clear that this was not the only effect of quercetin which would 
explain the ability of quercetin to synergise with BPV4 and activated ras to induce the 
malignant transformation of PalF cells. A previous study showed that quercetin,
BPV4 and ras expression were synergistic and necessary for the complete 
transformation of PalF cells even when the BPV4 genes were under the transcriptional 
control of the Molony Murine LTR promoter (Caimey and Campo, 1995). The results 
presented in figure 4.26b showed that, unlike the BPV4 LCR, the activity of the 
Molony Murine LTR was not increased in response to quercetin. Thus other effects of
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quercetin must have been responsible for the significant enhancement to 
transformation. The nature of these other effects had not as yet been studied.
In an attempt to identify other cellular changes induced in PalF cells as a result 
of exposure to quercetin, bearing in mind the observations which have been made in 
other studies (refer to section 5.1), we decided to test if quercetin was having an effect 
on protein phosphotyrosine levels.
5.2.1 Experimental procedure
106  PalF cells were seeded into 90mm tissue culture dishes. After an 
overnight incubation, the medium was changed. The fresh medium was supplemented 
with quercetin to a final concentration of 20pM. Two extra dishes, in which medium 
was supplemented with an equivalent volume of absolute ethanol (0 .1 % v/v), were set 
up in parallel to act as controls.
Cells were cultured in the appropriate environment (37°C and 5% CO2 ) for 48 
hours. At the end of the incubation period, medium containing quercetin (or ethanol) 
was removed and all cell monolayers were washed twice with PBS to remove any 
traces of quercetin. Two (duplicate) dishes of cells were harvested for total cellular 
protein according to the method detailed in section 2.3.1.9b. These protein samples 
corresponded to cells being harvested at time = 0 after removal of quercetin. The 
control (ethanol treated) cells were also harvested at this time.
To all other dishes of cells, a fresh volume of lxDMEM medium was added. 
Cells were replaced in the appropriate incubator and harvested at various time points 
after removal of quercetin. The rationale for harvesting cells at various times after 
removal of quercetin was to determine how long a phosphotyrosine change, if 
detected, would persist. Earlier experiments showed that the timing of exposure of 
PalF cells to quercetin was critical with regard to quercetin’s ability to synergise with 
BPV4 and ras and induce malignant transformation of PalF cells (Caimey and 
Campo, 1995). Only cells treated with quercetin for 48 hours either immediately 
before or immediately after transfection with BPV4 and ras became fully transformed.
The concentration of each protein sample was determined according to the 
method described in section 2.3.3.1. Approximately 20pg of each protein sample was 
loaded into separate wells in an SDS-polyacrylamide gel. The protein samples were 
electrophoresed through the SDS-polyacrylamide gel and subsequently transferred
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onto Hybond Cextra or a nitrocellulose filter as detailed in section 2.3.3.2. 
Phosphotyrosine proteins were detected using the appropriate primary and secondary 
antibodies as described in section 2.3.3.3.
5.2.2 Results
Figure 5.1 shows a number of proteins phosphorylated on tyrosine residues 
which were detected in extracts from PalF cells.
Compare first the pattern of protein bands in lanes 1 and 2 with those in lanes 
3 and 4. The protein extracts run in lanes 1 and 2 came from cells which were treated 
with 0.1% ethanol for 48 hours before harvesting and should represent normal 
phosphotyrosine-protein levels. The extracts run in lanes 3 and 4 came from cells 
which were similarly treated but with 20pM quercetin before harvesting. The arrows 
numbered 2 and 3 indicate two bands which are less intense in lanes 3 and 4 compared 
to the bands at the same position in lanes 1 and 2. This observation suggests that the 
levels of phosphotyrosine in these proteins were reduced as a result of exposure to 
quercetin. Removal of quercetin permitted these proteins to regain a normal level of 
phosphotyrosine. The recovery of the phosphotyrosine levels was already apparent 30 
minutes after quercetin had been removed from the culture medium (lanes 5 and 6 ).
The band at the top of the gel (indicated by arrow number 1) shows a different 
phosphotyrosine pattern. This protein was not readily detected in ethanol treated cells 
nor was it detected in cells harvested immediately after a 48 hour exposure to 
quercetin. Its expression was initially detected 30 minutes after quercetin had been 
removed from the culture medium. It was detected up to four hours after quercetin 
had been removed however was undetectable again by 8  hours. The transient increase 
in this one particular protein may be an artefact or a consequence of changing the 
medium. Alternatively it may be cell cycle related.
Certain proteins, such as cyclins, are only expressed in particular phases of the 
cell cycle. The transient expression of such proteins can be clearly detected in 
populations of synchronised cells. A synchronised cell population is one in which all 
the cells are progressing through the same phase of the cell cycle at the same time. 
Results in chapter 3 highlighted the ability of quercetin to induce growth inhibition 
and cell cycle arrest in PalF cells. Removal of quercetin releases cells from its 
inhibitory effects permitting them to grow normally. The sudden and synchronised
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release of cells back into a normal cycle would result in the synchronised expression 
of cell cycle regulated proteins. Thus protein band number 1 (figure 5.1) may 
correspond either to a protein which is transiently phosphorylated on tyrosine or a 
phosphotyrosine protein which is transiently expressed in the cell cycle.
The observations made from figure 5.1 suggest that quercetin can alter the 
phosphotyrosine status of several proteins in PalF cells.
Many enzymes, including kinases, are phosphorylated on tyrosine residues 
(Levy et a l, 1984). The activity of such enzymes often correlates with their 
phosphorylation status. Thus the ability of quercetin to alter the phosphorylation and 
subsequent activity of several proteins in a number of cell lines (Levy et a l, 1984; 
Srivastava and Chiasson, 1986; Matter et al., 1992) and now in PalF cells, may largely 
explain why quercetin can have such a profound effect on the normal functioning of 
so many different cell types.
5.3 Analysis to determine if the change in phosphotyrosine was due to a 
change in medium
It is possible that the changes which were induced in several of the 
phosphotyrosine proteins were independent of quercetin. They may have occurred as 
a result of simply changing the medium at the end of the 48 hours. To control for this 
possibility, the experiment described in the previous section was repeated in the 
absence of quercetin. If the changes in phosphotyrosine were genuinely the result of 
the medium being changed, the pattern of phosphotyrosine should again been seen to 
change, as illustrated in figure 5.1.
5.3.1 Experimental procedure
The experimental procedure employed was essentially identical to that 
described in section 5.3.1. The only difference was that cells were not treated with 
quercetin. Instead cells were cultured for 48 hours in lxDMEM supplemented with 
0.1% v/v absolute ethanol. Control dishes of cells were cultured in lxDMEM only.
As detailed in section 5.2.1, the medium in all dishes was changed at the end of the 48 
hour incubation. Control cells and cells corresponding to the 0 time point were 
harvested for total cellular protein immediately after the 48 hours. All other dishes of 
cells received a fresh volume of lxDMEM and were replaced in an appropriate
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incubator. Cells were sequentially harvested at various times after the medium 
change.
5.3.2 Results
As the protein blot in figure 5.2 illustrates, treating cells with ethanol for 48 
hours, followed by a medium change, did not elicit the same changes to the 
phosphotyrosine proteins that were produced by quercetin. This result confirms that 
quercetin can specifically induce changes to several phosphotyrosine proteins in PalF 
cells and that simply changing the medium has no detectable effect on 
phosphotyrosine levels.
5.4 The effect of quercetin on other PalF cell proteins
It is unlikely that the effects of quercetin would be limited to those proteins 
which can be phosphorylated on tyrosine residues. With the total cellular protein 
extracts already available, another SDS-polyacrylamide gel was run. The total protein 
profile was visualised by staining the gel with Coomassie blue and subsequently 
analysed for differences.
5.4.1 Experimental procedure
Approximately 20-3 Opg of total cellular protein extract, made from cells 
exposed to either quercetin or an equivalent volume of ethanol, was loaded into 
separate wells on an SDS-polyacrylamide gel. The protein extracts used were similar 
to those described in section 5.2.1 except that an extra time point (24 hours after 
removal of quercetin) was included. After electrophoresis, the gel was stained in a 
solution of 0.25% Coomassie Brilliant Blue (R250) for 20 minutes at room 
temperature followed by several rounds of destaining. The stained gel was then 
placed on a clean light box and photographed before being dried down onto Whatman 
3MM paper using a Biorad 583 gel drier. The methods of SDS-polyacrylamide gel 
electrophoresis and gel staining are described in detail in section 2.3.3.2.
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Figure 5.2 Western blot showing that changing the medium
does not alter the levels of phosphotyrosine in PalF cells
M l  2 3 4 5 6  7 8  9 10 11 12 13 14 15 16 17 18
200kd -
97.4kd -
69kd -
46kd -
30kd •
Each lime contains approxim ately 20pg  of protein extract. M = Size m arkers 
Lane 1 and 2: C ontrol lanes (untreated PalF cells)
C ells w ere treated w ith 0.1% v/v ethanol for 48 hours. At the end of this time, 
the m edium  was changed. Cells were harvested at various tim es after 
the m edium  change
Lane 3 and 4: Cells harvested im m ediately after 48 hour incubation in 0.1% ethanol
Lane 5 and 6 : Cells harvested 15 m inutes after m edium  change
Lane 7 and 8 : Cells harvested 30 m inutes after m edium  change
Lane 9 and 10: Cells harvested 1 hours after m edium  change
Lane 11 and 12: Cells harvested 2 hours after m edium  change
Lane 13 and 14: Cells harvested 4 hours after m edium  change
Lane 15 and 16: Cells harvested 8 hours after m edium  change
Lane 17 and 18: Cells harvested 24 hours after m edium  change
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5.4.2 Results
The Coomassie blue stained gel, shown in figure 5.3, only shows up the most 
abundant proteins in the total PalF protein extracts. Nevertheless, as the arrows to the 
right of the picture indicate, several protein bands show alterations in either their 
intensity or position within the gel.
Comparing primarily the banding patterns in lanes 1 and 2 with lanes 3 and 4; 
these lanes correspond to cells treated with either ethanol alone or 20pM quercetin 
respectively for 48 hours before harvesting. Close examination of the gel picture 
(figure 5.3) shows banding differences between the protein extracts (see bands 
indicated by the red arrows). Following the bands across the gel it can be seen that by 
24 hours after removal of quercetin, the protein profile of quercetin treated cells has 
reverted back to that of cells treated with ethanol. Some of the proteins recovered in 
less that 24 hours.
One of the protein bands, indicated by arrow #6 , however only begins to 
change 30 minutes after quercetin has been removed. A similar effect was seen in 
figure 5.1, where the uppermost band (see band #1 - figure 5.1) appeared 30 minutes 
after quercetin was removed, remained for up to 4 hours and then disappeared down to 
background levels again. As was suggested in section 5.2.2, the band indicated in 
figure 5.3 (approximately 70kd in size) may correspond to a protein which is cell 
cycle regulated. As shown in chapter 3, a quercetin concentration of 20pM can inhibit 
the growth of PalF cells by approximately 50% and induce at least a partial growth 
arrest. Removal of quercetin would release cells from this growth inhibition and 
allow cells to enter into a normal cycle of cell proliferation. This may explain the 
cyclic nature of the change in certain proteins.
Although the identity of any of the proteins shown to be altered in response to 
quercetin has not been determined, these results confirm that quercetin can directly 
affect a number of different proteins, and perhaps also their respective activities, in 
PalF cells.
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Chapter 6 
Discussion
Chapter 6 Discussion
6.1 Introduction
BPV4 naturally infects the mucous epithelium of the upper gastrointestinal 
tract in cattle and induces the formation of benign papillomas (Jarrett et a l , 1978a; 
Campo et al., 1980). These benign papillomas however have been shown to progress 
to squamous cell carcinomas at high frequency in animals which consume bracken 
fern in their diet (Jarrett et al., 1978b; Campo et al., 1984). Bracken fern, which 
covers extensive areas of the West Highlands of Scotland, is known to contain a 
number of compounds which possess mutagenic, carcinogenic and/or 
immunosuppressive properties (Evans,I.A. et al., 1982; Evans,W.C. et al., 1982). One 
of the more extensively studied mutagens found abundantly in bracken fern is 
quercetin. Quercetin is not exclusive to bracken fern; it is present in a wide range of 
edible plant products including vegetable, fruits, tea and wines (Herrmann, 1976; 
Kuhnau, 1976).
BPV4 alone, when transfected into cells in vitro, is non-transforming. The 
transforming potential of BPV4 is only realised when BPV4 DNA is cotransfected 
into PalF cells in co-operation with an exogenous oncogene such as activated ras 
(Jaggar et al., 1990). BPV4 plus ras, while inducing several cellular changes 
consistent with the transformed state, only partially transform PalF cells; the cells 
retain a finite life span and are unable to induce tumours in nude mice (Pennie et a l,
1993). It was observed however that PalF cells exposed to 20pM quercetin for a 
period of 48 hours after transfection with BPV4 DNA (or selected BPV4 sequences) 
plus ras, displayed additional characteristics of transformation; quercetin treated PalF 
cells transfected with BPV4 DNA plus activated ras were immortal and tumorigenic 
in the nude mouse assay system (Pennie and Campo, 1992; Caimey and Campo,
1995). These observations suggested that quercetin was capable of synergising with 
BPV4 (plus ras) to achieve full transformation of PalF cells. Furthermore, quercetin 
provided additional functions necessary for the complete transformation of PalF cells 
which were not provided by either BPV4 or ras.
The aim of this thesis has been to assess the effect of quercetin on PalF cells 
and attempt to identify a mechanism(s) by which quercetin may synergise with BPV4 
(and ras) to induce full cellular transformation.
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6.2 The effects of quercetin on PalF cell growth
The effect of quercetin on the growth of PalF cells was analysed using three 
separate assay methods. Each of the three assays produced similar results and 
indicated that a quercetin concentration in the range of 10-3 5 pM inhibited the growth 
rate and uptake of thymidine by approximately 50% (see section 3.2.2 and figures 3.2,
3.3 and 3.4). The level of growth inhibition was seen to be proportional to the 
concentration of quercetin in the culture medium showing that quercetin inhibits the 
growth of PalF cells in a concentration dependent manner.
As was discussed in detail in section 3.1, quercetin has been shown to inhibit 
the growth of a large number of cancer cell lines and primary cancer cells derived 
from a variety of anatomical sites (Scambia et a l , 1990a, b, and c, 1993,1994b; 
Piantelli et al., 1993, 1995; Ranelletti et a l, 1992; Avila et a l, 1994; Larocca et a l, 
1995; Plaumann et a l, 1996). In keeping with the observations for PalF cells, 
quercetin-induced growth inhibition was shown to be concentration dependent.
Unlike the cells and cell lines which have been used in previous studies, PalF cells are 
normal, primary bovine fibroblasts. The results from the experiments described in 
section 3.2.2 therefore confirm that quercetin can inhibit the growth of normal, 
untransformed cells in addition to partially or fully transformed tumour cells or cell 
lines.
The concentration of quercetin capable of inhibiting the growth of particular 
cells or cell lines is variable. Some studies report a quercetin IC 50% (the 
concentration of quercetin inhibiting growth of cells by 50%) ranging from InM to 
lpM  (Scambia et a l, 1990b, 1991; Ranelletti et a l, 1992; Larocca et a l, 1995; 
Piantelli et a l, 1995). Other cells however were only inhibited when quercetin was 
present at concentrations of ~ 20pM and higher (Hosokawa et a l, 1990; Avila et a l,
1994). Although the mechanism underlying the antiproliferative activity of quercetin 
remains to be clarified, there is evidence suggesting a role for type-II estrogen binding 
sites (type-II EBS) in many instances. Several studies have shown that quercetin can 
regulate the levels of type-II EBS and that the degree of quercetin-induced growth 
inhibition if often proportional to the number of type-II EBS expressed by a particular
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cell type. Cell which express type-II EBS are generally inhibited by quercetin present 
at nM concentrations. Furthermore, the relative type-II EBS binding affinities are in 
good correlation with the capacity of quercetin to induce these sites (Ranelletti et a l, 
1992; Scambia et a l, 1991,1993). Cells which have fewer or are negative for type-II 
EBS appear only to be inhibited by higher concentrations of quercetin (Hosokawa et 
a l, 1990; Avila et a l, 1994). In such cases, growth inhibition is more probably a 
consequence of quercetin’s ability to inhibit the activity of a number of cellular 
enzymes (Lang and Racker, 1974; Monaham et a l, 1975; Kuriki and Racker, 1976; 
Graziani et a l, 1983; Shosham and MacLennam, 1981; Kato et a l, 1983; Nishino et 
a l, 1984; Nakadate et a l, 1984; Verma et a l, 1988; Matter et a l, 1992).
The concentration of quercetin which was effective at inhibiting the growth of 
PalF cells was in the range of 10-35pM (section 3.2.2). This would indicate that PalF 
cells do not express or poorly express type-II EBS and that growth inhibition is more 
likely to be related to cellular enzyme inhibition.
Growth inhibition induced by quercetin is generally reversible (Scambia et a l, 
1990b; Ranelletti et a l, 1992). Cells can continue to grow normally after quercetin is 
removed from the culture medium. The same recovery from quercetin treatment has 
also been observed for PalF cells (personal observation). However a point is reached 
when the concentration of quercetin, rather than being simply growth inhibitory, 
becomes cytotoxic. Quercetin has been shown to induce apoptosis in cells which have 
been treated with higher quercetin concentrations (generally >50pM) particularly for 
prolonged periods of time (Yoshida et a l, 1992; Avila et a l, 1994; Plaumann et a l,
1996). The non-tumour cell line C3H10T1/2CL8 underwent apoptosis but only after 
cells had been treated with 120pM quercetin for 72 hours (Plaumann et a l, 1996).
The ability of quercetin to induce growth arrest and/or cell death under certain 
conditions is hardly surprising. It is quite usual for cells exposed to cellular stress or 
adverse culture conditions to growth arrest while retaining the potential to resume 
cycling when the cellular environment is again favourable. Yet in situations where 
adverse conditions persist, cells are generally induced to undergo apoptosis (Plaumann 
et a l, 1996; Iwata et a l, 1997; Zhan et a l, 1997).
Addition of quercetin to PalF cell culture medium, even at concentrations as 
high as IOOjiM, appeared not to induce significant levels of cell death as judged by the
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small number of floating cells in the medium (personal observation). Nevertheless, no 
specific assay was performed to accurately assess the level of apoptosis which may 
have been occurring as a result of quercetin treatment.
In summary, the results from the growth and cell cycle experiments described 
in chapter 3, and from other studies with quercetin (Scambia et a l , 1994a; Avila et a l , 
1994; Larocca et a l , 1995), suggest that the presence of quercetin is not compatible 
with normal cell growth of primary PalF cells and a large number transformed cell 
lines alike.
The ability of quercetin to inhibit the growth of a large number of tumour cell 
lines in vitro has lead to it being proposed as a potential therapeutic antitumour agent 
(Scambia et a l , 1990a; Avila et a l , 1994; Shimoi et a l , 1994; Piantelli et a l , 1995). 
The maximum tolerated dose for quercetin in humans has not yet been determined, 
however plasma concentrations of 12pM were achieved following an intravenous 
infusion of lOOmg with no apparent side effects (Gugler et a l , 1975). A quercetin 
concentration of 12pM is greater than that which has been shown effective in 
inhibiting several tumour cell lines and primary tumour cells in vitro (Scambia et a l , 
1990b; Larocca et a l , 1995). As has been discussed in detail in section 3.1, the 
effects of quercetin are numerous and diverse. Because quercetin can affect a large 
number of cellular targets, it is possible that its actions may cause the inhibition of one 
or more steps of the carcinogenic process. This may be viewed as a beneficial quality 
for an anticancer agent. With the potential to target a large number of cellular 
activities, quercetin may thus be more effective at inhibiting the growth of a larger 
number of diverse tumour types which possess a variety of molecular alterations when 
compared to an agent which inhibits one specific cellular function.
Alternatively, the fact that quercetin has such a large number of potential 
cellular effects suggests that the final outcome may be rather unpredictable. The 
unpredictable nature of quercetin treatment is clearly reflected in the results from a 
number of studies in which quercetin was shown to actually contributed to 
carcinogenesis (Pamukcu et a l , 1980; Pereira et a l, 1996). The mechanism(s) 
underlying the ability of quercetin to produce such contradictory effects is not 
understood. There is evidence to suggest that the actions of quercetin may be 
influenced by a number of factors including specific cell type, by what other cellular
199
changes have occurred in those cells as well as the physical, redox state of the cellular 
background (Okada et a l, 1990; Perona and Serrano, 1988; Dreher and Junod, 1996; 
Plaumann et a l, 1996). The ability of quercetin to contribute to the carcinogenic 
process highlights the need for additional study of the action of quercetin and its 
further evaluation as an anticancer agent should proceed with caution.
In addition to quercetin’s potential as an antitumour agent, the consumption of 
quercetin and other flavonoids as part of a normal diet has been related to a lower 
incidence of cancers of the stomach, colon (Haenszel et a l, 1980; Ranelletti et a l, 
1992), and breast (Adlercreutz, 1984) in humans. The chemopreventive properties of 
quercetin have been related to its antioxidant properties. However, quercetin has also 
been demonstrated to possess pro-oxidant properties. Quercetin has been shown to 
inhibit glutathione reductase (Elliott et a l, 1992) a key antioxidant enzyme Which 
protects a cell against oxidative stress. Combining this with quercetin's additional 
ability to produce reactive oxygen species (0 2+, H2 0 2, *OH) (Canada et a l, 1990; 
Elliott et a l, 1992) suggests that quercetin could be promoting extensive oxidative 
stress in vivo. Furthermore, quercetin inhibits O-methylation of catecholestrogens 
(Zhu and Leibr, 1996). Catecholestrogens have been postulated to mediate the 
induction of kidney tumours by estradiol in male Syrian hamsters. Hence quercetin 
has the potential to increase the production of potentially mutagenic free radicals and 
thereby potentiate estrogen-induced renal tumorigenesis.
Similar claims of chemopreventive activity have also been proposed for 
another common dietary antioxidant, p-carotene (Hennekens, 1986). P-carotene was 
suspected of lowering the risk of developing cancer, specifically lung cancer, and 
cardiovascular disease. Results from a large, long-term Scandinavian trial (ATBC 
trial) (Heinonen et a l, 1994) however failed to detect any significant protective effect 
with regard to lung cancer. In fact, there were significantly more new cases of lung 
cancer in the group given p-carotene dietary supplements. Although the finding of 
ATBC trial does not necessarily exclude potential benefits of P-carotene in the diet, it 
suggests that predicted benefits, regarding cancer prevention, may have been 
overestimated and highlights the potential of antioxidants such as P-carotene to have 
some harmful effects. Thus the chemopreventive activity of in vivo antioxidants has 
not yet been proven (Hennekens et a l, 1994).
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6.3 The effect of quercetin on cell cycle status and morphology of PalF cells
Preliminary analyses showed that the effects of quercetin on the cell cycle 
were only transient unless quercetin was replenished in the culture medium every 1 2  
hours. Quercetin appears to undergo a process of inactivation in culture medium 
although the specific mechanism of how quercetin is inactivated is not understood. 
One possibility is that quercetin is gradually oxidised. Because of the problems with 
quercetin stability, it was necessary to replenish the medium with a fresh volume of 
active quercetin every 1 2  hours to obtain a measurable cell cycle arrest.
Analysis of the effect of quercetin on the cell cycle status of PalF cells was 
performed for a range of quercetin concentrations over a 48 hour time period. The 
results, illustrated in figure 3.6 and 3.7 and described in section 3.3.2, show that 
quercetin can induce PalF cells to undergo cell cycle arrest. This observation 
complements the PalF cell growth assays discussed in sections 3.2.2 and 6.2 and 
shows that the growth inhibitory action of quercetin is not simply a dynamic balance 
between continued cell proliferation and cell death.
PalF cells treated with 20, 50 and IOOjjM  quercetin were seen to steadily 
accumulate in the G2/M phase of the cells cycle. An interesting observation however 
was that PalF cells were observed to accumulate in S-phase within 12 hours after 
quercetin was first added to the culture medium (see figure 3.7, panel 3). This 
accumulation of cells in S-phase was only clearly evident for PalF cells which were 
treated with 50 or lOOpM quercetin and had disappeared by 24 hours.
A complete G2/M arrest was not observed for PalF cells even when exposed to 
the highest concentration of quercetin. This observation suggests that a quercetin 
concentration of lOOpM was still insufficient to induce a complete cell cycle arrest. 
Alternatively, the experiment may have been terminated before a complete cell cycle 
arrest could be achieved. This is a plausible suggestion considering PalF cells were 
shown to take 36 to 48 hours to complete a single cell cycle (see section 3.2.2).
The results presented in figure 3.6 and 3.7 indicate that quercetin can also 
induce cells to arrest in G1/G0. Thus exposure of PalF cells to quercetin is associated 
with the establishment of two separate restriction points in the cell cycle, one in G l, 
the other in G2/M.
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The observations from the PalF cell cycle analysis have lead to the following 
model. After the addition of quercetin to the culture medium, cells begin to 
accumulate in S-phase. Either cells in mid to late G1 are being stimulated to enter S- 
phase or their ability to exit S is delayed or inhibited. Whatever the mechanism, the 
accumulation of cells in S-phase is transient. All cells that have already passed the 
quercetin-induced restriction point in G 1 continue through the cell cycle until they 
reach the second restriction point in G2. Likewise, cells which have travelled beyond 
the G2 block before quercetin has been added to the medium would enter and 
complete mitosis (M phase). Cell would then stop cycling once the G1 block was 
reached.
Quercetin is known to induce different types of cell cycle arrest (Yoshida et 
a l , 1990; Hosokawa et a l , 1990; Gong et a l , 1994; Sato et a l , 1994; Avila et a l , 
1994; Plaumann et a l , 1996). This may be related to the cell type involved, the 
cellular processes affected and/or the specific concentration of quercetin used. The 
specific mechanism(s) relating to a quercetin-induced cell cycle arrest has not been 
fully clarified. Nevertheless, some of the potential candidate proteins which have 
been shown to be modulated by quercetin and which may have a direct impact on 
normal cell proliferation include kinase enzymes such as phosphatidylinositol-3 
kinase (PI3-kinase) and viral src (Matter et a l , 1992; Graziani et a l, 1983), TGFp 
(Scambia et a l, 1994a), heat shock proteins (Elia and Santoro, 1994), and both wild 
type and mutant p53 (Plaumann et a l, 1996; Avila et a l, 1994).
In addition to growth inhibition and cell cycle arrest, quercetin was also shown 
to induce certain morphological changes in PalF cells (Figure 3.5). Cell density was 
reduced however this was most likely related to the decrease proliferation rate which 
was seen to be a consequence of quercetin in the culture medium. Other 
morphological changes induced by exposure to quercetin included cells having a 
flatter appearance and a more vacuolar cytoplasm. The morphological changes 
induced were more pronounced in PalF cells which were exposed to the highest 
concentrations of quercetin (50 and lOOpM). Thus, similar to the observations for 
PalF growth inhibition, the level of morphological change induced by quercetin was 
found to be dependent on and proportional to the concentration of quercetin present in 
the culture medium.
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6.4 Quercetin can increase the level of transcription from the BPV4 LCR 
when present as a promoter
As was mentioned in section 6.1, one of the primary aims of this thesis was to 
attempt to identify ways in which quercetin may be synergising with BPV4 DNA (plus 
activated ras) to achieve malignant transformation of PalF cells. One hypothesis was 
that quercetin was able to increase the level of viral transcription and consequently the 
levels of viral oncogenes. As a means of testing this hypothesis, a series of transient 
expression assays were performed to analyse the effect of quercetin treatment on the 
transcriptional activity of the BPV4 LCR.
Quercetin was shown to increase the level of transcription from the BPV4 
LCR by two to four fold in PalF (figure 4.1,4.8) and PalK cells (figure 4.11). This 
effect however was only observed when the LCR was functioning in a promoter 
capacity (figure 4.1); the LCR when present as an enhancer was unaffected by 
exposure to quercetin (figure 4.2). Thus the effect of quercetin on the BPV4 LCR is 
promoter specific.
The increase in transcription was also only realised when cells were treated 
with quercetin immediately after transfection (figure 4.1). This suggests that the 
effect(s) of quercetin is relatively short lived and that a cell will recover from 
exposure to quercetin quite quickly. The transient nature of quercetin treatment 
generally rules out the possibility that quercetin was inducing changes at the genetic 
level; a genetic change, such as a mutation, constitutes a permanent change and would 
thus persist in a cell in the long term.
The experiments described in section 4.2 showed that quercetin could 
consistently increase the level of viral transcription up to four fold over untreated 
cells. Although this may be regarded as a small to moderate increase in viral 
transcription, it may have a profound effect on cells in vivo and be sufficient to push 
cells into a more transformed state. Indeed, the degree of phenotypic transformation 
detected in various cell lines has been shown to correlate with the level of viral 
oncogene expression (von Knebel Deoberitz et al., 1994; Liu et al., 1995; Trujillo and 
Mounts, 1996).
The 3’terminal 21 base pair sequence of the LCR, encompassing nucleotides 
311-331, was proposed as a potentially interesting site with respect to quercetin
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responsiveness because of an identified TRE-like binding motif Deletion of this 21 
base pair stretch corresponded with a general drop in basal transcriptional activity 
(figure 4.9 and 4.12) and a drop in the response of the LCR to quercetin in both PalF 
and PalK cells (figure 4.8, 4.11). Replacement of this 21 base pair sequence with a 
stretch of 2 1  random nucleotides again resulted in a drop in response to quercetin in 
both PalF and PalK cells (figure 4.23). The drop in response to quercetin with the 
‘random’ LCR was similar to that observed with the 21 base pair truncated form of the 
LCR (figure 4.23). A significant drop in the basal level of transcription was observed 
for the LCR containing the 21 random nucleotides in place of the normal 3’sequence 
(figure 5.23). These results indicate that nucleotides 311 to 331 of the BPV4 LCR are 
important with respect to basal transcriptional activity and in mediating the 
transcriptional effects of quercetin.
TPA and quercetin were shown to have antagonistic effects on the activity of 
the collagenase TRE and on the BPV4 LCR (figure 4.4). This may be related to the 
known ability of quercetin to inhibit the action of enzymes which are activated by 
TPA treatment, such as protein kinase C (Gschwendt et al., 1983; Angel et al., 1987). 
Alternatively, quercetin and TPA may induce separate signal transduction pathways 
which are themselves incompatible and antagonistic.
An increase in the activity of the BPV4 LCR was only observed when cells 
were cultured in medium contain 10% serum (figure 4.4). It would appear that 
quercetin is dependent on serum growth factors, or anther constituent of serum, to 
modulate the activity of the BPV4 LCR. It is possible that the action of quercetin is in 
some way associated with a particular signal transduction pathway which is only 
activated by particular factors present in serum. Disruption of signal transduction as a 
consequence of low serum levels in the culture medium may thus inhibit the ability of 
quercetin to transduce its affects to various cellular targets. At present however the 
exact nature of quercetin’s dependence on serum is not known and represents an area 
for further study.
6.5 A cellular factor QX1 mediates the transcriptional effects of quercetin 
within the BPV4 LCR
Results from the transient expression assays indicated that the 21 base pair 
3’terminal sequence of the BPV4 LCR, encompassing nucleotides 311-331, was
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important in mediating the transcriptional changes induced by exposure of PalF and 
PalK cells to quercetin. A series of electromobility shift assays (EMSA) were 
performed in an attempt to ascertain if any protein was capable of binding to this 
region of the BPV4 LCR. As the results in figure 4.14 and 4.15 illustrate, a factor 
designated QX1 was identified as binding to an oligonucleotide which corresponded 
to the sequence of nucleotides from 301 to 331 of the BPV4 LCR. The addition of 
several unlabelled oligonucleotides as competitors confirmed that the binding of QX1 
to this oligonucleotide was specific. QX1 was also detected in chick embryo 
fibroblast cells (CEFs) (figure 4.15). Thus QX1 is not a PalF specific factor but is 
expressed in at least one other primary fibroblast cell from a different species.
The presence of a TRE-like element lead to the initial hypothesis that QX1 
may in fact be API. Further EMSA experiments however showed that QX1 and API 
displayed very different mobility in a polyacrylamide gel and confirmed that QX1 and 
API are not the same factors (figure 4.17). Supershift EMSAs, which employed 
antibodies to various subunits of classic API, indicated that QX1 was not composed 
of cJun or cFos subunits. As the results in figure 4.18 suggest however, QX1 may 
contain a subunit(s) which is related to cFos although the exact identity of any QX1 
composite protein has not yet been confirmed. The exclusion of API as a candidate 
for QX1 is in agreement with expression assay results in which TPA, which is known 
to increase the levels of API, had no affect on the transcriptional activity of the BPV4 
LCR. Furthermore, quercetin and TPA together displayed antagonistic effects with 
respect to the transcriptional activity of the BPV4 LCR and the collagenase TRE 
(figure 4.4).
A series of point mutations were introduced into the wtLCR oligonucleotide in 
an attempt to abolish binding of QX1 and thus potentially identify residues critical for 
the binding of QX1 to a region of the LCR. Mutating the TRE-like element to a 
canonical API-binding site, by virtue of a G to T transversion, did not exclude the 
binding of QX1 (figure 4.20). Indeed the binding of QX1 appeared to be 
strengthened. Furthermore, the conversion of the TRE-like element to a consensus 
API binding motif enabled API to bind strongly to the LCR mutant oligonucleotide 
(figure 4.20). Although both API and QX1 were shown to bind to this mutant LCR 
oligonucleotide, binding of each individual factor was mutually exclusive. This 
would suggest that while API and QX1 bind separate sites within the LCR
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oligonucleotide, their respective binding sites are actually located very close to each 
other and may in fact be overlapping.
Two more mutant LCR oligonucleotides were generated in which nucleotides 
5’ to the TRE-like element were changed (see figure 4.13 for details of mutants 
oligonucleotide sequences). Neither mutant #2 nor mutant #3 abolished binding of 
QX1 to the LCR. These observations exclude any of the mutated nucleotides as being 
important in the binding of QX1 to the LCR and further suggest that the binding site 
of QX1 lies downstream (3’), albeit marginally, of the TRE-like motif.
The only other binding site which has been identified within nucleotides 311 
to 331 of the BPV4 LCR is putative INR (initiator) element (Novina and Roy, 1996). 
INRs have been identified downstream of the TATA box in other viral and cellular 
genes. They have a general consensus sequence of PyA(+l)NT/APyPy (Javaheri et 
a l , 1994), where Py corresponds to a pyrimidine base. A similar sequence, 
TAGCTCT, exists at nucleotide 321-327 of the BPV4 LCR. The putative INR is 
consistent with the suspected position of the QX1 binding site. INRs bind a host of 
cellular proteins (IBP) many of which have been identified as either TAF, GTF or 
USF family members. Binding of an IBP to the INR assists the formation of the 
transcription pre-initiation complex and enhances promoter strength (Kaufmann and 
Smale, 1994). Deletion of nucleotides 311 to331 corresponded with a drop in the 
level of basal transcription and response of the LCR to quercetin, effects which are 
consistent with the removal of an INR. Thus QX1 may be an IBP which is regulated 
by quercetin.
There was no difference in the binding of QX1 from quercetin and ethanol 
treated control cells (figure 4.14). This shows that QX1 is also present in cells which 
have not been treated with quercetin. It further suggests that the effect of quercetin on 
QX1 is probably not to induce the de novo expression of QX1. It is possible however 
that quercetin may be affecting the activity of QX1 at the post-transcriptional level. In 
fact a similar effect of quercetin has been reported with regard to TGFp (Scambia et 
al., 1994a). Alternatively, quercetin treatment may induce phosphorylation changes 
on QX1 thus altering its activity.
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6.6 Epigenetic effects of quercetin
The effects of quercetin are numerous, diverse and complex. In light of this it 
is reasonable to suggest that alterations to the level of LCR transcription is not the 
only effect of quercetin which may explain its synergistic association with BPV4 
DNA and ras. Indeed, quercetin was seen to synergise with BPV4 plus ras to achieve 
full cellular transformation even when the BPV4 genes were being expressed from the 
Moloney murine LTR (figure 4.26a and 4.26b). This powerful viral promoter was 
found not to be up-regulated in response to quercetin exposure; rather the activity of 
the Moloney murine LTR was slightly reduced following quercetin treatment (figure 
4.26b).
As a means of identifying other cellular targets affected by quercetin in PalF 
cells, the phosphotyrosine status of proteins was analyses. Quercetin was shown to 
alter the phosphorylation status of a number of cellular proteins. Although the identity 
of the proteins affected has not been determined the results are strongly suggestive of 
the potential of quercetin to induce change at an epigenetic level.
Epigenetic changes are generally non-permanent, reversible changes to 
proteins or DNA. Proteins may be modified in a number of ways including 
phosphorylation. A phosphate moiety can be transferred on and off tyrosine, serine or 
threonine residues in many proteins. The presence or absence of protein 
phosphorylation is often related to the functional activity of a protein. Results from 
the phosphotyrosine analysis described in section 5.2.2, in combination with 
observations made by other workers (Graziani et al., 1983; End et al., 1987; Van 
Wart-Hood et a l, 1989; Matter et a l, 1992) confirm the potential of quercetin to 
affect the activity of various cellular proteins possibly by altering their 
phosphorylation status.
DNA can also be epigenetically modified by a process of methylation. DNA 
methylyation involves the enzymatic transfer of a methyl group from s-adenosyl-L- 
methionine to the 5’ position on a cytosine ring. Depending on the species, between 2 
to 7 percent of cytosine residues in animal cell DNA are methylated (Lewin, 1990). 
Most methyl moieties are found in CpG ‘doublets’. Between 60 to 90 percent of 
CpGs are methylated which accounts for most, if not all, of the methylcytosine in 
vertebrate genomes.
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Many cellular genes which are constitutively expressed, such as 
‘housekeeping’ genes, contain clusters of CpG sequences located upstream of the site 
of transcription initiation (Bird, 1986). These CpG-rich islands are generally 
unmethylated. Hypomethylation is generally associated with a gene which is 
undergoing transcription. Hypermethylation of CpG islands is often observed when 
gene expression has been silenced.
Quercetin has been shown to induce DNA hypermethylation (Ishikawa et al., 
1987). This suggests that quercetin treatment, through DNA hypermethylation, may 
lead to the transcriptional silencing of particular cellular genes, such as tumour 
suppressor genes. Thus by reducing the expression of cellular genes which can 
protect the cell against uncontrolled proliferation, quercetin may be promoting cellular 
transformation.
The ability of quercetin to synergise with BPV4 and ras to achieve full 
transformation has been shown to be limited to a time period shortly after transfection 
of PalF cells with BPV4 and ras DNA (Caimey and Campo, 1995). This suggests that 
the effects induced by quercetin which contribute to this synergistic process are 
relatively short lived. This supports the hypothesis that certain epigenetic events, 
induced by quercetin, are critical for the full transformation of PalF cells in 
association with BPV4 and ras expression.
6.7 Potential model for the role of quercetin in BPV4-associated cellular 
transformation
In light of the experimental observations which have been described in this 
thesis, a model to explain the contribution of quercetin to BPV4-associated cellular 
transformation is proposed.
Quercetin induces cell cycle arrest, possibly as a direct result of quercetin- 
induced DNA damage or cellular stress. The expression of BPV4 genes has been 
shown to be modulated by quercetin treatment. Increased expression of a viral gene 
like E7, which can bind and affect the normal activity of pRb, would stimulate cells to 
continue through the cell cycle. The stimulation of cells to undergo DNA synthesis 
under adverse conditions may give rise to cellular mutation. Topoisomerase II, an 
enzyme involved in the repair of DNA damage, has also been shown to be inhibited 
by quercetin and may result in a mutation going uncorrected (Austin et a l , 1992).
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Other epigenetic effects of quercetin, as indicated by the ability of quercetin to alter 
the phosphorylation status of several cellular proteins, suggests other cellular targets 
of quercetin, which when altered, may further contribute to the process of 
transformation.
The synergism between BPV4 (plus ras) expression and quercetin treatment 
appears only to occur in a limited time window, that is the period immediately 
following cellular transfection. Viral gene (and ras) expression may have to be at a 
maximum before quercetin can have a synergistic effect. Coupled with this is the 
observation that the effects of quercetin are short lived; quercetin appears to undergo a 
process of inactivation upon addition to cell culture medium.
The combined effects of quercetin treatment, oncogenic ras and increased 
BPV4 expression could potentially lead to the attainment of a DNA mutation(s) which 
ultimately leads to the establishment of a fully transformed cellular phenotype.
The model proposed above may be extended to the situation in vivo. However, 
certain physical restraints argue against quercetin having a role in BPV4-associated 
carcinogenesis. Quercetin is poorly absorbed in the gastrointestinal tract and is 
degraded by intestinal microflora (Ueno et a l , 1982). Furthermore, quercetin which is 
absorbed is rapidly inactivated by O-methylation catalysed by catechol-O- 
methyltransferase (Zhu et a l , 1994). These facts however are less important when 
considering BPV4-associated carcinogenesis in vivo. Quercetin (in bracken fern) 
would be ground directly into oral lesions via the mechanical action of chewing and 
would be in direct contact with lower GI lesions as the food was ingested. Thus the 
concentrations of quercetin, along with other chemicals in bracken necessary for 
carcinogenesis, are highest at the site of immediate interest.
Quercetin may be a contributory factor in similar cancers, namely of the oral 
cavity and gastrointestinal track, in humans. There has been a recent surge in interest 
in establishing the role of papillomaviruses in the aetiology of oral cancers (Yeudall, 
1992; Woods et al., 1993; Chen et al., 1997).
6 . 8  Future prospects
Results in chapter 3 showed that quercetin could inhibit the growth of PalF 
cells in a concentration dependent manner. It would be interesting to determine if
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PalF cells stably transfected with BPV4 DNA (plus ras) were more or less sensitive to 
the growth inhibitory effects of quercetin. Similarly, could BPV4 plus ras 
transformed cells be induced to undergo the same kind of growth arrest induced in 
normal PalF cells following continued quercetin treatment.
It is currently unknown if quercetin can induce or suppress the expression of 
wild type p53 in PalF cells. A study by Plaumann et al. (1996) showed that quercetin 
could induce p53 expression in a non-tumorigenic cell line, C3H10T1/2CL8. The 
ability of quercetin to induce the expression of p53 indicates that quercetin may be 
inducing a level of DNA damage. The presence of DNA damage has been shown to 
result in cell cycle arrest (Plaumann et al., 1996). Therefore by determining the p53 
status in quercetin treated PalF cells it may be possible to identify a potential mediator 
in the quercetin induced cell cycle arrest.
The ability of quercetin to induce apoptosis in PalF cells has not yet been 
determined. If apoptosis is induced it would be interesting to determine if this was 
p53 dependent or not.
Results in this thesis have shown that quercetin can increase the level of 
transcription from the BPV4 LCR. The next step would be to determine if quercetin 
treatment can actually give rise to a detectable increase in the level of viral proteins. It 
is appreciated though that this may be a technically veiy difficult experiment to 
perform.
The use of mutant oligonucleotides has thus far been unsuccessful in positively 
identifying bases critical for the binding of QX1 within the 3’terminal 21 base pair 
region of the BPV4 LCR. The initial screening was rather limited with only 3 
different mutant oligonucleotides used. It is reasonable to suggest that by generating 
several more mutant LCR oligonucleotides, carrying base substitutions 3’ to those 
previously changed, a QX1 binding site may be identified.
In the event that a specific binding motif was identified, its response to 
quercetin could be assess by cloning the element upstream of a suitable promoter 
driving a reporter gene and thus confirm that quercetin can induce an increase in 
transcription. It would also be interesting to determine if other quercetin response 
elements (QRE) were located elsewhere in the LCR or in the regulatory regions of 
other viruses or cellular genes.
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As yet it is not known if QX1 is a novel transcription factor. With the 
identification of a QRE, the next step would therefore be to try to purity and 
characterise QX1.
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